[{"id":"10.1002\/14651858.CD008395.pub2_0","text":"Unsimplified text:\nThree RCTs (333 participants) were identified, two of which were multicentre trials comprising only participants positive for respiratory syncytial virus (RSV).\nThe other trial enrolled participants clinically diagnosed with bronchiolitis from a hospital in Italy.\nAll studies used 2.5 mL (1 mg\/mL) of nebulised rhDNase compared with placebo either as a daily or a twice daily dose.\nAdjunctive therapy included nebulised salbutamol, steroids, supplemental oxygen, intravenous fluids or tube feeding, nasal washing, nasal decongestants and antibiotics.\nOverall, nebulised rhDNase showed no benefit in clinically meaningful outcomes.\nMeta-analysis favoured the control group with a shorter duration of hospital stay (MD 0.50; 95% CI 0.10 to 0.90, P = 0.01) and better clinical score improvement (SMD -0.24; 95% CI -0.50 to 0.01, P = 0.06).\nThe largest trial showed no difference in supplemental oxygen use or intensive care unit (ICU) admission.\nIn one RCT, four out of 11 patients in the treatment group had atelectasis.\nTwo of these patients showed distinctive clinical improvement after nebulised rhDNase.\nThere was no significant difference in adverse events.\nThese included temporary desaturation, temporary coughing, increased coughing, facial rash, hoarseness, dyspnoea and bad taste, reported in a total of 11 patients from both treatment groups.\nThe results based on the three included studies in this review did not support the use of nebulised rhDNase in children under 24 months of age hospitalised with acute bronchiolitis.\nIn these patients, treatment did not shorten the length of hospitalisation or improve clinical outcomes.\nIt might have a role in severe bronchiolitis complicated by atelectasis, but further clinical studies would need to be performed.\n\n\nSimplified text:\nThis review found that nebulised rhDNase did not shorten the length of hospital stay or improve clinical outcomes. It might have a role in severe bronchiolitis complicated by atelectasis, but further clinical studies would need to be performed. The results based on the three included studies in this review did not support the use in children under 24 months.","label":["Factuality 2","Fluency 1","Simplicity 1"]},{"id":"10.1002\/14651858.CD008395.pub2_1","text":"Unsimplified text:\nThree RCTs (333 participants) were identified, two of which were multicentre trials comprising only participants positive for respiratory syncytial virus (RSV).\nThe other trial enrolled participants clinically diagnosed with bronchiolitis from a hospital in Italy.\nAll studies used 2.5 mL (1 mg\/mL) of nebulised rhDNase compared with placebo either as a daily or a twice daily dose.\nAdjunctive therapy included nebulised salbutamol, steroids, supplemental oxygen, intravenous fluids or tube feeding, nasal washing, nasal decongestants and antibiotics.\nOverall, nebulised rhDNase showed no benefit in clinically meaningful outcomes.\nMeta-analysis favoured the control group with a shorter duration of hospital stay (MD 0.50; 95% CI 0.10 to 0.90, P = 0.01) and better clinical score improvement (SMD -0.24; 95% CI -0.50 to 0.01, P = 0.06).\nThe largest trial showed no difference in supplemental oxygen use or intensive care unit (ICU) admission.\nIn one RCT, four out of 11 patients in the treatment group had atelectasis.\nTwo of these patients showed distinctive clinical improvement after nebulised rhDNase.\nThere was no significant difference in adverse events.\nThese included temporary desaturation, temporary coughing, increased coughing, facial rash, hoarseness, dyspnoea and bad taste, reported in a total of 11 patients from both treatment groups.\nThe results based on the three included studies in this review did not support the use of nebulised rhDNase in children under 24 months of age hospitalised with acute bronchiolitis.\nIn these patients, treatment did not shorten the length of hospitalisation or improve clinical outcomes.\nIt might have a role in severe bronchiolitis complicated by atelectasis, but further clinical studies would need to be performed.\n\n\nSimplified text:\nThree randomised controlled trials (RCTs) with 333 participants were identified, two of which were multicentre trials comprising only participants positive for respiratory syncytial virus (RSV). The other trial enrolled participants clinically diagnosed with bronchiolitis from a hospital in Italy. Adjunctive therapy included nebulised salbutamol, steroids, supplemental oxygen, intravenous fluids or tube feeding, nasal washing, nasal decongestants and antibiotics. In these patients, treatment did not shorten the length of hospitalisation or improve clinical outcomes. The largest trial showed no difference in supplemental oxygen use or intensive care unit (ICU) admission. These included temporary desaturation, temporary coughing, increased coughing, facial rash, hoarseness, dyspnoea and bad taste, reported in a total of 11 patients from both treatment groups. The results based on the three included studies in this review did not support the use of rhDNase in children under 24 months of age hospitalised with acute broncholitis. It might have a role in patients with atelectasis, but further clinical studies would need to be performed.","label":["Factuality 2","Fluency 1","Simplicity 0"]},{"id":"10.1002\/14651858.CD010185.pub3_0","text":"Unsimplified text:\nTwo studies with a total of 181 participants met the inclusion criteria, 116 undergoing the percutaneous technique and 65 treated by cut-down femoral artery access.\nOne study had a small sample size and did not adequately report method of randomisation, allocation concealment or pre-selected outcomes.\nThe second study was a larger study with few sources of bias and good methodology.\nWe observed no significant difference in mortality between groups, with only one mortality occurring overall, in the totally percutaneous group (risk ratio (RR) 1.50; 95% confidence interval (CI) 0.06 to 36.18; 181 participants; moderate-quality evidence).\nOnly one study reported aneurysm exclusion.\nIn this study we observed only one failure of aneurysm exclusion in the surgical cut-down femoral artery access group (RR 0.17, 95% CI 0.01 to 4.02; 151 participants; moderate-quality evidence).\nNo wound infections occurred in the cut-down femoral artery access group or the percutaneous group across either study (moderate-quality evidence).\nThere was no difference in major complication rate between cut-down femoral artery access and percutaneous groups (RR 0.91, 95% CI 0.20 to 1.68; 181 participants; moderate-quality evidence); or in bleeding complications and haematoma (RR 0.94, 95% CI 0.31 to 2.82; 181 participants; high-quality evidence).\nOnly one study reported long-term complication rates at six months, with no differences between the percutaneous and cut-down femoral artery access group (RR 1.03, 95% CI 0.34 to 3.15; 134 participants; moderate-quality evidence).\nWe detected differences in surgery time, with percutaneous approach being significantly faster than cut-down femoral artery access (mean difference (MD) -31.46 minutes; 95% CI -47.51 minutes to -15.42 minutes; 181 participants; moderate-quality evidence).\nOnly one study reported duration of ITU (intensive treatment unit) and hospital stay, with no difference found between groups.\nThis review shows moderate-quality evidence of no difference between the percutaneous approach compared with cut-down femoral artery access group for short-term mortality, aneurysm exclusion, major complications, wound infection and long-term (six month) complications, and high-quality evidence for no difference in bleeding complications and haematoma.\nThere was a difference in operating time, with moderate-quality evidence showing that the percutaneous approach was faster than the cut-down femoral artery access technique.\nWe downgraded the quality of the evidence to moderate as a result of the limited number of studies, low event numbers and imprecision.\nAs the number of included studies were limited, further research into this technique would be beneficial.\nThe search identified one ongoing study, which may provide an improved evidence base in the future.\n\n\nSimplified text:\nWe searched the medical literature up to January 2015. We found two studies with 181 participants, with 116 undergoing the percutaneous approach and 65 treated by cut-down femoral artery access. One study had a small number and did not adequately report methods of randomisation, allocation concealment or pre-selected outcomes. The other study was a larger, well conducted and well conducted study with few sources of bias and good methodology. The two studies showed that there was no difference between the two approaches in mortality, major complications, wound infection, bleeding complications or hospital stay. However, there was a small reduction in operating time, with moderate-quality evidence showing that the method was faster than the other. No wound infections occurred in the groups. We did not find differences in bleeding complications and haematoma. The quality of the evidence was moderate as the number of studies was small and the results were imprecise. As the number was limited, more research into this technique would be beneficial. The search identified one ongoing study, which may provide an improved evidence base in the future.","label":["Factuality 0","Fluency 2","Simplicity 2"]},{"id":"10.1002\/14651858.CD010185.pub3_1","text":"Unsimplified text:\nTwo studies with a total of 181 participants met the inclusion criteria, 116 undergoing the percutaneous technique and 65 treated by cut-down femoral artery access.\nOne study had a small sample size and did not adequately report method of randomisation, allocation concealment or pre-selected outcomes.\nThe second study was a larger study with few sources of bias and good methodology.\nWe observed no significant difference in mortality between groups, with only one mortality occurring overall, in the totally percutaneous group (risk ratio (RR) 1.50; 95% confidence interval (CI) 0.06 to 36.18; 181 participants; moderate-quality evidence).\nOnly one study reported aneurysm exclusion.\nIn this study we observed only one failure of aneurysm exclusion in the surgical cut-down femoral artery access group (RR 0.17, 95% CI 0.01 to 4.02; 151 participants; moderate-quality evidence).\nNo wound infections occurred in the cut-down femoral artery access group or the percutaneous group across either study (moderate-quality evidence).\nThere was no difference in major complication rate between cut-down femoral artery access and percutaneous groups (RR 0.91, 95% CI 0.20 to 1.68; 181 participants; moderate-quality evidence); or in bleeding complications and haematoma (RR 0.94, 95% CI 0.31 to 2.82; 181 participants; high-quality evidence).\nOnly one study reported long-term complication rates at six months, with no differences between the percutaneous and cut-down femoral artery access group (RR 1.03, 95% CI 0.34 to 3.15; 134 participants; moderate-quality evidence).\nWe detected differences in surgery time, with percutaneous approach being significantly faster than cut-down femoral artery access (mean difference (MD) -31.46 minutes; 95% CI -47.51 minutes to -15.42 minutes; 181 participants; moderate-quality evidence).\nOnly one study reported duration of ITU (intensive treatment unit) and hospital stay, with no difference found between groups.\nThis review shows moderate-quality evidence of no difference between the percutaneous approach compared with cut-down femoral artery access group for short-term mortality, aneurysm exclusion, major complications, wound infection and long-term (six month) complications, and high-quality evidence for no difference in bleeding complications and haematoma.\nThere was a difference in operating time, with moderate-quality evidence showing that the percutaneous approach was faster than the cut-down femoral artery access technique.\nWe downgraded the quality of the evidence to moderate as a result of the limited number of studies, low event numbers and imprecision.\nAs the number of included studies were limited, further research into this technique would be beneficial.\nThe search identified one ongoing study, which may provide an improved evidence base in the future.\n\n\nSimplified text:\nWe found two studies with a total of 181 participants, 116 undergoing the percutaneous technique and 65 treated by cut-down femoral artery access. One study was a larger study with few sources of bias and good methodology. This review shows moderate-quality evidence of no difference in short-term mortality, aneurysm exclusion, major complications, wound infection and long-term (six month) complications. No wound infections occurred in either group across either study. Only one study reported duration of ITU (intensive treatment unit) and hospital stay, with no difference found between groups. There was a difference in operating time, with moderate- quality evidence showing that the percentage of bleeding complications and haematoma was faster. We downgraded the quality of the evidence to moderate as a result of the limited number of studies, low event numbers and imprecision. As the number of included studies were limited, further research into this technique would be beneficial. The search identified one ongoing study, which may provide an improved evidence base in the future.","label":["Factuality 2","Fluency 2","Simplicity 2"]},{"id":"10.1002\/14651858.CD003172_0","text":"Unsimplified text:\nTwo trials met the inclusion criteria.\nThe sponge was significantly less effective in both trials in preventing overall pregnancy than was the diaphragm.\nIn the larger USA trial, the 12-month cumulative life-table termination rates per 100 women for overall pregnancy were 17.4 for the sponge and 12.8 for the diaphragm.\nThe rates were 24.5 for the sponge and 10.9 for the diaphragm in the UK trial.\nSimilarly, discontinuation rates at 12 months were higher with the sponge than with the diaphragm (Odds ratio 1.31; 95% CI 1.07 to 1.59).\nAllergic-type reactions were more common with the sponge, although discontinuation for discomfort differed in the two trials.\nNo new trials have been identified since the initial review.\nThe sponge was less effective than the diaphragm in preventing pregnancy.\nDiscontinuation rates were higher at 12 months as well.\nOther randomized controlled trials will be needed to resolve the potential role of spermicides in preventing sexually transmitted infections or in causing adverse effects.\n\n\nSimplified text:\nThis review found that spermicides are less effective than the diaphragm in preventing pregnancy in preventing sexually transmitted infections or causing adverse effects. Other randomized controlled trials are needed to answer this question.","label":["Factuality 0","Fluency 2","Simplicity 1"]},{"id":"10.1002\/14651858.CD003172_1","text":"Unsimplified text:\nTwo trials met the inclusion criteria.\nThe sponge was significantly less effective in both trials in preventing overall pregnancy than was the diaphragm.\nIn the larger USA trial, the 12-month cumulative life-table termination rates per 100 women for overall pregnancy were 17.4 for the sponge and 12.8 for the diaphragm.\nThe rates were 24.5 for the sponge and 10.9 for the diaphragm in the UK trial.\nSimilarly, discontinuation rates at 12 months were higher with the sponge than with the diaphragm (Odds ratio 1.31; 95% CI 1.07 to 1.59).\nAllergic-type reactions were more common with the sponge, although discontinuation for discomfort differed in the two trials.\nNo new trials have been identified since the initial review.\nThe sponge was less effective than the diaphragm in preventing pregnancy.\nDiscontinuation rates were higher at 12 months as well.\nOther randomized controlled trials will be needed to resolve the potential role of spermicides in preventing sexually transmitted infections or in causing adverse effects.\n\n\nSimplified text:\nThis review found that the sponge was less effective than the diaphragm in preventing pregnancy. Allergic-type reactions were more common with the sponge, although discontinuation for discomfort differed in the two trials. No new trials have been identified since the initial review. Other randomized controlled trials will be needed to resolve the potential role of spermicides in preventing sexually transmitted infections or in causing adverse effects.","label":["Factuality 2","Fluency 2","Simplicity 2"]},{"id":"10.1002\/14651858.CD011335.pub2_0","text":"Unsimplified text:\nSixteen studies were identified for possible inclusion in the review, six of which were included.\nThree studies investigated prevention and three studies investigated amelioration.\nDue to differences between studies in the interventions being evaluated, a meta-analysis was not possible.\nTwo studies investigated a pharmacological intervention for the prevention of cognitive deficits; memantine compared with placebo, and d-threo-methylphenidate HCL compared with placebo.\nIn the first study the primary cognitive outcome of memory at six months did not reach significance, but there was significant improvement in overall cognitive function compared to placebo, with similar adverse events across groups.\nThe second study found no statistically significant difference between arms, with few adverse events.\nThe third study investigated a rehabilitation program for the prevention of cognitive deficits but did not carry out a statistical comparison of cognitive performance between groups.\nThree studies investigated the use of a pharmacological intervention for the treatment of cognitive deficits; methylphenidate compared with modafinil, two different doses of modafinil, and donepezil compared with placebo.\nThe first study found improvements in cognitive function in both the methylphenidate and modafinil arms; few adverse events were reported.\nThe second study combined treatment arms and found improvements across all cognitive tests, however, a number of adverse events were reported.\nBoth studies were limited by a small sample size.\nThe third study did not find an improvement in the primary cognitive outcome of overall performance, but did find improvement in an individual test of memory, compared to placebo; adverse events were not reported.\nNo non-pharmacological studies for the amelioration of cognitive deficits were eligible.\nThere were a number of limitations across studies but few without high risks of bias.\nThere is supportive evidence that memantine may help prevent cognitive deficits for adults with brain metastases receiving cranial irradiation.\nThere is supportive evidence that donepezil may have a role in treating cognitive deficits in adults with primary or metastatic brain tumours who have been treated with cranial irradiation.\nPatient withdrawal affected the statistical power of both studies.\nFurther research that tries to minimise the withdrawal of consent, and subsequently reduce the requirement for imputation procedures, may offer a higher quality of evidence.\nThere is no strong evidence to support any non-pharmacological interventions (medical or cognitive\/behavioural) in the prevention or amelioration of cognitive deficits.\nNon-randomised studies appear promising but are as yet to be conclusive via translation into high quality evidence.\nFurther research is required.\n\n\nSimplified text:\nThis review of 16 randomised controlled trials found that there was no strong evidence to support the use of pharmacological or psychological treatments for the prevention or amelioration of cognitive deficits in adults with brain tumours who have had cranial irradiation. However, there is some evidence that a drug called memantine may help prevent cognitive deficits for adults who have brain tumour. There is also some support that donepezil may have a role in treating cognitive deficits of adults with primary or metastatic brain cancer who have been treated with cranial radiation. Further research is needed.","label":["Factuality 1","Fluency 2","Simplicity 1"]},{"id":"10.1002\/14651858.CD011335.pub2_1","text":"Unsimplified text:\nSixteen studies were identified for possible inclusion in the review, six of which were included.\nThree studies investigated prevention and three studies investigated amelioration.\nDue to differences between studies in the interventions being evaluated, a meta-analysis was not possible.\nTwo studies investigated a pharmacological intervention for the prevention of cognitive deficits; memantine compared with placebo, and d-threo-methylphenidate HCL compared with placebo.\nIn the first study the primary cognitive outcome of memory at six months did not reach significance, but there was significant improvement in overall cognitive function compared to placebo, with similar adverse events across groups.\nThe second study found no statistically significant difference between arms, with few adverse events.\nThe third study investigated a rehabilitation program for the prevention of cognitive deficits but did not carry out a statistical comparison of cognitive performance between groups.\nThree studies investigated the use of a pharmacological intervention for the treatment of cognitive deficits; methylphenidate compared with modafinil, two different doses of modafinil, and donepezil compared with placebo.\nThe first study found improvements in cognitive function in both the methylphenidate and modafinil arms; few adverse events were reported.\nThe second study combined treatment arms and found improvements across all cognitive tests, however, a number of adverse events were reported.\nBoth studies were limited by a small sample size.\nThe third study did not find an improvement in the primary cognitive outcome of overall performance, but did find improvement in an individual test of memory, compared to placebo; adverse events were not reported.\nNo non-pharmacological studies for the amelioration of cognitive deficits were eligible.\nThere were a number of limitations across studies but few without high risks of bias.\nThere is supportive evidence that memantine may help prevent cognitive deficits for adults with brain metastases receiving cranial irradiation.\nThere is supportive evidence that donepezil may have a role in treating cognitive deficits in adults with primary or metastatic brain tumours who have been treated with cranial irradiation.\nPatient withdrawal affected the statistical power of both studies.\nFurther research that tries to minimise the withdrawal of consent, and subsequently reduce the requirement for imputation procedures, may offer a higher quality of evidence.\nThere is no strong evidence to support any non-pharmacological interventions (medical or cognitive\/behavioural) in the prevention or amelioration of cognitive deficits.\nNon-randomised studies appear promising but are as yet to be conclusive via translation into high quality evidence.\nFurther research is required.\n\n\nSimplified text:\nSix studies were identified for possible inclusion in the review, six of which were eligible. Two studies investigated a pharmacological intervention for the prevention of cognitive deficits; memantine compared with placebo, and d-threo-methylphenidate HCL compared to placebo. In the first study the primary cognitive outcome of memory at six months did not reach significance, but there was a significant improvement in overall cognitive function in both the methylphenidate and modafinil arms, with similar adverse events across groups. There is supportive evidence that memantine may help prevent cognitive deficits for adults with brain metastases receiving cranial irradiation. The second study investigated a rehabilitation program for people with cognitive deficits but did not carry out a statistical comparison of cognitive performance between groups. The third study did not find an improvement in the primary outcome of overall performance, but did find improvement in an individual test of memory, compared to a placebo; adverse events were not reported. No non-pharmacological studies for the amelioration of cognitive disorders were eligible for inclusion in this review. Three studies investigated the use of a medication to treat cognitive deficits in adults with primary or metastatic brain tumours. The first study found improvements in cognitive function, both in both groups, but the second study found no difference between the groups, and the third study found that donepezil may have a role in treating cognitive deficits. There was no strong evidence to support any non-drug interventions (medical or cognitive\/behavioural) in the prevention or amelion of cognitive impairments. Non-randomised studies appear promising but are as yet to be conclusive via translation into high quality evidence. Further research is required. Further trials that minimise the withdrawal of consent, and subsequently reduce the requirement for imputation procedures, may offer a higher quality of evidence.","label":["Factuality 1","Fluency 2","Simplicity 0"]},{"id":"10.1002\/14651858.CD005293.pub2_0","text":"Unsimplified text:\nTwo studies assessed as at high risk of bias, reporting data from 26 analysed participants were included in this review.\nThe age range of participants was from 17 to 55 years.\nBoth trials investigated the effectiveness of low-level laser treatment compared to placebo laser therapy on inferior alveolar sensory deficit as a result of iatrogenic injury.\nPatient-reported altered sensation was partially reported in one study and fully reported in another.\nFollowing treatment with laser therapy, there was some evidence of an improvement in the subjective assessment of neurosensory deficit in the lip and chin areas compared to placebo, though the estimates were imprecise: a difference in mean change in neurosensory deficit of the chin of 8.40 cm (95% confidence interval (CI) 3.67 to 13.13) and a difference in mean change in neurosensory deficit of the lip of 21.79 cm (95% CI 5.29 to 38.29).\nThe overall quality of the evidence for this outcome was very low; the outcome data were fully reported in one small study of 13 patients, with differential drop-out in the control group, and patients suffered only partial loss of sensation.\nNo studies reported on the effects of the intervention on the remaining primary outcomes of pain, difficulty eating or speaking or taste.\nNo studies reported on quality of life or adverse events.\nThe overall quality of the evidence was very low as a result of limitations in the conduct and reporting of the studies, indirectness of the evidence and the imprecision of the results.\nThere is clearly a need for randomised controlled clinical trials to investigate the effectiveness of surgical, medical and psychological interventions for iatrogenic inferior alveolar and lingual nerve injuries.\nPrimary outcomes of this research should include: patient-focused morbidity measures including altered sensation and pain, pain, quantitative sensory testing and the effects of delayed treatment.\n\n\nSimplified text:\nWe included two randomised controlled trials (clinical studies where people are randomly put into one of two or more treatment or control groups) in this review. The age of the participants ranged from 17 to 55 years. Both trials investigated the effectiveness of low-level laser treatment compared to placebo laser treatment on inferior alveolar and lingual nerve injury as a result of iatrogenic injury. The studies were of very low quality. There was some evidence that there was some improvement in the subjective assessment (i.e. the way in which people feel the pain in the affected area of the tongue) following treatment with laser treatment, although the results were imprecise. However, the overall quality of the evidence was very low due to limitations in the conduct of the studies, the way the studies were conducted and the way they were conducted. There is clearly a need for randomise controlled clinical trials to investigate the effects of surgical, medical, psychological or psychological treatments on the effects in patients.","label":["Factuality 1","Fluency 2","Simplicity 0"]},{"id":"10.1002\/14651858.CD005293.pub2_1","text":"Unsimplified text:\nTwo studies assessed as at high risk of bias, reporting data from 26 analysed participants were included in this review.\nThe age range of participants was from 17 to 55 years.\nBoth trials investigated the effectiveness of low-level laser treatment compared to placebo laser therapy on inferior alveolar sensory deficit as a result of iatrogenic injury.\nPatient-reported altered sensation was partially reported in one study and fully reported in another.\nFollowing treatment with laser therapy, there was some evidence of an improvement in the subjective assessment of neurosensory deficit in the lip and chin areas compared to placebo, though the estimates were imprecise: a difference in mean change in neurosensory deficit of the chin of 8.40 cm (95% confidence interval (CI) 3.67 to 13.13) and a difference in mean change in neurosensory deficit of the lip of 21.79 cm (95% CI 5.29 to 38.29).\nThe overall quality of the evidence for this outcome was very low; the outcome data were fully reported in one small study of 13 patients, with differential drop-out in the control group, and patients suffered only partial loss of sensation.\nNo studies reported on the effects of the intervention on the remaining primary outcomes of pain, difficulty eating or speaking or taste.\nNo studies reported on quality of life or adverse events.\nThe overall quality of the evidence was very low as a result of limitations in the conduct and reporting of the studies, indirectness of the evidence and the imprecision of the results.\nThere is clearly a need for randomised controlled clinical trials to investigate the effectiveness of surgical, medical and psychological interventions for iatrogenic inferior alveolar and lingual nerve injuries.\nPrimary outcomes of this research should include: patient-focused morbidity measures including altered sensation and pain, pain, quantitative sensory testing and the effects of delayed treatment.\n\n\nSimplified text:\nThis review included two randomised controlled clinical trials, reporting data from 26 participants. The age range of participants was from 17 to 55 years. Both trials investigated the effectiveness of low-level laser treatment compared to placebo laser therapy on inferior alveolar sensory deficit as a result of iatrogenic injury. No studies reported on quality of life or adverse events. There was some evidence of an improvement in the subjective assessment of neurosensory deficit in the lip and chin areas, though the estimates were imprecise. The overall quality of the evidence for this outcome was very low; the outcome data were fully reported in one small study of 13 patients, with differential drop-out in the control group, and patients suffered only partial loss of sensation. No trials reported on the effects of the intervention on the remaining primary outcomes of pain, difficulty eating or speaking or taste. There is clearly a need for randomised clinical trials to investigate the effectiveness and safety of surgical, medical and psychological interventions for the treatment of inferior and lingual nerve injuries. Primary outcomes of this research should include: patient-focused morbidity measures including altered sensation and pain, pain, quantitative sensory testing and the effect of delayed treatment.","label":["Factuality 2","Fluency 2","Simplicity 2"]},{"id":"10.1002\/14651858.CD009278.pub2_0","text":"Unsimplified text:\nTwo trials (281 pregnancies and 282 fetuses) met our inclusion criteria.\nHowever, the two trials had significant clinical and methodological heterogeneity such that a meta-analysis combining trial data was considered inappropriate.\nOne trial (involving 161 pregnancies) was based on women with a history of diabetes.\nIt showed no statistically significant difference between using combined oestrogen and progestogen and using placebo for all our proposed primary outcomes, namely, miscarriage (risk ratio (RR) 0.95, 95% confidence interval (CI) 0.32 to 2.80), perinatal death (RR 0.94, 95% CI 0.53 to 1.69) and preterm birth (less than 34 weeks of gestation) (RR 0.91, 95% CI 0.80 to 1.04).\nIn terms of this review's secondary outcomes, use of combined oestrogen and progestogen was associated with an increased risk of maternal cancer in the reproductive system (RR 6.65, 95% CI 1.56 to 28.29).\nHowever, for the outcome of cancer other than that of the reproductive system in mothers, there was no difference between groups.\nSimilarly, there were no differences between the combined oestrogen and progestogen group versus placebo for other secondary outcomes reported: low birthweight of less than 2500 g, genital abnormalities in the offspring, abnormalities other than genital tract in the offspring, cancer in the reproductive system in the offspring, or cancer other than of the reproductive system in the offspring.\nThe second study was based on pregnant women who had undergone in-vitro fertilisation (IVF).\nThis study showed no difference in the rate of miscarriage between the combined oestrogen and progesterone group and the no treatment group (RR 0.66, 95% CI 0.23 to 1.85).\nThe study did not report on this review's other primary outcomes (perinatal death or rates of preterm birth), nor on any of our proposed secondary outcomes.\nThere is an insufficient evidence from randomised controlled trials to assess the use of combined oestrogen and progesterone for preventing miscarriages.\nWe strongly recommend further research in this area.\n\n\nSimplified text:\nWe searched the medical literature for randomised controlled trials (clinical trials where women are randomly put into one of two or more treatment or control groups) that compared the effects on miscarriage, perinatal death, and preterm birth rates. We found only two trials that met our review requirements. One study was based on 161 pregnant women who had diabetes. This study did not show a difference in the number of miscarriages between the women who received the treatment and those who did not receive treatment. The other was based of pregnant women with IVF who had undergone IVF and did not report on miscarriage. There was no difference between the treatment groups for all our main outcomes. In addition, there was an increased risk for maternal cancer in the reproductive system in mothers. However, there were not differences in the rate of cancer other than that of the reproductive systems in the mothers or the babies in the babies. We did not find sufficient evidence that the treatment of women with diabetes or IVF to prevent miscarriage was beneficial or harmful. We recommend that further research is carried out in this area.","label":["Factuality 1","Fluency 2","Simplicity 1"]},{"id":"10.1002\/14651858.CD009278.pub2_1","text":"Unsimplified text:\nTwo trials (281 pregnancies and 282 fetuses) met our inclusion criteria.\nHowever, the two trials had significant clinical and methodological heterogeneity such that a meta-analysis combining trial data was considered inappropriate.\nOne trial (involving 161 pregnancies) was based on women with a history of diabetes.\nIt showed no statistically significant difference between using combined oestrogen and progestogen and using placebo for all our proposed primary outcomes, namely, miscarriage (risk ratio (RR) 0.95, 95% confidence interval (CI) 0.32 to 2.80), perinatal death (RR 0.94, 95% CI 0.53 to 1.69) and preterm birth (less than 34 weeks of gestation) (RR 0.91, 95% CI 0.80 to 1.04).\nIn terms of this review's secondary outcomes, use of combined oestrogen and progestogen was associated with an increased risk of maternal cancer in the reproductive system (RR 6.65, 95% CI 1.56 to 28.29).\nHowever, for the outcome of cancer other than that of the reproductive system in mothers, there was no difference between groups.\nSimilarly, there were no differences between the combined oestrogen and progestogen group versus placebo for other secondary outcomes reported: low birthweight of less than 2500 g, genital abnormalities in the offspring, abnormalities other than genital tract in the offspring, cancer in the reproductive system in the offspring, or cancer other than of the reproductive system in the offspring.\nThe second study was based on pregnant women who had undergone in-vitro fertilisation (IVF).\nThis study showed no difference in the rate of miscarriage between the combined oestrogen and progesterone group and the no treatment group (RR 0.66, 95% CI 0.23 to 1.85).\nThe study did not report on this review's other primary outcomes (perinatal death or rates of preterm birth), nor on any of our proposed secondary outcomes.\nThere is an insufficient evidence from randomised controlled trials to assess the use of combined oestrogen and progesterone for preventing miscarriages.\nWe strongly recommend further research in this area.\n\n\nSimplified text:\nThis review identified two randomised controlled trials (involving 161 pregnancies) that compared the use of combined oestrogen and progestogen with placebo. One study was based on pregnant women with a history of diabetes. The second study involved pregnant women who had undergone in-vitro fertilisation (IVF). Both studies were based on women who were at high risk of developing cancer in the reproductive system. In terms of this review's secondary outcomes, use of both drugs was associated with an increased risk of maternal cancer in reproductive system (RR 6.65, 95% confidence interval (CI) 1.56 to 28.29). However, for the outcome of cancer other than that of reproductive system in mothers, there was no difference between groups. Similarly, there were no differences between the groups for other secondary outcomes reported: low birthweight of less than 2500 g, genital abnormalities in the offspring, abnormalities other than genital tract in the female offspring, or cancer in a reproductive system other than reproductive system of the mother. The study did not report on any of our other primary outcomes (perinatal death or rates of preterm birth), nor on our proposed secondary outcomes. There is an insufficient evidence from randomised clinical trials to assess the effectiveness of combining oestrogens and progesterone for preventing miscarriages. We strongly recommend further research in this area.","label":["Factuality 2","Fluency 2","Simplicity 1"]},{"id":"10.1002\/14651858.CD007954_0","text":"Unsimplified text:\nThere were fourteen studies (16 comparisons) with extractable data included in the review, of which ten studies examined TCAs, two examined SSRIs and two included both classes, all compared with placebo.\nThe number of participants in the intervention groups was 1364 and in the placebo groups 919.\nNearly all studies were of short duration, typically 6-8 weeks.\nPooled estimates of efficacy data showed an RR of 1.24, 95% CI 1.11-1.38 in favour of TCAs against placebo.\nFor SSRIs this was 1.28, 95% CI 1.15 to 1.43..\nThe numbers needed to treat (NNT) for TCAs ranged from 7 to 16 {median NNT 9} patient expected event rate ranged from 63% to 26% respectively) and for SSRIs from 7 to 8 {median NNT 7} (patient expected event rate ranged from 48% to 42% respectively) .\nThe numbers needed to harm (NNH for withdrawal due to side effects) ranged from 4 to 30 for TCAs (excluding three studies with no harmful events leading to withdrawal) and 20 to 90 for SSRIs.\nBoth TCAs and SSRIs are effective for depression treated in primary care.\n\n\nSimplified text:\nThis review of fourteen studies found that both TCAs and SSRIs are effective for depression treated in primary care. The number of participants in the intervention groups was 1364 and in the placebo groups 919. Nearly all studies were short duration, typically 6-8 weeks.","label":["Factuality 2","Fluency 1","Simplicity 2"]},{"id":"10.1002\/14651858.CD007954_1","text":"Unsimplified text:\nThere were fourteen studies (16 comparisons) with extractable data included in the review, of which ten studies examined TCAs, two examined SSRIs and two included both classes, all compared with placebo.\nThe number of participants in the intervention groups was 1364 and in the placebo groups 919.\nNearly all studies were of short duration, typically 6-8 weeks.\nPooled estimates of efficacy data showed an RR of 1.24, 95% CI 1.11-1.38 in favour of TCAs against placebo.\nFor SSRIs this was 1.28, 95% CI 1.15 to 1.43..\nThe numbers needed to treat (NNT) for TCAs ranged from 7 to 16 {median NNT 9} patient expected event rate ranged from 63% to 26% respectively) and for SSRIs from 7 to 8 {median NNT 7} (patient expected event rate ranged from 48% to 42% respectively) .\nThe numbers needed to harm (NNH for withdrawal due to side effects) ranged from 4 to 30 for TCAs (excluding three studies with no harmful events leading to withdrawal) and 20 to 90 for SSRIs.\nBoth TCAs and SSRIs are effective for depression treated in primary care.\n\n\nSimplified text:\nThis review of 14 studies found that both TCAs and SSRIs are effective for depression treated in primary care. The number of participants in the intervention groups was 1364 and in the placebo groups 919. Nearly all studies were of short duration, typically 6-8 weeks. The numbers needed to harm (NNH for withdrawal due to side effects) ranged from 4 to 30 for TCAs (excluding three studies with no harmful events leading to withdrawal) and 20 to 90 for SSRI.","label":["Factuality 2","Fluency 1","Simplicity 1"]},{"id":"10.1002\/14651858.CD008039.pub3_0","text":"Unsimplified text:\nNo new studies were found for this update.\nNine included studies (4373 participants, 5223 attacks) compared ibuprofen with placebo or other active comparators; none combined ibuprofen with a self-administered antiemetic.\nAll studies treated attacks with single doses of medication.\nFor ibuprofen 400 mg versus placebo, NNTs for 2-hour pain-free (26% versus 12% with placebo), 2-hour headache relief (57% versus 25%) and 24-hour sustained headache relief (45% versus 19%) were 7.2, 3.2 and 4.0, respectively.\nFor ibuprofen 200 mg versus placebo, NNTs for 2-hour pain-free (20% versus 10%) and 2-hour headache relief (52% versus 37%) were 9.7 and 6.3, respectively.\nThe higher dose was significantly better than the lower dose for 2-hour headache relief.\nSoluble formulations of ibuprofen 400 mg were better than standard tablets for 1-hour, but not 2-hour headache relief.\nSimilar numbers of participants experienced adverse events, which were mostly mild and transient, with ibuprofen and placebo.\nIbuprofen 400 mg did not differ from rofecoxib 25 mg for 2-hour headache relief or 24-hour headache relief.\nWe found no new studies since the last version of this review.\nIbuprofen is an effective treatment for acute migraine headaches, providing pain relief in about half of sufferers, but complete relief from pain and associated symptoms for only a minority.\nNNTs for all efficacy outcomes were better with 400 mg than 200 mg in comparisons with placebo, and soluble formulations provided more rapid relief.\nAdverse events were mostly mild and transient, occurring at the same rate as with placebo.\n\n\nSimplified text:\nWe searched the medical literature to find studies that compared ibuprofen with placebo, rofecoxib or other active treatments for acute migraine headaches. We found nine studies (4373 participants, 5223 attacks) that compared the effects on pain, headache and associated symptoms with placebo or another active treatment. All studies treated attacks with single doses of medication. The results showed that the higher dose was significantly better than the lower dose for pain relief in about half of the patients. Soluble formulations were better than standard tablets, but not 2-hour headache relief. Similar numbers of patients experienced side effects, which were mostly mild and transient, and occurred at the same rate as with placebo.","label":["Factuality 1","Fluency 2","Simplicity 2"]},{"id":"10.1002\/14651858.CD008039.pub3_1","text":"Unsimplified text:\nNo new studies were found for this update.\nNine included studies (4373 participants, 5223 attacks) compared ibuprofen with placebo or other active comparators; none combined ibuprofen with a self-administered antiemetic.\nAll studies treated attacks with single doses of medication.\nFor ibuprofen 400 mg versus placebo, NNTs for 2-hour pain-free (26% versus 12% with placebo), 2-hour headache relief (57% versus 25%) and 24-hour sustained headache relief (45% versus 19%) were 7.2, 3.2 and 4.0, respectively.\nFor ibuprofen 200 mg versus placebo, NNTs for 2-hour pain-free (20% versus 10%) and 2-hour headache relief (52% versus 37%) were 9.7 and 6.3, respectively.\nThe higher dose was significantly better than the lower dose for 2-hour headache relief.\nSoluble formulations of ibuprofen 400 mg were better than standard tablets for 1-hour, but not 2-hour headache relief.\nSimilar numbers of participants experienced adverse events, which were mostly mild and transient, with ibuprofen and placebo.\nIbuprofen 400 mg did not differ from rofecoxib 25 mg for 2-hour headache relief or 24-hour headache relief.\nWe found no new studies since the last version of this review.\nIbuprofen is an effective treatment for acute migraine headaches, providing pain relief in about half of sufferers, but complete relief from pain and associated symptoms for only a minority.\nNNTs for all efficacy outcomes were better with 400 mg than 200 mg in comparisons with placebo, and soluble formulations provided more rapid relief.\nAdverse events were mostly mild and transient, occurring at the same rate as with placebo.\n\n\nSimplified text:\nWe found nine studies (4373 participants, 5223 attacks) comparing ibuprofen with placebo or other active comparators; none of the studies combined ibuprafen with a self-administered antiemetic. The higher dose was better than the lower dose for 2-hour headache relief, but not for 24-hour relief. Soluble formulations were better than standard tablets for 1-hour, but did not provide complete headache relief. Similar numbers of participants experienced adverse events, which were mostly mild and transient. Adverse events occurred at the same rate as with placebo. Ibuproen 400 mg did not differ from rofecoxib 25 mg in terms of pain relief or headache relief for 2 hours or 24 hours. No new studies were found since the last version of this review.","label":["Factuality 1","Fluency 2","Simplicity 2"]},{"id":"10.1002\/14651858.CD009729.pub2_0","text":"Unsimplified text:\nWe included 43 randomized controlled trials (3497 participants with dry eye).\nDue to the heterogeneity of study characteristics among the included trials with respect to types of diagnostic criteria, interventions, comparisons, and measurements taken, our ability to perform meta-analyses was limited.\nThe review found that, in general, there was uncertainty whether different OTC artificial tears provide similar relief of signs and symptoms when compared with each other or placebo.\nNevertheless, we found that 0.2% polyacrylic acid-based artificial tears were consistently more effective at treating dry eye symptoms than 1.4% polyvinyl alcohol-based artificial tears in two trials assessing this comparison (175 participants).\nAll other included artificial tears produced contradictory between-group results or found no between-group differences.\nOur review also found that OTC artificial tears may be generally safe, but not without adverse events.\nOverall, we assessed the quality of evidence as low due to high risks of bias among included trials and poor reporting of outcome measures which were insufficient for quantitative analysis.\nFurthermore, we identified an additional 18 potentially eligible trials that were reported only in clinical trial registers with no associated results or publications.\nThese trials reportedly enrolled 2079 total participants for whom no data are available.\nSuch lack of reporting of trial results represents a high risk of publication bias.\nOTC artificial tears may be safe and effective means for treating dry eye syndrome; the literature indicates that the majority of OTC artificial tears may have similar efficacies.\nThis conclusion could be greatly skewed by the inconsistencies in study designs and inconsistencies in reporting trial results.\nAdditional research is therefore needed before we can draw robust conclusions about the effectiveness of individual OTC artificial tear formulations.\n\n\nSimplified text:\nWe found 43 randomized controlled trials involving 3497 participants with dry eye. The review found that, in general, there was uncertainty whether different OTC artificial tears provide similar relief of dry eye symptoms when compared with each other or placebo. However, we found that the majority of OTC tears may have similar efficacies. We also found that there were inconsistencies among the included trials in the way they were conducted, making it difficult for us to combine their results. Overall, we assessed the quality of the evidence as low, mainly because of the inconsistency among the trials and poor reporting. Further research is needed before we can draw any firm conclusions about the effectiveness or safety of individual OTO artificial tears.","label":["Factuality 2","Fluency 2","Simplicity 1"]},{"id":"10.1002\/14651858.CD009729.pub2_1","text":"Unsimplified text:\nWe included 43 randomized controlled trials (3497 participants with dry eye).\nDue to the heterogeneity of study characteristics among the included trials with respect to types of diagnostic criteria, interventions, comparisons, and measurements taken, our ability to perform meta-analyses was limited.\nThe review found that, in general, there was uncertainty whether different OTC artificial tears provide similar relief of signs and symptoms when compared with each other or placebo.\nNevertheless, we found that 0.2% polyacrylic acid-based artificial tears were consistently more effective at treating dry eye symptoms than 1.4% polyvinyl alcohol-based artificial tears in two trials assessing this comparison (175 participants).\nAll other included artificial tears produced contradictory between-group results or found no between-group differences.\nOur review also found that OTC artificial tears may be generally safe, but not without adverse events.\nOverall, we assessed the quality of evidence as low due to high risks of bias among included trials and poor reporting of outcome measures which were insufficient for quantitative analysis.\nFurthermore, we identified an additional 18 potentially eligible trials that were reported only in clinical trial registers with no associated results or publications.\nThese trials reportedly enrolled 2079 total participants for whom no data are available.\nSuch lack of reporting of trial results represents a high risk of publication bias.\nOTC artificial tears may be safe and effective means for treating dry eye syndrome; the literature indicates that the majority of OTC artificial tears may have similar efficacies.\nThis conclusion could be greatly skewed by the inconsistencies in study designs and inconsistencies in reporting trial results.\nAdditional research is therefore needed before we can draw robust conclusions about the effectiveness of individual OTC artificial tear formulations.\n\n\nSimplified text:\nWe included 43 randomised controlled trials (3497 participants with dry eye) in this review. Due to the heterogeneity of study characteristics among the included trials with respect to types of diagnostic criteria, interventions, comparisons, and measurements taken, our ability to perform meta-analyses was limited. The review found that, in general, there was uncertainty whether different OTC artificial tears provide similar relief of signs and symptoms when compared with each other or placebo. Nevertheless, we found that 0.2% polyacrylic acid-based artificial tears were consistently more effective at treating dry eye symptoms than 1.4% polyvinyl alcohol-based tears in two trials assessing this comparison (175 participants). Our review also found that OTC tears may be generally safe, but not without adverse events. Overall, we assessed the quality of evidence as low due to high risks of bias among included trials and poor reporting of outcome measures which were insufficient for quantitative analysis. Furthermore, we identified an additional 18 potentially eligible trials that were reported only in clinical trial registers with no associated results or publications. These trials reportedly enrolled 2079 total participants for whom no data are available. Additional research is therefore needed before we can draw robust conclusions about the effectiveness of individual OTC tear formulations.","label":["Factuality 2","Fluency 2","Simplicity 2"]},{"id":"10.1002\/14651858.CD006517.pub3_0","text":"Unsimplified text:\nOne randomised trial in 136 patients studied maintaining lamivudine in second-line regimens or not.\nThere was no difference in virological outcomes in the group who maintained lamivudine and those who did not in their subsequent regimens.\nTwo other small observational studies reported in abstract form also did not report a difference in the proportion of those with viral suppression after six months and time to HIV-1 RNA suppression among those on a lamivudine (3TC) or emtricitabine (FTC) regimen compared to those on a 3TC\/FTC-sparing second-line regimen.\nThere were no trials identified comparing boosted protease inhibitors (PIs) or nucleoside backbone combinations after first-line failure on non-thymidine analog combinations.\nObservational studies of populations starting ART in resource-limited settings suggest that short-term response on boosted PI-based regimens is encouraging.\nThere is limited evidence to evaluate second-line therapies in patients with HIV who fail first-line treatment with a WHO-recommended regimen.\nOne randomised trial in 136 patients and two observational studies (both of low quality) suggest no difference in virological suppression whether or not lamivudine is maintained in a second-line regimen.\nWhile outcomes of second-line regimens with boosted PIs are favourable in general, there are no studies comparing boosted PIs directly in populations starting second-line regimens.\nCurrent recommendations are based on available resources and patient- and public-health-level considerations.\n\n\nSimplified text:\nThis review found one small randomised controlled study in 136 patients that compared the effect of maintaining the antiretroviral drug, lamivudine, in second-line treatment in patients with HIV who had failed to receive the recommended regimen. There was not enough evidence to determine whether or not there was any difference between those who maintained the drug and those who did not in their subsequent treatment. Two other small observational studies did not show a difference in the proportion of patients with viral suppression after six months and time to viral suppression among those who were maintained in a lamivuzine regimen compared to those on a 3TC\/FTC regimen.","label":["Factuality 2","Fluency 1","Simplicity 1"]},{"id":"10.1002\/14651858.CD006517.pub3_1","text":"Unsimplified text:\nOne randomised trial in 136 patients studied maintaining lamivudine in second-line regimens or not.\nThere was no difference in virological outcomes in the group who maintained lamivudine and those who did not in their subsequent regimens.\nTwo other small observational studies reported in abstract form also did not report a difference in the proportion of those with viral suppression after six months and time to HIV-1 RNA suppression among those on a lamivudine (3TC) or emtricitabine (FTC) regimen compared to those on a 3TC\/FTC-sparing second-line regimen.\nThere were no trials identified comparing boosted protease inhibitors (PIs) or nucleoside backbone combinations after first-line failure on non-thymidine analog combinations.\nObservational studies of populations starting ART in resource-limited settings suggest that short-term response on boosted PI-based regimens is encouraging.\nThere is limited evidence to evaluate second-line therapies in patients with HIV who fail first-line treatment with a WHO-recommended regimen.\nOne randomised trial in 136 patients and two observational studies (both of low quality) suggest no difference in virological suppression whether or not lamivudine is maintained in a second-line regimen.\nWhile outcomes of second-line regimens with boosted PIs are favourable in general, there are no studies comparing boosted PIs directly in populations starting second-line regimens.\nCurrent recommendations are based on available resources and patient- and public-health-level considerations.\n\n\nSimplified text:\nOne randomised trial in 136 patients and two observational studies (both of low quality) suggest no difference in virological outcomes in the group who maintained lamivudine and those who did not in their subsequent regimens. Two other small observational studies reported in abstract form also did not report a difference in the proportion of those with viral suppression after six months and time to HIV-1 RNA suppression among those on a lamivuxine (3TC) or emtricitabine (FTC) regimen compared to those on 3TC\/FTC-sparing second-line regimen. There were no trials identified comparing boosted protease inhibitors (PIs) or nucleoside backbone combinations after first-line failure on non-thymidine analog combinations.","label":["Factuality 2","Fluency 1","Simplicity 2"]},{"id":"10.1002\/14651858.CD008874.pub2_0","text":"Unsimplified text:\nWe included 133 (127 cohort type and 6 case-control) studies involving 844,206 participants.\nWe evaluated a total of seven different prespecified index tests in the 133 studies, as well as 69 non-prespecified, and 32 combinations.\nFor the prespecified index tests, we found six studies for the Mallampati test, 105 for the modified Mallampati test, six for the Wilson risk score, 52 for thyromental distance, 18 for sternomental distance, 34 for the mouth opening test, and 30 for the upper lip bite test.\nDifficult face mask ventilation was the reference standard in seven studies, difficult laryngoscopy in 92 studies, difficult tracheal intubation in 50 studies, and failed intubation in two studies.\nAcross all studies, we judged the risk of bias to be variable for the different domains; we mostly observed low risk of bias for patient selection, flow and timing, and unclear risk of bias for reference standard and index test.\nApplicability concerns were generally low for all domains.\nFor difficult laryngoscopy, the summary sensitivity ranged from 0.22 (95% confidence interval (CI) 0.13 to 0.33; mouth opening test) to 0.67 (95% CI 0.45 to 0.83; upper lip bite test) and the summary specificity ranged from 0.80 (95% CI 0.74 to 0.85; modified Mallampati test) to 0.95 (95% CI 0.88 to 0.98; Wilson risk score).\nThe upper lip bite test for diagnosing difficult laryngoscopy provided the highest sensitivity compared to the other tests (P < 0.001).\nFor difficult tracheal intubation, summary sensitivity ranged from 0.24 (95% CI 0.12 to 0.43; thyromental distance) to 0.51 (95% CI 0.40 to 0.61; modified Mallampati test) and the summary specificity ranged from 0.87 (95% CI 0.82 to 0.91; modified Mallampati test) to 0.93 (0.87 to 0.96; mouth opening test).\nThe modified Mallampati test had the highest sensitivity for diagnosing difficult tracheal intubation compared to the other tests (P < 0.001).\nFor difficult face mask ventilation, we could only estimate summary sensitivity (0.17, 95% CI 0.06 to 0.39) and specificity (0.90, 95% CI 0.81 to 0.95) for the modified Mallampati test.\nBedside airway examination tests, for assessing the physical status of the airway in adults with no apparent anatomical airway abnormalities, are designed as screening tests.\nScreening tests are expected to have high sensitivities.\nWe found that all investigated index tests had relatively low sensitivities with high variability.\nIn contrast, specificities were consistently and markedly higher than sensitivities across all tests.\nThe standard bedside airway examination tests should be interpreted with caution, as they do not appear to be good screening tests.\nAmong the tests we examined, the upper lip bite test showed the most favourable diagnostic test accuracy properties.\nGiven the paucity of available data, future research is needed to develop tests with high sensitivities to make them useful, and to consider their use for screening difficult face mask ventilation and failed intubation.\nThe 27 studies in 'Studies awaiting classification' may alter the conclusions of the review, once we have assessed them.\n\n\nSimplified text:\nWe found 133 studies involving 844,206 participants. We found that we could not combine the results from all the studies because the studies were too different from each other. The studies were small, and the results were not consistent across the studies. However, we found that the upper lip bite test was the most accurate test for diagnosing difficult face mask ventilation and the modified Mallampati test had the highest accuracy. We also found that there were too few studies for us to draw any conclusions about the accuracy of these tests. More research is needed in this area.","label":["Factuality 1","Fluency 2","Simplicity 2"]},{"id":"10.1002\/14651858.CD008874.pub2_1","text":"Unsimplified text:\nWe included 133 (127 cohort type and 6 case-control) studies involving 844,206 participants.\nWe evaluated a total of seven different prespecified index tests in the 133 studies, as well as 69 non-prespecified, and 32 combinations.\nFor the prespecified index tests, we found six studies for the Mallampati test, 105 for the modified Mallampati test, six for the Wilson risk score, 52 for thyromental distance, 18 for sternomental distance, 34 for the mouth opening test, and 30 for the upper lip bite test.\nDifficult face mask ventilation was the reference standard in seven studies, difficult laryngoscopy in 92 studies, difficult tracheal intubation in 50 studies, and failed intubation in two studies.\nAcross all studies, we judged the risk of bias to be variable for the different domains; we mostly observed low risk of bias for patient selection, flow and timing, and unclear risk of bias for reference standard and index test.\nApplicability concerns were generally low for all domains.\nFor difficult laryngoscopy, the summary sensitivity ranged from 0.22 (95% confidence interval (CI) 0.13 to 0.33; mouth opening test) to 0.67 (95% CI 0.45 to 0.83; upper lip bite test) and the summary specificity ranged from 0.80 (95% CI 0.74 to 0.85; modified Mallampati test) to 0.95 (95% CI 0.88 to 0.98; Wilson risk score).\nThe upper lip bite test for diagnosing difficult laryngoscopy provided the highest sensitivity compared to the other tests (P < 0.001).\nFor difficult tracheal intubation, summary sensitivity ranged from 0.24 (95% CI 0.12 to 0.43; thyromental distance) to 0.51 (95% CI 0.40 to 0.61; modified Mallampati test) and the summary specificity ranged from 0.87 (95% CI 0.82 to 0.91; modified Mallampati test) to 0.93 (0.87 to 0.96; mouth opening test).\nThe modified Mallampati test had the highest sensitivity for diagnosing difficult tracheal intubation compared to the other tests (P < 0.001).\nFor difficult face mask ventilation, we could only estimate summary sensitivity (0.17, 95% CI 0.06 to 0.39) and specificity (0.90, 95% CI 0.81 to 0.95) for the modified Mallampati test.\nBedside airway examination tests, for assessing the physical status of the airway in adults with no apparent anatomical airway abnormalities, are designed as screening tests.\nScreening tests are expected to have high sensitivities.\nWe found that all investigated index tests had relatively low sensitivities with high variability.\nIn contrast, specificities were consistently and markedly higher than sensitivities across all tests.\nThe standard bedside airway examination tests should be interpreted with caution, as they do not appear to be good screening tests.\nAmong the tests we examined, the upper lip bite test showed the most favourable diagnostic test accuracy properties.\nGiven the paucity of available data, future research is needed to develop tests with high sensitivities to make them useful, and to consider their use for screening difficult face mask ventilation and failed intubation.\nThe 27 studies in 'Studies awaiting classification' may alter the conclusions of the review, once we have assessed them.\n\n\nSimplified text:\nWe included 133 studies involving 844,206 participants in our review. We found seven different prespecified index tests in the 133 studies, as well as 69 non-prespecified, and 32 combinations of these tests. We also found six studies for the Mallampati test, 105 for the modified version of the tested test, six for the Wilson risk score, 52 for thyromental distance, 18 for sternomental distance and 34 for the upper lip bite test. We judged the risk of bias to be variable for the different domains; we mostly observed low risk of systematic bias for patient selection, flow and timing, and unclear risk of selection bias for reference standard and index test. The standard bedside airway examination tests should be interpreted with caution, as they do not appear to be good screening tests. Among the tests we examined, we found that the mouth opening test showed the most favourable diagnostic test accuracy properties. Given the paucity of available data, future research is needed to develop tests with high sensitivities to make them useful, and to consider their use for screening difficult face mask ventilation and failed intubation. The 27 studies awaiting classification in 'Studies awaiting classification' may alter the conclusions of the review, once we have assessed them.","label":["Factuality 1","Fluency 2","Simplicity 0"]},{"id":"10.1002\/14651858.CD003048.pub3_0","text":"Unsimplified text:\nSixty-three studies met the inclusion criteria with a total of 8014 participants.\nOf these, 56 trials recruited infants and young children.\nThe trials varied in the definition used for acute diarrhoea and the end of the diarrhoeal illness, as well as in the risk of bias.\nThe trials were undertaken in a wide range of different settings and also varied greatly in organisms tested, dosage, and participants' characteristics.\nNo adverse events were attributed to the probiotic intervention.\nProbiotics reduced the duration of diarrhoea, although the size of the effect varied considerably between studies.\nThe average of the effect was significant for mean duration of diarrhoea (mean difference 24.76 hours; 95% confidence interval 15.9 to 33.6 hours; n=4555, trials=35) diarrhoea lasting 4 days (risk ratio 0.41; 0.32 to 0.53; n=2853, trials=29) and stool frequency on day 2 (mean difference 0.80; 0.45 to 1.14; n=2751, trials=20).\nThe differences in effect size between studies was not explained by study quality, probiotic strain, the number of different strains, the viability of the organisms, dosage of organisms, the causes of diarrhoea, or the severity of the diarrhoea, or whether the studies were done in developed or developing countries.\nUsed alongside rehydration therapy, probiotics appear to be safe and have clear beneficial effects in shortening the duration and reducing stool frequency in acute infectious diarrhoea.\nHowever, more research is needed to guide the use of particular probiotic regimens in specific patient groups.\n\n\nSimplified text:\nThis review found that probiotics can reduce the duration of acute infectious diarrhoea, although the size of the effect varied considerably between studies. Probiotics appear to be safe and have clear beneficial effects in shortening the duration and reducing stool frequency. However, more research is needed to guide the use of particular probiotic regimens in specific patient groups.","label":["Factuality 2","Fluency 2","Simplicity 2"]},{"id":"10.1002\/14651858.CD003048.pub3_1","text":"Unsimplified text:\nSixty-three studies met the inclusion criteria with a total of 8014 participants.\nOf these, 56 trials recruited infants and young children.\nThe trials varied in the definition used for acute diarrhoea and the end of the diarrhoeal illness, as well as in the risk of bias.\nThe trials were undertaken in a wide range of different settings and also varied greatly in organisms tested, dosage, and participants' characteristics.\nNo adverse events were attributed to the probiotic intervention.\nProbiotics reduced the duration of diarrhoea, although the size of the effect varied considerably between studies.\nThe average of the effect was significant for mean duration of diarrhoea (mean difference 24.76 hours; 95% confidence interval 15.9 to 33.6 hours; n=4555, trials=35) diarrhoea lasting 4 days (risk ratio 0.41; 0.32 to 0.53; n=2853, trials=29) and stool frequency on day 2 (mean difference 0.80; 0.45 to 1.14; n=2751, trials=20).\nThe differences in effect size between studies was not explained by study quality, probiotic strain, the number of different strains, the viability of the organisms, dosage of organisms, the causes of diarrhoea, or the severity of the diarrhoea, or whether the studies were done in developed or developing countries.\nUsed alongside rehydration therapy, probiotics appear to be safe and have clear beneficial effects in shortening the duration and reducing stool frequency in acute infectious diarrhoea.\nHowever, more research is needed to guide the use of particular probiotic regimens in specific patient groups.\n\n\nSimplified text:\nThis review included 63 studies with a total of 8014 participants. The trials were undertaken in a wide range of different settings and also varied greatly in organisms tested, dosage, and participants' characteristics. Of these, 56 trials recruited infants and young children. Probiotics reduced the duration of diarrhoea, although the size of the effect varied considerably between studies. No adverse events were attributed to the probiotic intervention. The differences in effect size between studies was not explained by study quality, probiotic strain, the number of different probiotic strains, the viability of the organisms, dosage of organisms, the causes of diarrhoeal illness, or whether the studies were done in developed or developing countries. Used alongside rehydration therapy, probiotics appear to be safe and have clear beneficial effects in shortening the duration and reducing stool frequency in acute infectious diarrhoeas. However, more research is needed to guide the use of particular probiotic regimens in specific patient groups.","label":["Factuality 2","Fluency 2","Simplicity 1"]},{"id":"10.1002\/14651858.CD009929.pub2_0","text":"Unsimplified text:\nWe included only one study that compared nidotherapy-enhanced standard care with standard care alone (total 52 participants); this study was classified by its authors as a 'pilot study'.\nThe duration of the included study was 18 months in total.\nThe single study examined the short-term (up to six months) and medium-term (between six and 12 months) effects of nidotherapy-enhanced standard care versus standard care.\nNidotherapy-enhanced standard care was favoured over standard care for social functioning in both the short term (n = 50, 1 RCT, MD -2.10, 95% CI -4.66 to 0.46) and medium term (n = 37, 1 RCT, MD -1.70, 95% CI -4.60 to 1.20, Very low quality); however, these results did not reach statistical significance.\nResults concerning engagement with non-inpatient services favoured the intervention group in both the short term (n = 50, 1 RCT, MD 2.00, 95% CI 0.13 to 3.87) and medium term (n = 37, 1 RCT, MD 1.70, 95% CI -0.09 to 3.49), with statistical significance evident in the short term, but not in the medium term.\nResults of people leaving the study early favoured the intervention in the short term (n = 52, 1 RCT, RR 0.86, 95% CI 0.06 to 12.98), with slight favour of the control group at medium term (n = 50, 1 RCT, RR 0.99, 95% CI 0.39 to 2.54); again, these results did not reach statistical significance.\nResults for the adverse effects\/events of death (measured by 12 months) favoured the intervention (n = 52, 1 RCT, RR 0.29, 95% CI 0.01 to 6.74, Very low quality) but with no statistical significance.\nSkewed results were available for mental state, service use, and economic outcomes, and present a mixed picture of the benefits of nidotherapy.\nFurther research is needed into the possible benefits or harms of this newly-formulated therapy.\nUntil such research is available, patients, clinicians, managers and policymakers should consider it an experimental approach.\n\n\nSimplified text:\nWe found only a single randomised controlled trial that compared the effects on social functioning, mental state, service use, and economic effects. We found that people who received nidotherapy were more likely than those who did not receive it to engage in social activities such as social activities in both the short and medium-term. However, these results did not reach statistical significance. People who received the treatment were less likely to engage with non-inpatient services in the short-term, but more likely to do so in the medium term. People receiving the treatment also had fewer adverse effects on their mental state than those not receiving it. People in the treatment group were also less likely than people not receiving treatment to experience side effects of the treatment. The quality of the study was rated as very low or very low, meaning that we are very uncertain about the results. Further research is needed into the possible benefits or harms of this treatment. Until such research is available, patients, clinicians, managers and policymakers should consider it an experimental approach.","label":["Factuality 0","Fluency 1","Simplicity 0"]},{"id":"10.1002\/14651858.CD009929.pub2_1","text":"Unsimplified text:\nWe included only one study that compared nidotherapy-enhanced standard care with standard care alone (total 52 participants); this study was classified by its authors as a 'pilot study'.\nThe duration of the included study was 18 months in total.\nThe single study examined the short-term (up to six months) and medium-term (between six and 12 months) effects of nidotherapy-enhanced standard care versus standard care.\nNidotherapy-enhanced standard care was favoured over standard care for social functioning in both the short term (n = 50, 1 RCT, MD -2.10, 95% CI -4.66 to 0.46) and medium term (n = 37, 1 RCT, MD -1.70, 95% CI -4.60 to 1.20, Very low quality); however, these results did not reach statistical significance.\nResults concerning engagement with non-inpatient services favoured the intervention group in both the short term (n = 50, 1 RCT, MD 2.00, 95% CI 0.13 to 3.87) and medium term (n = 37, 1 RCT, MD 1.70, 95% CI -0.09 to 3.49), with statistical significance evident in the short term, but not in the medium term.\nResults of people leaving the study early favoured the intervention in the short term (n = 52, 1 RCT, RR 0.86, 95% CI 0.06 to 12.98), with slight favour of the control group at medium term (n = 50, 1 RCT, RR 0.99, 95% CI 0.39 to 2.54); again, these results did not reach statistical significance.\nResults for the adverse effects\/events of death (measured by 12 months) favoured the intervention (n = 52, 1 RCT, RR 0.29, 95% CI 0.01 to 6.74, Very low quality) but with no statistical significance.\nSkewed results were available for mental state, service use, and economic outcomes, and present a mixed picture of the benefits of nidotherapy.\nFurther research is needed into the possible benefits or harms of this newly-formulated therapy.\nUntil such research is available, patients, clinicians, managers and policymakers should consider it an experimental approach.\n\n\nSimplified text:\nWe found only one study that compared nidotherapy-enhanced standard care with standard care alone (total 52 participants). The duration of the included study was 18 months in total. This study was classified by its authors as a 'pilot study'. The single study examined the short-term and medium-term (up to six months) and between six and 12 months) effects of nid therapies for people with schizophrenia. Skewed results were available for mental state, service use, and economic outcomes, and present a mixed picture of the benefits and harms. Further research is needed into the possible benefits or harms of this newly-formulated therapy. Until such research is available, patients, clinicians, managers and policymakers should consider it an experimental approach.","label":["Factuality 2","Fluency 2","Simplicity 2"]},{"id":"10.1002\/14651858.CD011790.pub2_0","text":"Unsimplified text:\nOur searches identified two new published studies with classic design, and one new published study with an enriched enrolment randomised withdrawal (EERW) design.\nWe included eight studies.\nFive (3283 participants) had a classic design in which participants were randomised at the start of the study to pregabalin (150, 300, 450, or 600 mg daily) or placebo, with assessment after 8 to 13 weeks of stable treatment.\nNo studies included active comparators.\nStudies had low risk of bias, except that the last observation carried forward (LOCF) imputation method used in analyses of the primary outcomes could overestimate treatment effect.\nPregabalin increased the number of participants experiencing substantial benefit (at least 50% pain intensity reduction after 12 or 13 weeks' stable treatment (450 mg: RR 1.8, 95% CI 1.4 to 2.1, 1874 participants, 5 studies, high quality evidence)).\nSubstantial benefit with pregabalin 300 to 600 mg was experienced by about 14% of participants with placebo, but about 9% more with pregabalin 300 to 600 mg (22% to 24%) (high quality evidence).\nPregabalin increased the number of participants experiencing moderate benefit (at least 30% pain intensity reduction after 12 or 13 weeks' stable treatment) (450 mg: RR 1.5, 95% CI (1.3 to 1.7), 1874 participants, 5 studies, high quality evidence).\nModerate benefit with pregabalin 300 to 600 mg was experienced by about 28% of participants with placebo, but about 11% more with pregabalin 300 to 600 mg (39% to 43%) (high quality evidence).\nA similar magnitude of effect was found using PGIC of 'very much improved' and 'much or very much improved'.\nNNTs for these outcomes ranged between 7 and 14 (high quality evidence).\nA small study (177 participants) compared nightly with twice-daily pregabalin, and concluded there was no difference in effect.\nTwo studies (1492 participants began initial dose titration, 687 participants randomised) had an EERW design in which those with good pain relief after titration were randomised, double blind, to continuing the effective dose (300 to 600 mg pregabalin daily) or a short down-titration to placebo for 13 or 26 weeks.\nWe calculated the outcome of maintained therapeutic response (MTR) without withdrawal, equivalent to a moderate benefit.\nOf those randomised, 40% had MTR with pregabalin and 20% with placebo (high quality evidence).\nThe NNT was 5, but normalised to the starting population tested it was 12.\nAbout 10% of the initial population would have achieved the MTR outcome, similar to the result from studies of classic design.\nMTR had no imputation concerns.\nThe majority (70% to 90%) of participants in all treatment groups experienced adverse events.\nSpecific adverse events were more common with pregabalin than placebo, in particular dizziness, somnolence, weight gain, and peripheral oedema, with number needed to harm of 3.7, 7.4, 18, and 19 respectively for all doses combined (high quality evidence).\nSerious adverse events did not differ between active treatment groups and placebo (very low quality evidence).\nWithdrawals for any reason were more common with pregabalin than placebo only with the 600 mg dose in studies of classic design.\nWithdrawals due to adverse events were about 10% higher with pregabalin than placebo, but withdrawals due to lack of efficacy were about 6% lower (high quality evidence).\nPregabalin 300 to 600 mg produces a major reduction in pain intensity over 12 to 26 weeks with tolerable adverse events for a small proportion of people (about 10% more than placebo) with moderate or severe pain due to fibromyalgia.\nThe degree of pain relief is known to be accompanied by improvements in other symptoms, quality of life, and function.\nThese results are similar to other effective medicines in fibromyalgia (milnacipran, duloxetine).\n\n\nSimplified text:\nWe searched the medical literature up until August 2015. We found eight studies. Five studies had a classic design in which participants were randomised at the start of the treatment to either pregabalin (150, 300, 450, or 600 mg daily) or placebo, with assessment after 8 to 13 weeks of treatment. Two studies had an EERW design, where those with good pain relief after starting treatment were randomly assigned to either continuing the treatment (300 to 600 mg or placebo daily), or stopping treatment at the end of the study, or continuing treatment for at least 26 weeks. We included eight studies in this review. The studies had low to very low methodological quality, which means that we are uncertain about the results. The evidence is current to August 2016. Pregabalin increased the number of people with moderate or severe pain who experienced substantial or moderate pain reduction after 12 or 13 weeks' treatment. This was similar to other effective medicines in fibromyalgia, such as duloxetine, but was not as good as other painkillers. The number needed for pain relief was about 1.7, 7.4, 18, 18 and 19 for moderate, moderate, or very good pain reduction, and about 2.3, 10, 15, 20, 24, or 24 for moderate or very much better pain relief. The quality of the evidence ranged from very low quality to very good quality. Withdrawals from the studies were more common than with placebo (withdrawals due to side effects were about 10% more common), but withdrawals were about 6% lower (high quality of evidence), mainly because of side effects. Serious side effects did not differ between active treatment and placebo (very low quality evidence), which means we are very uncertain about these results. Side effects included dizziness, somnolence, weight gain, weight loss, nausea, vomiting, dry mouth, abdominal pain, tiredness, drowsiness, and tiredness. The majority of people in the studies experienced side effects with the drugs.","label":["Factuality 1","Fluency 1","Simplicity 0"]},{"id":"10.1002\/14651858.CD011790.pub2_1","text":"Unsimplified text:\nOur searches identified two new published studies with classic design, and one new published study with an enriched enrolment randomised withdrawal (EERW) design.\nWe included eight studies.\nFive (3283 participants) had a classic design in which participants were randomised at the start of the study to pregabalin (150, 300, 450, or 600 mg daily) or placebo, with assessment after 8 to 13 weeks of stable treatment.\nNo studies included active comparators.\nStudies had low risk of bias, except that the last observation carried forward (LOCF) imputation method used in analyses of the primary outcomes could overestimate treatment effect.\nPregabalin increased the number of participants experiencing substantial benefit (at least 50% pain intensity reduction after 12 or 13 weeks' stable treatment (450 mg: RR 1.8, 95% CI 1.4 to 2.1, 1874 participants, 5 studies, high quality evidence)).\nSubstantial benefit with pregabalin 300 to 600 mg was experienced by about 14% of participants with placebo, but about 9% more with pregabalin 300 to 600 mg (22% to 24%) (high quality evidence).\nPregabalin increased the number of participants experiencing moderate benefit (at least 30% pain intensity reduction after 12 or 13 weeks' stable treatment) (450 mg: RR 1.5, 95% CI (1.3 to 1.7), 1874 participants, 5 studies, high quality evidence).\nModerate benefit with pregabalin 300 to 600 mg was experienced by about 28% of participants with placebo, but about 11% more with pregabalin 300 to 600 mg (39% to 43%) (high quality evidence).\nA similar magnitude of effect was found using PGIC of 'very much improved' and 'much or very much improved'.\nNNTs for these outcomes ranged between 7 and 14 (high quality evidence).\nA small study (177 participants) compared nightly with twice-daily pregabalin, and concluded there was no difference in effect.\nTwo studies (1492 participants began initial dose titration, 687 participants randomised) had an EERW design in which those with good pain relief after titration were randomised, double blind, to continuing the effective dose (300 to 600 mg pregabalin daily) or a short down-titration to placebo for 13 or 26 weeks.\nWe calculated the outcome of maintained therapeutic response (MTR) without withdrawal, equivalent to a moderate benefit.\nOf those randomised, 40% had MTR with pregabalin and 20% with placebo (high quality evidence).\nThe NNT was 5, but normalised to the starting population tested it was 12.\nAbout 10% of the initial population would have achieved the MTR outcome, similar to the result from studies of classic design.\nMTR had no imputation concerns.\nThe majority (70% to 90%) of participants in all treatment groups experienced adverse events.\nSpecific adverse events were more common with pregabalin than placebo, in particular dizziness, somnolence, weight gain, and peripheral oedema, with number needed to harm of 3.7, 7.4, 18, and 19 respectively for all doses combined (high quality evidence).\nSerious adverse events did not differ between active treatment groups and placebo (very low quality evidence).\nWithdrawals for any reason were more common with pregabalin than placebo only with the 600 mg dose in studies of classic design.\nWithdrawals due to adverse events were about 10% higher with pregabalin than placebo, but withdrawals due to lack of efficacy were about 6% lower (high quality evidence).\nPregabalin 300 to 600 mg produces a major reduction in pain intensity over 12 to 26 weeks with tolerable adverse events for a small proportion of people (about 10% more than placebo) with moderate or severe pain due to fibromyalgia.\nThe degree of pain relief is known to be accompanied by improvements in other symptoms, quality of life, and function.\nThese results are similar to other effective medicines in fibromyalgia (milnacipran, duloxetine).\n\n\nSimplified text:\nWe searched for studies that compared pregabalin with placebo in people with fibromyalgia. We found eight studies with a total of 3283 participants. Five studies (3283 participants) had a classic design in which participants were randomised at the start of the study to treatment with either a drug (150, 300, 450, or 600 mg daily) or placebo, with assessment after 8 to 13 weeks of stable treatment. Two studies (1492 participants began initial dose titration, 687 participants randomised) had an enriched enrolment randomised withdrawal (EERW) design, in which those with good pain relief after titration were randomized, double blind, to continuing the effective dose of 300 to 600 mg per day or a short down-titration to placebo for 13 or 26 weeks. One study (177 participants) compared a daily dose of 600 mg to a twice-daily dose, and concluded there was no difference in effect between the two doses. The majority (70% to 90%) of participants in all treatment groups experienced adverse events. Withdrawals due to adverse events were about 10% higher with pregABalin than placebo, but withdrawals due to lack of efficacy were about 6% lower (high quality evidence). Substantial improvement in pain was experienced by about 14% of participants with placebo, and about 9% more with 300 to600 mg (22% to 24%) compared with placebo. Moderate improvement was experienced in pain by about 28% of people with placebo and about 11% more by people with 300 and 600 mg (39% to 43%) compared. These results are similar to other effective medicines (milnacipran, duloxetine). Specific adverse events, in particular dizziness, somnolence, weight gain, and peripheral oedema, with number needed to harm of 3.7, 7.4, 18, and 19 respectively for all doses combined, with high quality evidence. The number of people who withdrew from the studies for any reason were more common with the 600 mg dose in studies of classic design. About 10% of the initial population would have achieved the MTR outcome, similar to the result from studies of standard design. The degree of pain relief is known to be accompanied by improvements in other symptoms, quality of life, and function.","label":["Factuality 1","Fluency 1","Simplicity 0"]},{"id":"10.1002\/14651858.CD009395.pub2_0","text":"Unsimplified text:\nWe included one trial (involving 135 women with mild pre-eclampsia at term).\nAn additional six studies are awaiting further assessment.\nThe included trial compared magnesium sulphate with a placebo and was at a low risk of bias.\nThe trial did not report any of this review's prespecified primary outcomes.\nThere was no significant difference between magnesium sulphate and placebo in Apgar score less than seven at five minutes (risk ratio (RR) 0.51; 95% confidence interval (CI) 0.05 to 5.46; 135 infants), nor gestational age at birth (mean difference (MD) -0.20 weeks; 95% CI -0.62 to 0.22; 135 infants).\nThere were significantly more maternal side effects (feeling warm and flushed) in the magnesium sulphate group than in the placebo group (RR 3.81; 95% CI 2.22 to 6.53; 135 women).\nHowever, no significant difference in adverse effects severe enough to cease treatment was observed (RR 3.04; 95% CI 0.13 to 73.42; 135 women).\nThere were no significant differences seen between groups in the rates of postpartum haemorrhage (RR 4.06; 95% CI 0.47 to 35.38; 135 women) and caesarean section (RR 0.80; 95% CI 0.39 to 1.63; 135 women).\nThere is currently insufficient evidence to assess the efficacy and safety of magnesium sulphate when administered to women for neuroprotection of the term fetus.\nAs there has been recent evidence for the use of magnesium sulphate for neuroprotection of the preterm fetus, high-quality randomised controlled trials are needed to determine the safety profile and neurological outcomes for the term fetus.\nStrategies to reduce maternal side effects during treatment also require evaluation.\n\n\nSimplified text:\nWe found one small randomised controlled trials (involving 135 women with mild pre-eclampsia at term) that compared magnesium sulphate with a placebo. There was not enough evidence from this small study to be able to draw any conclusions about the efficacy and safety of the treatment. There were more maternal side effects (feeling warm and flushed), but no serious side effects severe enough to stop treatment were seen. The trial did not report any of this review's prespecified primary outcomes. As there has been recent evidence for the use for the protection of the baby's brain during pregnancy, more research is needed to determine the safety profile of this treatment. Strategies to reduce adverse effects during treatment also require evaluation.","label":["Factuality 2","Fluency 2","Simplicity 2"]},{"id":"10.1002\/14651858.CD009395.pub2_1","text":"Unsimplified text:\nWe included one trial (involving 135 women with mild pre-eclampsia at term).\nAn additional six studies are awaiting further assessment.\nThe included trial compared magnesium sulphate with a placebo and was at a low risk of bias.\nThe trial did not report any of this review's prespecified primary outcomes.\nThere was no significant difference between magnesium sulphate and placebo in Apgar score less than seven at five minutes (risk ratio (RR) 0.51; 95% confidence interval (CI) 0.05 to 5.46; 135 infants), nor gestational age at birth (mean difference (MD) -0.20 weeks; 95% CI -0.62 to 0.22; 135 infants).\nThere were significantly more maternal side effects (feeling warm and flushed) in the magnesium sulphate group than in the placebo group (RR 3.81; 95% CI 2.22 to 6.53; 135 women).\nHowever, no significant difference in adverse effects severe enough to cease treatment was observed (RR 3.04; 95% CI 0.13 to 73.42; 135 women).\nThere were no significant differences seen between groups in the rates of postpartum haemorrhage (RR 4.06; 95% CI 0.47 to 35.38; 135 women) and caesarean section (RR 0.80; 95% CI 0.39 to 1.63; 135 women).\nThere is currently insufficient evidence to assess the efficacy and safety of magnesium sulphate when administered to women for neuroprotection of the term fetus.\nAs there has been recent evidence for the use of magnesium sulphate for neuroprotection of the preterm fetus, high-quality randomised controlled trials are needed to determine the safety profile and neurological outcomes for the term fetus.\nStrategies to reduce maternal side effects during treatment also require evaluation.\n\n\nSimplified text:\nWe found only one randomised controlled trial (involving 135 women with mild pre-eclampsia at term). The included trial compared magnesium sulphate with a placebo and was at a low risk of bias. There is currently insufficient evidence to assess the efficacy and safety of magnesium sulfate when administered to women for neuroprotection of the term fetus. As there has been recent evidence for the use of magnesium sulphates for the protection of the preterm fetus, high-quality trials are needed to determine the safety profile and neurological outcomes for the term newborn.","label":["Factuality 1","Fluency 1","Simplicity 1"]},{"id":"10.1002\/14651858.CD009046.pub2_0","text":"Unsimplified text:\nFour studies met all of the eligibility criteria for inclusion within the review.\nTwo used combination therapies consisting of a pharmacotherapy combined with cognitive and behavioural therapies, whilst the remaining two used cognitive and behavioural therapy through counselling, one via text message support and the other delivered via clinic doctors trained in smoking cessation techniques.\nSmoking cessation data were pooled across all studies producing a statistically and clinically significant effect in favour of the intervention (risk ratio 1.43, 95%CI 1.03 to 1.98, p=0.032), however following sensitivity analysis a statistically non-significant but clinically significant effect was observed in favour of the intervention (risk ratio 1.33, 95%CI 0.95 to 1.85, p=NS) .\nA significant health disparity exists, whereby Indigenous populations, a minority, are over-represented in the burden of smoking-related morbidity and mortality.\nThis review highlights the paucity of evidence available to evaluate the effectiveness of smoking cessation interventions, despite the known success of these interventions in non-Indigenous populations.\nDue to this lack of published investigations, the external validity of this review is limited, as is the ability to draw reliable conclusions from the results.\nThe limited but available evidence reported does indicate that smoking cessation interventions specifically targeted at Indigenous populations can produce smoking abstinence.\nHowever this evidence base is not strong with a small number of methodologically sound trials investigating these interventions.\nMore rigorous trials are now required to assist in bridging the gap between tobacco related health disparities in Indigenous and non-Indigenous populations.\n\n\nSimplified text:\nThis review of four studies found that smoking cessation interventions targeted at Indigenous populations can produce smoking abstinence. However, there was not enough evidence to draw reliable conclusions from the results of these studies. More research is needed to find out whether these interventions can help to reduce smoking-related health disparities in Indigenous and non-Indigenous populations. This review highlights the paucity of evidence available to evaluate the effectiveness of smoking cessation programmes, despite the known success of these programmes.","label":["Factuality 2","Fluency 2","Simplicity 2"]},{"id":"10.1002\/14651858.CD009046.pub2_1","text":"Unsimplified text:\nFour studies met all of the eligibility criteria for inclusion within the review.\nTwo used combination therapies consisting of a pharmacotherapy combined with cognitive and behavioural therapies, whilst the remaining two used cognitive and behavioural therapy through counselling, one via text message support and the other delivered via clinic doctors trained in smoking cessation techniques.\nSmoking cessation data were pooled across all studies producing a statistically and clinically significant effect in favour of the intervention (risk ratio 1.43, 95%CI 1.03 to 1.98, p=0.032), however following sensitivity analysis a statistically non-significant but clinically significant effect was observed in favour of the intervention (risk ratio 1.33, 95%CI 0.95 to 1.85, p=NS) .\nA significant health disparity exists, whereby Indigenous populations, a minority, are over-represented in the burden of smoking-related morbidity and mortality.\nThis review highlights the paucity of evidence available to evaluate the effectiveness of smoking cessation interventions, despite the known success of these interventions in non-Indigenous populations.\nDue to this lack of published investigations, the external validity of this review is limited, as is the ability to draw reliable conclusions from the results.\nThe limited but available evidence reported does indicate that smoking cessation interventions specifically targeted at Indigenous populations can produce smoking abstinence.\nHowever this evidence base is not strong with a small number of methodologically sound trials investigating these interventions.\nMore rigorous trials are now required to assist in bridging the gap between tobacco related health disparities in Indigenous and non-Indigenous populations.\n\n\nSimplified text:\nThis review identified four randomised controlled trials (clinical studies where people are randomly put into one of two or more treatment groups) investigating the effectiveness of smoking cessation interventions specifically targeted at Indigenous populations. Four studies met all of the eligibility criteria for inclusion within the review. Two studies used combination therapies consisting of a pharmacotherapy combined with cognitive and behavioural therapies, whilst the remaining two used Cognitive and behavioural therapy through counselling, one via text message support and the other delivered via clinic doctors trained in smoking cessation techniques. Due to this lack of published investigations, the external validity of this review is limited, as is the ability to draw reliable conclusions from the results. This review highlights the paucity of evidence available to evaluate the effectiveness, despite the known success of these interventions in non-Indigenous populations. The limited but available evidence reported does indicate that smoking cessation treatments specifically targeted to Indigenous populations can produce smoking abstinence. However, this evidence base is not strong with a small number of methodologically sound trials investigating these interventions. More rigorous trials are now required to assist in bridging the gap between tobacco related health disparities in Indigenous and other populations.","label":["Factuality 1","Fluency 0","Simplicity 0"]},{"id":"10.1002\/14651858.CD003408.pub3_0","text":"Unsimplified text:\nWe included 13 studies (5686 patients).\nWe judged blinding of participants and personnel and blinding of outcome assessment to be at high risk in about 50% of the included studies and at low risk in 25% to 30% of the studies.\nRegardless of the high risk of performance bias these studies were included based on the low weight the studies had in the meta-analysis.\nWe rated 75% of the studies as low risk for selection, attrition and reporting bias.\nAll 13 studies reported some type of hospital mortality (28-day, 30-day, 60-day or ICU mortality).\nWe considered studies of high-risk surgery patients (eight studies) and general intensive care patients (five studies) separately as subgroups for meta-analysis.\nThe pooled risk ratio (RR) for mortality for the studies of general intensive care patients was 1.02 (95% confidence interval (CI) 0.96 to 1.09) and for the studies of high-risk surgery patients the RR was 0.98 (95% CI 0.74 to 1.29).\nOf the eight studies of high-risk surgery patients, five evaluated the effectiveness of pre-operative optimization but there was no difference in mortality when these studies were examined separately.\nPAC did not affect general ICU LOS (reported by four studies) or hospital LOS (reported by nine studies).\nFour studies, conducted in the United States (US), reported costs based on hospital charges billed, which on average were higher in the PAC groups.\nTwo of these studies qualified for analysis and did not show a statistically significant hospital cost difference (mean difference USD 900, 95% CI -2620 to 4420, P = 0.62).\nPAC is a diagnostic and haemodynamic monitoring tool but not a therapeutic intervention.\nOur review concluded that use of a PAC did not alter the mortality, general ICU or hospital LOS, or cost for adult patients in intensive care.\nThe quality of evidence was high for mortality and LOS but low for cost analysis.\nEfficacy studies are needed to determine if there are optimal PAC-guided management protocols, which when applied to specific patient groups in ICUs could result in benefits such as shock reversal, improved organ function and less vasopressor use.\nNewer, less-invasive haemodynamic monitoring tools need to be validated against PAC prior to clinical use in critically ill patients.\n\n\nSimplified text:\nWe searched the medical literature up to January 2014 and found 13 studies involving a total of 5686 patients. We found that there was not enough evidence from these studies for us to make any conclusions about the effects on mortality, hospital mortality, or hospital costs. However, we found that when we combined the results from the studies, there was no difference in mortality or costs between the groups of patients in the studies. The quality of the studies ranged from low to very low. We rated the quality of evidence for mortality as high and the quality for hospital costs as low, meaning that we are very uncertain about the results. More research is needed to determine if there are more effective ways of using a pacemaker in intensive care units. Newer, less-invasive monitoring tools need to be validated against pacemakers before they can be used in critically ill patients. Efficacy studies are needed.","label":["Factuality 0","Fluency 1","Simplicity 1"]},{"id":"10.1002\/14651858.CD003408.pub3_1","text":"Unsimplified text:\nWe included 13 studies (5686 patients).\nWe judged blinding of participants and personnel and blinding of outcome assessment to be at high risk in about 50% of the included studies and at low risk in 25% to 30% of the studies.\nRegardless of the high risk of performance bias these studies were included based on the low weight the studies had in the meta-analysis.\nWe rated 75% of the studies as low risk for selection, attrition and reporting bias.\nAll 13 studies reported some type of hospital mortality (28-day, 30-day, 60-day or ICU mortality).\nWe considered studies of high-risk surgery patients (eight studies) and general intensive care patients (five studies) separately as subgroups for meta-analysis.\nThe pooled risk ratio (RR) for mortality for the studies of general intensive care patients was 1.02 (95% confidence interval (CI) 0.96 to 1.09) and for the studies of high-risk surgery patients the RR was 0.98 (95% CI 0.74 to 1.29).\nOf the eight studies of high-risk surgery patients, five evaluated the effectiveness of pre-operative optimization but there was no difference in mortality when these studies were examined separately.\nPAC did not affect general ICU LOS (reported by four studies) or hospital LOS (reported by nine studies).\nFour studies, conducted in the United States (US), reported costs based on hospital charges billed, which on average were higher in the PAC groups.\nTwo of these studies qualified for analysis and did not show a statistically significant hospital cost difference (mean difference USD 900, 95% CI -2620 to 4420, P = 0.62).\nPAC is a diagnostic and haemodynamic monitoring tool but not a therapeutic intervention.\nOur review concluded that use of a PAC did not alter the mortality, general ICU or hospital LOS, or cost for adult patients in intensive care.\nThe quality of evidence was high for mortality and LOS but low for cost analysis.\nEfficacy studies are needed to determine if there are optimal PAC-guided management protocols, which when applied to specific patient groups in ICUs could result in benefits such as shock reversal, improved organ function and less vasopressor use.\nNewer, less-invasive haemodynamic monitoring tools need to be validated against PAC prior to clinical use in critically ill patients.\n\n\nSimplified text:\nWe included 13 studies (5686 patients) in this review. We judged the quality of the included studies to be high in about 50% of the studies and at low in about 25% to 30%. The quality of evidence was high for mortality and LOS but low for cost analysis. Of the eight studies of high-risk surgery patients, five evaluated the effectiveness of pre-operative optimization but there was no difference in mortality when these studies were examined separately. Our review concluded that use of a PAC did not alter the mortality, general ICU or hospital LOS, or cost for adult patients in intensive care. PAC is a diagnostic and haemodynamic monitoring tool but not a therapeutic intervention. Efficacy studies are needed to determine if there are optimal PAC-guided management protocols, which when applied to specific patient groups in ICUs could result in benefits such as shock reversal, improved organ function and less vasopressor use. Newer, less-invasive haemodynamics monitoring tools need to be validated against PAC prior to clinical use in critically ill patients.","label":["Factuality 2","Fluency 1","Simplicity 0"]},{"id":"10.1002\/14651858.CD001452.pub4_0","text":"Unsimplified text:\nSix studies (n = 478) of variable quality were included.\nA composite outcome of Infant Pain Scale (NIPS), Neonatal Facial Action Coding System (NFCS) and\/or Premature Infant Pain Profile (PIPP) score was reported in 288 infants, who did not receive a sweet tasting solution.\nMeta-analysis showed a significant reduction in the venepuncture versus the heel lance group (SMD -0.76, 95% CI -1.00 to -0.52; I2 = 0%).\nWhen a sweet tasting solution was provided the SMD remained significant favouring the venepuncture group (SMD - 0.38, 95% CI -0.69 to -0.07).\nThe typical RD for requiring more than one skin puncture for venepuncture versus heel lance (reported in 4 studies; n = 254) was -0.34 (95% CI -0.43 to -0.25; I2 = 97%).\nThe NNT to avoid one repeat skin puncture was 3 (95% CI 2 to 4).\nCry characteristics favoured the venepuncture group but the differences were reduced by the provision of sweet tasting solutions prior to either procedure.\nVenepuncture, when performed by a skilled phlebotomist, appears to be the method of choice for blood sampling in term neonates.\nThe use of a sweet tasting solution further reduces the pain.\nFurther well designed randomised controlled trials should be conducted in settings where several individuals perform the procedures.\n\n\nSimplified text:\nThis review of six randomised controlled trials found that venepuncture, when performed by a skilled phlebotomist, appears to be the method of choice for blood sampling in term neonates. The use of a sweet tasting solution further reduces the pain. Further well designed randomise controlled trials should be conducted in settings where several individuals perform the procedures.","label":["Factuality 2","Fluency 2","Simplicity 2"]},{"id":"10.1002\/14651858.CD001452.pub4_1","text":"Unsimplified text:\nSix studies (n = 478) of variable quality were included.\nA composite outcome of Infant Pain Scale (NIPS), Neonatal Facial Action Coding System (NFCS) and\/or Premature Infant Pain Profile (PIPP) score was reported in 288 infants, who did not receive a sweet tasting solution.\nMeta-analysis showed a significant reduction in the venepuncture versus the heel lance group (SMD -0.76, 95% CI -1.00 to -0.52; I2 = 0%).\nWhen a sweet tasting solution was provided the SMD remained significant favouring the venepuncture group (SMD - 0.38, 95% CI -0.69 to -0.07).\nThe typical RD for requiring more than one skin puncture for venepuncture versus heel lance (reported in 4 studies; n = 254) was -0.34 (95% CI -0.43 to -0.25; I2 = 97%).\nThe NNT to avoid one repeat skin puncture was 3 (95% CI 2 to 4).\nCry characteristics favoured the venepuncture group but the differences were reduced by the provision of sweet tasting solutions prior to either procedure.\nVenepuncture, when performed by a skilled phlebotomist, appears to be the method of choice for blood sampling in term neonates.\nThe use of a sweet tasting solution further reduces the pain.\nFurther well designed randomised controlled trials should be conducted in settings where several individuals perform the procedures.\n\n\nSimplified text:\nThis review found that venepuncture, when performed by a skilled phlebotomist, appears to be the method of choice for blood sampling in term neonates. The use of a sweet tasting solution prior to the procedure reduced the pain. Cry characteristics favoured the procedure but the differences were reduced by the provision of sweet tasting solutions prior to either procedure. Further well designed randomised controlled trials should be conducted in settings where several individuals perform the procedures.","label":["Factuality 2","Fluency 1","Simplicity 2"]},{"id":"10.1002\/14651858.CD008977.pub2_0","text":"Unsimplified text:\nTwo small studies of poor methodological quality including 52 women with a dehisced and\/or infected episiotomy wound at point of entry have been included.\nOnly one small study presented data in relation to wound healing at less than four weeks, (the primary outcome measure for this review), although no reference was made to demonstrate how healing was measured.\nThere was a trend to favour this outcome in the resuturing group, however, this difference was not statistically significant (risk ratio (RR) 1.69, 95% confidence interval (CI) 0.73 to 3.88, one study, 17 women).\nSimilarly, only one trial reported on rates of dyspareunia (a secondary outcome measure for this review) at two months and six months with no statistically significant difference between both groups; two months, (RR 0.44, 95% CI 0.18 to 1.11, one study, 26 women) and six months, (RR 0.39, 95% CI 0.04 to 3.87, one study 32 women).\nThis trial also included data on the numbers of women who resumed sexual intercourse by two months and six months.\nSignificantly more women in the secondary suturing group had resumed intercourse by two months (RR 1.78, 95% CI 1.10 to 2.89, one study, 35 women), although by six months there was no significant difference between the two groups (RR 1.08, 95% CI, 0.91 to 1.28).\nNeither of the trials included data in relation to the following prespecified secondary outcome measures: pain at any time interval; the woman's satisfaction with the aesthetic results of the perineal wound; exclusive breastfeeding; maternal anxiety or depression.\nBased on this review, there is currently insufficient evidence available to either support or refute secondary suturing for the management of broken down perineal wounds following childbirth.\nThere is an urgent need for a robust randomised controlled trial to evaluate fully the comparative effects of both treatment options.\n\n\nSimplified text:\nThe review authors searched the medical literature to find studies that compared the use of secondary suturing or resuturing. They found only two small studies of poor quality that included 52 women with broken down or infected wounds following childbirth. These studies did not provide sufficient evidence to either support or refute the use or rejection of the use, or both, for the treatment of broken down wounds after childbirth. There is an urgent need for a robust randomised controlled trial to evaluate fully the comparative effects of both treatment options.","label":["Factuality 2","Fluency 2","Simplicity 2"]},{"id":"10.1002\/14651858.CD008977.pub2_1","text":"Unsimplified text:\nTwo small studies of poor methodological quality including 52 women with a dehisced and\/or infected episiotomy wound at point of entry have been included.\nOnly one small study presented data in relation to wound healing at less than four weeks, (the primary outcome measure for this review), although no reference was made to demonstrate how healing was measured.\nThere was a trend to favour this outcome in the resuturing group, however, this difference was not statistically significant (risk ratio (RR) 1.69, 95% confidence interval (CI) 0.73 to 3.88, one study, 17 women).\nSimilarly, only one trial reported on rates of dyspareunia (a secondary outcome measure for this review) at two months and six months with no statistically significant difference between both groups; two months, (RR 0.44, 95% CI 0.18 to 1.11, one study, 26 women) and six months, (RR 0.39, 95% CI 0.04 to 3.87, one study 32 women).\nThis trial also included data on the numbers of women who resumed sexual intercourse by two months and six months.\nSignificantly more women in the secondary suturing group had resumed intercourse by two months (RR 1.78, 95% CI 1.10 to 2.89, one study, 35 women), although by six months there was no significant difference between the two groups (RR 1.08, 95% CI, 0.91 to 1.28).\nNeither of the trials included data in relation to the following prespecified secondary outcome measures: pain at any time interval; the woman's satisfaction with the aesthetic results of the perineal wound; exclusive breastfeeding; maternal anxiety or depression.\nBased on this review, there is currently insufficient evidence available to either support or refute secondary suturing for the management of broken down perineal wounds following childbirth.\nThere is an urgent need for a robust randomised controlled trial to evaluate fully the comparative effects of both treatment options.\n\n\nSimplified text:\nTwo small studies of poor methodological quality including 52 women with a dehisced and\/or infected episiotomy wound at point of entry have been included in this review. Only one small study presented data in relation to wound healing at less than four weeks, (the primary outcome measure for this review), although no reference was made to demonstrate how wound healing was measured. This trial also included data on the numbers of women who resumed sexual intercourse by two months and six months. Neither of the trials included data for the following prespecified secondary outcome measures: pain at any time interval; the woman's satisfaction with the aesthetic results of the perineal wound; exclusive breastfeeding; maternal anxiety or depression; and maternal anxiety and depression. Based on this review, there is currently insufficient evidence available to either support or refute secondary suturing for the management of broken down wounds following childbirth. There is an urgent need for a robust randomised controlled trial to evaluate fully the comparative effects of both treatment options.","label":["Factuality 2","Fluency 2","Simplicity 1"]},{"id":"10.1002\/14651858.CD004559.pub4_0","text":"Unsimplified text:\nWe included 18 studies involving 2521 participants.\nThe methodological quality of 17 included studies was poor.\nIncluded RCTs separately compared medicinal herbs with different antiviral drugs, precluding any pooling of results.\nOnly three indicated that compared with antiviral drugs, Chinese medicinal herbs may be effective in preventing influenza and alleviating influenza symptoms.\n'Ganmao' capsules were found to be more effective than amantadine in decreasing influenza symptoms and speeding recovery in one study (in which adverse reactions were mentioned in the amantadine group although no data were reported).\nThere were no significant differences between 'E Shu You' and ribavirin in treating influenza, nor in the occurrence of adverse reactions.\nTen studies reported mild adverse reactions.\nMost Chinese medical herbs in the included studies showed similar effects to antiviral drugs in preventing or treating influenza.\nFew were shown to be superior to antiviral drugs.\nNo obvious adverse events were reported in the included studies.\nHowever, current evidence remains weak due to methodological limitations of the trials.\nMore high-quality RCTs with larger numbers of participants and clear reporting are needed.\n\n\nSimplified text:\nWe found 18 studies involving 2521 participants that compared Chinese medicinal herbs to antiviral drugs. Most of the included studies showed similar effects in preventing or treating influenza. Few were found to be better than antiviral drug treatment. Most Chinese medical herbs in the studies reported mild side effects. However, the quality of the studies was poor and more high-quality studies are needed.","label":["Factuality 2","Fluency 2","Simplicity 2"]},{"id":"10.1002\/14651858.CD004559.pub4_1","text":"Unsimplified text:\nWe included 18 studies involving 2521 participants.\nThe methodological quality of 17 included studies was poor.\nIncluded RCTs separately compared medicinal herbs with different antiviral drugs, precluding any pooling of results.\nOnly three indicated that compared with antiviral drugs, Chinese medicinal herbs may be effective in preventing influenza and alleviating influenza symptoms.\n'Ganmao' capsules were found to be more effective than amantadine in decreasing influenza symptoms and speeding recovery in one study (in which adverse reactions were mentioned in the amantadine group although no data were reported).\nThere were no significant differences between 'E Shu You' and ribavirin in treating influenza, nor in the occurrence of adverse reactions.\nTen studies reported mild adverse reactions.\nMost Chinese medical herbs in the included studies showed similar effects to antiviral drugs in preventing or treating influenza.\nFew were shown to be superior to antiviral drugs.\nNo obvious adverse events were reported in the included studies.\nHowever, current evidence remains weak due to methodological limitations of the trials.\nMore high-quality RCTs with larger numbers of participants and clear reporting are needed.\n\n\nSimplified text:\nWe included 18 studies involving 2521 participants in this review. The studies compared Chinese medicinal herbs with different antiviral drugs. Most Chinese herbs in the included studies showed similar effects to antiviral medicines in preventing or treating influenza. Only three studies showed that compared with antiviral medications, Chinese herbs may be effective in preventing influenza and alleviating influenza symptoms. 'Ganmao' capsules were found to be more effective than amantadine in decreasing influenza symptoms and speeding recovery in one study. There were no significant differences between 'E Shu You' and ribavirin in treating influenza, nor in the occurrence of adverse reactions. No obvious side effects were reported in any of the studies. However, the quality of the evidence was poor. More high-quality studies with larger numbers of participants and clear reporting are needed.","label":["Factuality 2","Fluency 2","Simplicity 0"]},{"id":"10.1002\/14651858.CD011953.pub2_0","text":"Unsimplified text:\nOur search strategy identified 8 studies (580 participants) as eligible for inclusion in this review.\nInterventions included: thrombolytic therapy versus placebo (1 study); low versus high dose thrombolytic therapy (1); alteplase versus urokinase (1); short versus long thrombolytic dwell (1); thrombolytic therapy versus percutaneous fibrin sheath stripping (1); fibrin sheath stripping versus over-the-wire catheter exchange (1); and over-the-wire catheter exchange versus exchange with and without angioplasty sheath disruption (1).\nNo two studies compared the same interventions.\nMost studies had a high risk of bias due to poor study design, broad inclusion criteria, low patient numbers and industry involvement.\nBased on low certainty evidence, thrombolytic therapy may restore catheter function when compared to placebo (149 participants: RR 4.05, 95% CI 1.42 to 11.56) but there is no data available to suggest an optimal dose or administration method.\nThe certainty of this evidence is reduced due to the fact that it is based on only a single study with wide confidence limits, high risk of bias and imprecision in the estimates of adverse events (149 participants: RR 2.03, 95% CI 0.38 to 10.73).\nBased on the available evidence, physical disruption of a fibrin sheath using interventional radiology techniques appears to be equally efficacious as the use of a pharmaceutical thrombolytic agent for the immediate management of dysfunctional catheters (57 participants: RR 0.92, 95% CI 0.80 to 1.07).\nCatheter patency is poor following use of thrombolytic agents with studies reporting median catheter survival rates of 14 to 42 days and was reported to improve significantly by fibrin sheath stripping or catheter exchange (37 participants: MD -27.70 days, 95% CI -51.00 to -4.40).\nCatheter exchange was reported to be superior to sheath disruption with respect to catheter survival (30 participants: MD 213.00 days, 95% CI 205.70 to 220.30).\nThere is insufficient evidence to suggest any specific intervention is superior in terms of ensuring either dialysis adequacy or reduced risk of adverse events.\nThrombolysis, fibrin sheath disruption and over-the-wire catheter exchange are effective and appropriate therapies for immediately restoring catheter patency in dysfunctional cuffed and tunnelled HD catheters.\nOn current data there is no evidence to support physical intervention over the use of pharmaceutical agents in the acute setting.\nPharmacological interventions appear to have a bridging role and long-term catheter survival may be improved by fibrin sheath disruption and is probably superior following catheter exchange.\nThere is no evidence favouring any of these approaches with respect to dialysis adequacy or risk of adverse events.\nThe current review is limited by the small number of available studies with limited numbers of patients enrolled.\nMost of the studies included in this review were judged to have a high risk of bias and were potentially influenced by pharmaceutical industry involvement.\nFurther research is required to adequately address the question of the most efficacious and clinically appropriate technique for HD catheter dysfunction.\n\n\nSimplified text:\nWe searched the medical literature and found eight randomised controlled trials (clinical studies where people are randomly put into one or more treatment or the other), involving a total of 580 participants. The evidence is current up-to-date as September 2018. The review found that thrombolytic therapy may restore catheter function when compared to placebo, but there is not enough information to recommend an optimal dose or administration method. There is insufficient evidence to suggest that any specific treatment is better than another in terms of ensuring adequate dialysis adequacy or reducing the number or severity of side effects. The current review is limited by the small number of available studies with limited numbers of patients enrolled. Most studies had poor study design, low patient numbers and industry involvement. Further research is required to adequately address the question of the most efficacious treatment for HD catheter dysfunction.","label":["Factuality 2","Fluency 2","Simplicity 2"]},{"id":"10.1002\/14651858.CD011953.pub2_1","text":"Unsimplified text:\nOur search strategy identified 8 studies (580 participants) as eligible for inclusion in this review.\nInterventions included: thrombolytic therapy versus placebo (1 study); low versus high dose thrombolytic therapy (1); alteplase versus urokinase (1); short versus long thrombolytic dwell (1); thrombolytic therapy versus percutaneous fibrin sheath stripping (1); fibrin sheath stripping versus over-the-wire catheter exchange (1); and over-the-wire catheter exchange versus exchange with and without angioplasty sheath disruption (1).\nNo two studies compared the same interventions.\nMost studies had a high risk of bias due to poor study design, broad inclusion criteria, low patient numbers and industry involvement.\nBased on low certainty evidence, thrombolytic therapy may restore catheter function when compared to placebo (149 participants: RR 4.05, 95% CI 1.42 to 11.56) but there is no data available to suggest an optimal dose or administration method.\nThe certainty of this evidence is reduced due to the fact that it is based on only a single study with wide confidence limits, high risk of bias and imprecision in the estimates of adverse events (149 participants: RR 2.03, 95% CI 0.38 to 10.73).\nBased on the available evidence, physical disruption of a fibrin sheath using interventional radiology techniques appears to be equally efficacious as the use of a pharmaceutical thrombolytic agent for the immediate management of dysfunctional catheters (57 participants: RR 0.92, 95% CI 0.80 to 1.07).\nCatheter patency is poor following use of thrombolytic agents with studies reporting median catheter survival rates of 14 to 42 days and was reported to improve significantly by fibrin sheath stripping or catheter exchange (37 participants: MD -27.70 days, 95% CI -51.00 to -4.40).\nCatheter exchange was reported to be superior to sheath disruption with respect to catheter survival (30 participants: MD 213.00 days, 95% CI 205.70 to 220.30).\nThere is insufficient evidence to suggest any specific intervention is superior in terms of ensuring either dialysis adequacy or reduced risk of adverse events.\nThrombolysis, fibrin sheath disruption and over-the-wire catheter exchange are effective and appropriate therapies for immediately restoring catheter patency in dysfunctional cuffed and tunnelled HD catheters.\nOn current data there is no evidence to support physical intervention over the use of pharmaceutical agents in the acute setting.\nPharmacological interventions appear to have a bridging role and long-term catheter survival may be improved by fibrin sheath disruption and is probably superior following catheter exchange.\nThere is no evidence favouring any of these approaches with respect to dialysis adequacy or risk of adverse events.\nThe current review is limited by the small number of available studies with limited numbers of patients enrolled.\nMost of the studies included in this review were judged to have a high risk of bias and were potentially influenced by pharmaceutical industry involvement.\nFurther research is required to adequately address the question of the most efficacious and clinically appropriate technique for HD catheter dysfunction.\n\n\nSimplified text:\nWe searched the medical literature up to April 2015 and identified eight studies with a total of 580 participants. Most of the studies had a high risk of bias due to poor study design, broad inclusion criteria, low patient numbers and industry involvement. Based on low certainty evidence, thrombolytic therapy may restore catheter function when compared to placebo but there is no data available to suggest an optimal dose or administration method. The certainty of this evidence is reduced due to the fact that it is based on only a single study with wide confidence limits and imprecision in the estimates of adverse events (149 participants). Based on the available evidence, physical disruption of a fibrin sheath using interventional radiology techniques appears to be equally efficacious as the use of a pharmaceutical drug for the immediate management of dysfunctional catheters. There is insufficient evidence to suggest any specific intervention is superior in terms of ensuring either dialysis adequacy or reduced risk of side effects. The current review is limited by the small number of available studies with limited numbers of patients enrolled. Further research is required to adequately address the question of the most efficacious and clinically appropriate technique for HD catheter dysfunction.","label":["Factuality 2","Fluency 1","Simplicity 0"]},{"id":"10.1002\/14651858.CD003368.pub3_0","text":"Unsimplified text:\nWe identified 17 trials reporting on 22 treatment comparisons (2674 patients randomised).\nFifteen trials (20 treatment comparisons) reported results for tumour response and 11 trials (14 treatment comparisons) published time-to-event data for overall survival.\nThere were 1532 deaths in 2116 women randomised to trials of the addition of a drug to the regimen and control (the regimen alone).\nThere was no detectable difference in overall survival between these patients, with an overall HR of 0.96 (95% confidence interval (CI) 0.87 to 1.07, P = 0.47) and no significant heterogeneity.\nWe found no difference in time to progression between these regimens, with an overall HR of 0.93 (95% CI 0.81 to 1.07, P = 0.31) and no significant heterogeneity.\nAddition of a drug to the regimen was favourably associated with overall tumour response rates (odds ratio 1.21, 95% CI 1.01 to 1.44, P = 0.04) although we observed significant heterogeneity for this outcome across the trials.\nWhere measured, acute toxicities such as alopecia, nausea and vomiting and leucopenia were more common with the addition of a drug.\nThe addition of one or more drugs to the regimen shows a statistically significant advantage for tumour response in women with metastatic breast cancer but the results suggest no difference in survival time or time to progression.\nThe positive effect on tumour response was also associated with increased toxicity.\n\n\nSimplified text:\nWe found 17 trials reporting on 22 treatment comparisons (2674 patients randomised). Fifteen trials (20 treatment comparisons) provided results for tumour response and 11 trials (14 treatment comparisons). There were 1532 deaths in 2116 women randomised to trials of the addition of a drug to the regimen (the regimen alone) or the regimen alone. There was no detectable difference in overall survival between these patients, with an overall HR of 0.96. We found no evidence that there was a difference in time to progression between these regimens. The addition of one or more drugs to the chemotherapy regimen shows a statistically significant advantage in tumour progression in women with metastatic breast cancer but the results suggest no difference in survival time or progression. The positive effect on tumour growth was also associated with increased toxicity. Where measured, acute toxicities such as alopecia, nausea and vomiting and leucopenia were more common with the addition.","label":["Factuality 1","Fluency 2","Simplicity 0"]},{"id":"10.1002\/14651858.CD003368.pub3_1","text":"Unsimplified text:\nWe identified 17 trials reporting on 22 treatment comparisons (2674 patients randomised).\nFifteen trials (20 treatment comparisons) reported results for tumour response and 11 trials (14 treatment comparisons) published time-to-event data for overall survival.\nThere were 1532 deaths in 2116 women randomised to trials of the addition of a drug to the regimen and control (the regimen alone).\nThere was no detectable difference in overall survival between these patients, with an overall HR of 0.96 (95% confidence interval (CI) 0.87 to 1.07, P = 0.47) and no significant heterogeneity.\nWe found no difference in time to progression between these regimens, with an overall HR of 0.93 (95% CI 0.81 to 1.07, P = 0.31) and no significant heterogeneity.\nAddition of a drug to the regimen was favourably associated with overall tumour response rates (odds ratio 1.21, 95% CI 1.01 to 1.44, P = 0.04) although we observed significant heterogeneity for this outcome across the trials.\nWhere measured, acute toxicities such as alopecia, nausea and vomiting and leucopenia were more common with the addition of a drug.\nThe addition of one or more drugs to the regimen shows a statistically significant advantage for tumour response in women with metastatic breast cancer but the results suggest no difference in survival time or time to progression.\nThe positive effect on tumour response was also associated with increased toxicity.\n\n\nSimplified text:\nThis review of trials found that the addition of one or more drugs to the regimen shows a statistically significant advantage for tumour response in women with metastatic breast cancer, but the results suggest no difference in survival time or time to progression. There were 1532 deaths in 2116 women randomised to trials of the addition to the chemotherapy regimen and control (the regimen alone). Where measured, acute toxicities such as alopecia, nausea and vomiting and leucopenia were more common with the added drugs.","label":["Factuality 2","Fluency 2","Simplicity 2"]},{"id":"10.1002\/14651858.CD002214.pub3_0","text":"Unsimplified text:\nTen random or quasi-random controlled trials reported on a total of 1896 patients.\nThere was no statistically significant effect on inpatient mortality (OR 1.10, 95% CI 0.56 to 2.16) or mortality to longest follow up (OR 0.92, 95% CI 0.65 to 1.29) but higher quality studies showed a larger non-significant increase in inpatient mortality (OR 1.52, 95% CI 0.86 to 2.68).\nDischarge to institutional care was reduced for the NLU (OR 0.44 95% CI 0.22 to 0.89) and functional status at discharge increased (SMD 0.37, 95% CI 0.20 to 0.54) but there was a near significant increase in inpatient stay (WMD 5.13 days 95% CI -0.5 days to 10.76 days).\nEarly readmissions were reduced (OR 0.52 95% CI 0.34 to 0.80).\nOne study compared a NLU for the chronically critically ill with ICU care.\nMortality (OR 0.62 95% CI 0.35 to 1.10) and length of inpatient stay differ did not differ (WMD 2 days, 95% CI 10.96 to -6.96 days).\nEarly readmissions were reduced (OR 0.33 95% CI 0.12 to 0.94).\nCosts of care on the NLU were higher for UK studies but lower for US based studies.\nThere is some evidence that patients discharged from a NLU are better prepared for discharge but it is unclear if this is simply a product of an increased length of inpatient stay.\nNo statistically significant adverse effects were noted but the possibility of increased early mortality cannot be discounted.\nMore research is needed.\n\n\nSimplified text:\nThis review of 10 randomised controlled trials found that patients discharged from the neonatal intensive care unit were less likely to die and were better prepared for discharge from the unit. However, there was an increase in the length of stay and early readmissions for patients who were discharged from a neonate's unit. More research is needed.","label":["Factuality 1","Fluency 2","Simplicity 2"]},{"id":"10.1002\/14651858.CD002214.pub3_1","text":"Unsimplified text:\nTen random or quasi-random controlled trials reported on a total of 1896 patients.\nThere was no statistically significant effect on inpatient mortality (OR 1.10, 95% CI 0.56 to 2.16) or mortality to longest follow up (OR 0.92, 95% CI 0.65 to 1.29) but higher quality studies showed a larger non-significant increase in inpatient mortality (OR 1.52, 95% CI 0.86 to 2.68).\nDischarge to institutional care was reduced for the NLU (OR 0.44 95% CI 0.22 to 0.89) and functional status at discharge increased (SMD 0.37, 95% CI 0.20 to 0.54) but there was a near significant increase in inpatient stay (WMD 5.13 days 95% CI -0.5 days to 10.76 days).\nEarly readmissions were reduced (OR 0.52 95% CI 0.34 to 0.80).\nOne study compared a NLU for the chronically critically ill with ICU care.\nMortality (OR 0.62 95% CI 0.35 to 1.10) and length of inpatient stay differ did not differ (WMD 2 days, 95% CI 10.96 to -6.96 days).\nEarly readmissions were reduced (OR 0.33 95% CI 0.12 to 0.94).\nCosts of care on the NLU were higher for UK studies but lower for US based studies.\nThere is some evidence that patients discharged from a NLU are better prepared for discharge but it is unclear if this is simply a product of an increased length of inpatient stay.\nNo statistically significant adverse effects were noted but the possibility of increased early mortality cannot be discounted.\nMore research is needed.\n\n\nSimplified text:\nThis review of trials found that patients discharged from a non-intensive care unit are better prepared for discharge but it is unclear if this is simply a product of an increased length of inpatient stay. No statistically significant adverse effects were noted but the possibility of increased early mortality cannot be discounted. More research is needed. One study compared a NLU for the chronically critically ill with ICU care. Costs of care on the NLU were higher for UK studies but lower for US based studies.","label":["Factuality 2","Fluency 2","Simplicity 2"]},{"id":"10.1002\/14651858.CD009601.pub2_0","text":"Unsimplified text:\nWe included 11 studies including 414 participants in the review.\nTwo trials compared therapeutic ultrasound with placebo, two compared one ultrasound regimen with another, two compared ultrasound with another non-surgical intervention, and six compared ultrasound as part of a multi-component intervention with another non-surgical intervention (for example, exercises and splint).\nThe risk of bias was low in some studies and unclear or high in other studies, with only two reporting that the allocation sequence was concealed and six reporting that participants were blinded.\nOverall, there is insufficient evidence that one therapeutic ultrasound regimen is more efficacious than another.\nOnly two studies reported the primary outcome of interest, short-term overall improvement (any measure in which patients indicate the intensity of their complaints compared with baseline, for example, global rating of improvement, satisfaction with treatment, within three months post-treatment).\nOne low quality trial with 68 participants found that when compared with placebo, therapeutic ultrasound may increase the chance of experiencing short-term overall improvement at the end of seven weeks treatment (RR 2.36; 95% CI 1.40 to 3.98), although losses to follow-up and failure to adjust for the correlation between wrists in participants with bilateral CTS in this study suggest that this data should be interpreted with caution.\nAnother low quality trial with 60 participants found that at three months post-treatment therapeutic ultrasound plus splint increased the chance of short-term overall improvement (patient satisfaction) when compared with splint alone (RR 3.02; 95% CI 1.36 to 6.72), but decreased the chance of short-term overall improvement when compared with low-level laser therapy plus splint (RR 0.87; 95% CI 0.57 to 1.33), though participants were not blinded to treatment, it was unclear if the random allocation sequence was adequately concealed, and there was a potential unit of analysis error.\nDifferences between groups receiving different frequencies and intensities of ultrasound, and between ultrasound as part of a multi-component intervention versus other non-surgical interventions, were generally small and not statistically significant for symptoms, function, and neurophysiologic parameters.\nNo studies reported any adverse effects of therapeutic ultrasound, but this outcome was only measured in three studies.\nMore adverse effects data are required before any firm conclusions on the safety of therapeutic ultrasound can be made.\nThere is only poor quality evidence from very limited data to suggest that therapeutic ultrasound may be more effective than placebo for either short- or long-term symptom improvement in people with CTS.\nThere is insufficient evidence to support the greater benefit of one type of therapeutic ultrasound regimen over another or to support the use of therapeutic ultrasound as a treatment with greater efficacy compared to other non-surgical interventions for CTS, such as splinting, exercises, and oral drugs.\nMore methodologically rigorous studies are needed to determine the effectiveness and safety of therapeutic ultrasound for CTS.\n\n\nSimplified text:\nWe found 11 studies including 414 participants in the review. Two trials compared therapeutic ultrasound with placebo, two trials compared ultrasound with another ultrasound treatment (for example, exercises and splint), and six studies compared ultrasound as part of a multi-component treatment with another treatment. One low quality trial found that when compared to placebo, therapeutic ultrasound may increase the chance of experiencing short-term overall improvement at the end of seven weeks treatment. Another low quality study found that at three months post-treatment therapeutic ultrasound plus splint increased the chance that patients were more satisfied with their treatment than splint alone, but decreased the chance for short term overall improvement when compared with low-level laser therapy plus splib. Overall, there is only poor quality evidence from very limited data to suggest that therapeutic ultrasound is more effective than placebo for either short or long-term symptom improvement in people with CTS. There is not enough evidence to support the greater benefit of one type of therapeutic ultrasound regimen over another or for the use of ultrasound as a treatment with greater efficacy compared to other treatments, such as splinting, exercises, and oral drugs. More methodologically rigorous studies are needed before any firm conclusions can be made.","label":["Factuality 2","Fluency 2","Simplicity 2"]},{"id":"10.1002\/14651858.CD009601.pub2_1","text":"Unsimplified text:\nWe included 11 studies including 414 participants in the review.\nTwo trials compared therapeutic ultrasound with placebo, two compared one ultrasound regimen with another, two compared ultrasound with another non-surgical intervention, and six compared ultrasound as part of a multi-component intervention with another non-surgical intervention (for example, exercises and splint).\nThe risk of bias was low in some studies and unclear or high in other studies, with only two reporting that the allocation sequence was concealed and six reporting that participants were blinded.\nOverall, there is insufficient evidence that one therapeutic ultrasound regimen is more efficacious than another.\nOnly two studies reported the primary outcome of interest, short-term overall improvement (any measure in which patients indicate the intensity of their complaints compared with baseline, for example, global rating of improvement, satisfaction with treatment, within three months post-treatment).\nOne low quality trial with 68 participants found that when compared with placebo, therapeutic ultrasound may increase the chance of experiencing short-term overall improvement at the end of seven weeks treatment (RR 2.36; 95% CI 1.40 to 3.98), although losses to follow-up and failure to adjust for the correlation between wrists in participants with bilateral CTS in this study suggest that this data should be interpreted with caution.\nAnother low quality trial with 60 participants found that at three months post-treatment therapeutic ultrasound plus splint increased the chance of short-term overall improvement (patient satisfaction) when compared with splint alone (RR 3.02; 95% CI 1.36 to 6.72), but decreased the chance of short-term overall improvement when compared with low-level laser therapy plus splint (RR 0.87; 95% CI 0.57 to 1.33), though participants were not blinded to treatment, it was unclear if the random allocation sequence was adequately concealed, and there was a potential unit of analysis error.\nDifferences between groups receiving different frequencies and intensities of ultrasound, and between ultrasound as part of a multi-component intervention versus other non-surgical interventions, were generally small and not statistically significant for symptoms, function, and neurophysiologic parameters.\nNo studies reported any adverse effects of therapeutic ultrasound, but this outcome was only measured in three studies.\nMore adverse effects data are required before any firm conclusions on the safety of therapeutic ultrasound can be made.\nThere is only poor quality evidence from very limited data to suggest that therapeutic ultrasound may be more effective than placebo for either short- or long-term symptom improvement in people with CTS.\nThere is insufficient evidence to support the greater benefit of one type of therapeutic ultrasound regimen over another or to support the use of therapeutic ultrasound as a treatment with greater efficacy compared to other non-surgical interventions for CTS, such as splinting, exercises, and oral drugs.\nMore methodologically rigorous studies are needed to determine the effectiveness and safety of therapeutic ultrasound for CTS.\n\n\nSimplified text:\nWe included 11 studies including 414 participants in the review. Two trials compared therapeutic ultrasound with placebo, two compared one ultrasound regimen with another, and six compared ultrasound as part of a multi-component intervention with another non-surgical intervention (for example, exercises and splint). The risk of bias was low in some studies and unclear or high in other studies, with only two reporting that the allocation sequence was concealed and six reporting that participants were blinded. Overall, there is insufficient evidence that one therapeutic ultrasound regimen is more efficacious than another. One low quality trial with 68 participants found that therapeutic ultrasound may increase the chance of experiencing short-term overall improvement at the end of seven weeks treatment (RR 2.36; 95% CI 1.40 to 3.98), although losses to follow-up and failure to adjust for the correlation between wrists in participants with bilateral CTS in this study suggest that this data should be interpreted with caution. Differences between groups receiving different frequencies and intensities of ultrasound, and between ultrasound and other non-surgery interventions, were generally small and not statistically significant for symptoms, function, and neurophysiologic parameters. More studies are needed to determine the effectiveness and safety of therapeutic ultrasound for CTS. More adverse effects data are required before any firm conclusions can be made. There is only poor quality evidence from very limited data to suggest that there may be more effective than placebo for either short- or long-term symptom improvement in people with CTS, but there is not enough evidence to support the use of one type of ultrasound regimen over another. More methodologically rigorous studies are required.","label":["Factuality 2","Fluency 1","Simplicity 0"]},{"id":"10.1002\/14651858.CD002091.pub2_0","text":"Unsimplified text:\nWe included eight studies involving approximately 10,000 participants.\nThe active interventions were pravastatin, atorvastatin, simvastatin, clofibrate, and conjugated oestrogen.\nFixed-effect analysis showed no overall effect on stroke recurrence but statin therapy alone had a marginal benefit in reducing subsequent cerebrovascular events in those with a previous history of stroke or TIA (odds ratio (OR) 0.88, 95% confidence interval (CI) 0.77 to 1.00).\nThere was no evidence that such intervention reduced all-cause mortality or sudden death (OR 1.00, 95% CI 0.83 to 1.20).\nThree statin trials showed a reduction in subsequent serious vascular events (OR 0.74, 95% CI 0.67 to 0.82).\nThere is evidence that statin therapy in patients with a history of ischaemic stroke or TIA significantly reduces subsequent major coronary events but only marginally reduces the risk of stroke recurrence.\nThere is no clear evidence of beneficial effect from statins in those with previous haemorrhagic stroke and it is unclear whether statins should be started immediately post stroke or later.\nIn view of this and the evidence of the benefit of statin therapy in those with a history of CHD, patients with ischaemic stroke or TIA, with or without a history of established CHD, should receive statins.\n\n\nSimplified text:\nWe found eight studies involving approximately 10,000 participants. The active treatments were pravastatin, atorvastates, simvastate, clofibrate, and conjugated oestrogen. There was no clear evidence of beneficial effect from statin therapy in those with previous haemorrhagic stroke and it is unclear whether statins should be started immediately after stroke or later. There is evidence that statin treatment in patients with ischaemic stroke or stroke or TIA significantly reduces subsequent major coronary events but only marginally reduces the risk of stroke recurrence.","label":["Factuality 2","Fluency 2","Simplicity 2"]},{"id":"10.1002\/14651858.CD002091.pub2_1","text":"Unsimplified text:\nWe included eight studies involving approximately 10,000 participants.\nThe active interventions were pravastatin, atorvastatin, simvastatin, clofibrate, and conjugated oestrogen.\nFixed-effect analysis showed no overall effect on stroke recurrence but statin therapy alone had a marginal benefit in reducing subsequent cerebrovascular events in those with a previous history of stroke or TIA (odds ratio (OR) 0.88, 95% confidence interval (CI) 0.77 to 1.00).\nThere was no evidence that such intervention reduced all-cause mortality or sudden death (OR 1.00, 95% CI 0.83 to 1.20).\nThree statin trials showed a reduction in subsequent serious vascular events (OR 0.74, 95% CI 0.67 to 0.82).\nThere is evidence that statin therapy in patients with a history of ischaemic stroke or TIA significantly reduces subsequent major coronary events but only marginally reduces the risk of stroke recurrence.\nThere is no clear evidence of beneficial effect from statins in those with previous haemorrhagic stroke and it is unclear whether statins should be started immediately post stroke or later.\nIn view of this and the evidence of the benefit of statin therapy in those with a history of CHD, patients with ischaemic stroke or TIA, with or without a history of established CHD, should receive statins.\n\n\nSimplified text:\nWe included eight randomised controlled trials involving approximately 10,000 participants. The active interventions were pravastatin, atorvastatin (a statin), simvastin, clofibrate, and conjugated oestrogen. There is evidence that statin therapy in patients with a history of ischaemic stroke or TIA significantly reduces subsequent major coronary events but only marginally reduces the risk of stroke recurrence. There was no clear evidence of beneficial effect from statins in those with previous haemorrhagic stroke and it is unclear whether statins should be started immediately post stroke or later. In view of this and the evidence of the benefit of statin treatment in patients who have had a previous heart attack or stroke, with or without an established history of heart disease, patients with stroke or stroke or who have not had a heart attack should receive statins.","label":["Factuality 2","Fluency 2","Simplicity 0"]},{"id":"10.1002\/14651858.CD004704.pub4_0","text":"Unsimplified text:\nEleven campaigns met the inclusion criteria for this review.\nStudies differed in design, settings, duration, content and intensity of intervention, length of follow-up, methods of evaluation and also in definitions and measures of smoking behaviour used.\nAmong seven campaigns reporting smoking prevalence, significant decreases were observed in the California and Massachusetts statewide tobacco control campaigns compared with the rest of the USA.\nSome positive effects on prevalence in the whole population or in the subgroups were observed in three of the remaining seven studies.\nThree large-scale campaigns of the seven presenting results for tobacco consumption found statistically significant decreases.\nAmong the eight studies presenting abstinence or quit rates, four showed some positive effect, although in one of them the effect was measured for quitting and cutting down combined.\nAmong the three that did not show significant decreases, one demonstrated a significant intervention effect on smokers and ex-smokers combined.\nThere is evidence that comprehensive tobacco control programmes which include mass media campaigns can be effective in changing smoking behaviour in adults, but the evidence comes from a heterogeneous group of studies of variable methodological quality.\nOne state-wide tobacco control programme (Massachusetts) showed positive results up to eight years after the campaign.\nAnother (California) showed positive results during the period of adequate funding and implementation and in final evaluation since the beginning of the programme.\nSix of nine studies carried out in communities or regions showed some positive effects on smoking behaviour and at least one significant change in smoking prevalence (Sydney).\nThe intensity and duration of mass media campaigns may influence effectiveness, but length of follow-up and concurrent secular trends and events can make this difficult to quantify.\nNo consistent relationship was observed between campaign effectiveness and age, education, ethnicity or gender.\n\n\nSimplified text:\nThis systematic review of 11 studies found that comprehensive tobacco control programmes which include mass media campaigns can be effective in changing smoking behaviour in adults, but the evidence comes from a heterogeneous group of studies of variable methodological quality. There is some evidence that comprehensive programmes can have positive effects on smoking behaviour, but there is not enough evidence to say whether they are more effective than other types of programmes.","label":["Factuality 1","Fluency 2","Simplicity 2"]},{"id":"10.1002\/14651858.CD004704.pub4_1","text":"Unsimplified text:\nEleven campaigns met the inclusion criteria for this review.\nStudies differed in design, settings, duration, content and intensity of intervention, length of follow-up, methods of evaluation and also in definitions and measures of smoking behaviour used.\nAmong seven campaigns reporting smoking prevalence, significant decreases were observed in the California and Massachusetts statewide tobacco control campaigns compared with the rest of the USA.\nSome positive effects on prevalence in the whole population or in the subgroups were observed in three of the remaining seven studies.\nThree large-scale campaigns of the seven presenting results for tobacco consumption found statistically significant decreases.\nAmong the eight studies presenting abstinence or quit rates, four showed some positive effect, although in one of them the effect was measured for quitting and cutting down combined.\nAmong the three that did not show significant decreases, one demonstrated a significant intervention effect on smokers and ex-smokers combined.\nThere is evidence that comprehensive tobacco control programmes which include mass media campaigns can be effective in changing smoking behaviour in adults, but the evidence comes from a heterogeneous group of studies of variable methodological quality.\nOne state-wide tobacco control programme (Massachusetts) showed positive results up to eight years after the campaign.\nAnother (California) showed positive results during the period of adequate funding and implementation and in final evaluation since the beginning of the programme.\nSix of nine studies carried out in communities or regions showed some positive effects on smoking behaviour and at least one significant change in smoking prevalence (Sydney).\nThe intensity and duration of mass media campaigns may influence effectiveness, but length of follow-up and concurrent secular trends and events can make this difficult to quantify.\nNo consistent relationship was observed between campaign effectiveness and age, education, ethnicity or gender.\n\n\nSimplified text:\nThis review of studies found that comprehensive tobacco control programmes which include mass media campaigns can be effective in changing smoking behaviour in adults, but the evidence comes from a heterogeneous group of studies of variable methodological quality. Studies differed in design, settings, duration, content and intensity of intervention, length of follow-up, methods of evaluation and also in definitions and measures of smoking behaviour used. Six of nine studies carried out in communities or regions showed some positive effects on smoking behaviour and at least one significant change in smoking prevalence (Sydney). One study (California) showed positive results during the period of adequate funding and implementation and in final evaluation since the beginning of the programme. Among the three studies that did not show significant decreases in smoking, one demonstrated a significant intervention effect on smokers and ex-smokers combined. The intensity and duration of the mass media campaign may influence effectiveness, but there is a lack of data on the effects of mass media on smoking prevalence.","label":["Factuality 1","Fluency 2","Simplicity 1"]},{"id":"10.1002\/14651858.CD010802.pub2_0","text":"Unsimplified text:\nWe included 24 studies with a total of 2166 participants, 23 of which provided data for meta-analysis.\nThirteen studies had low risk of selection bias, five studies reported adequate blinding of outcome assessment and 15 studies had low risk of attrition bias.\nSeventeen studies that compared yoga versus no therapy provided moderate-quality evidence showing that yoga improved health-related quality of life (pooled SMD 0.22, 95% CI 0.04 to 0.40; 10 studies, 675 participants), reduced fatigue (pooled SMD -0.48, 95% CI -0.75 to -0.20; 11 studies, 883 participants) and reduced sleep disturbances in the short term (pooled SMD -0.25, 95% CI -0.40 to -0.09; six studies, 657 participants).\nThe funnel plot for health-related quality of life was asymmetrical, favouring no therapy, and the funnel plot for fatigue was roughly symmetrical.\nThis hints at overall low risk of publication bias.\nYoga did not appear to reduce depression (pooled SMD -0.13, 95% CI -0.31 to 0.05; seven studies, 496 participants; low-quality evidence) or anxiety (pooled SMD -0.53, 95% CI -1.10 to 0.04; six studies, 346 participants; very low-quality evidence) in the short term and had no medium-term effects on health-related quality of life (pooled SMD 0.10, 95% CI -0.23 to 0.42; two studies, 146 participants; low-quality evidence) or fatigue (pooled SMD -0.04, 95% CI -0.36 to 0.29; two studies, 146 participants; low-quality evidence).\nInvestigators reported no serious adverse events.\nFour studies that compared yoga versus psychosocial\/educational interventions provided moderate-quality evidence indicating that yoga can reduce depression (pooled SMD -2.29, 95% CI -3.97 to -0.61; four studies, 226 participants), anxiety (pooled SMD -2.21, 95% CI -3.90 to -0.52; three studies, 195 participants) and fatigue (pooled SMD -0.90, 95% CI -1.31 to -0.50; two studies, 106 participants) in the short term.\nVery low-quality evidence showed no short-term effects on health-related quality of life (pooled SMD 0.81, 95% CI -0.50 to 2.12; two studies, 153 participants) or sleep disturbances (pooled SMD -0.21, 95% CI -0.76 to 0.34; two studies, 119 participants).\nNo trial adequately reported safety-related data.\nThree studies that compared yoga versus exercise presented very low-quality evidence showing no short-term effects on health-related quality of life (pooled SMD -0.04, 95% CI -0.30 to 0.23; three studies, 233 participants) or fatigue (pooled SMD -0.21, 95% CI -0.66 to 0.25; three studies, 233 participants); no trial provided safety-related data.\nModerate-quality evidence supports the recommendation of yoga as a supportive intervention for improving health-related quality of life and reducing fatigue and sleep disturbances when compared with no therapy, as well as for reducing depression, anxiety and fatigue, when compared with psychosocial\/educational interventions.\nVery low-quality evidence suggests that yoga might be as effective as other exercise interventions and might be used as an alternative to other exercise programmes.\n\n\nSimplified text:\nWe found 24 studies that compared yoga with no treatment or other exercise interventions. The evidence is current to April 2016. We found that yoga improved health-related quality of life, reduced fatigue and sleep disturbances, as well as reduced fatigue, in the short-term. Yoga did not appear to reduce depression, anxiety or fatigue. Yoga was not as effective as other exercise programmes and might be used as an alternative to exercise programmes. The quality of the evidence ranged from moderate to very low, meaning that we are uncertain about the results. The overall quality was moderate to low. The studies did not report safety-related information. No serious adverse effects were reported.","label":["Factuality 0","Fluency 1","Simplicity 2"]},{"id":"10.1002\/14651858.CD010802.pub2_1","text":"Unsimplified text:\nWe included 24 studies with a total of 2166 participants, 23 of which provided data for meta-analysis.\nThirteen studies had low risk of selection bias, five studies reported adequate blinding of outcome assessment and 15 studies had low risk of attrition bias.\nSeventeen studies that compared yoga versus no therapy provided moderate-quality evidence showing that yoga improved health-related quality of life (pooled SMD 0.22, 95% CI 0.04 to 0.40; 10 studies, 675 participants), reduced fatigue (pooled SMD -0.48, 95% CI -0.75 to -0.20; 11 studies, 883 participants) and reduced sleep disturbances in the short term (pooled SMD -0.25, 95% CI -0.40 to -0.09; six studies, 657 participants).\nThe funnel plot for health-related quality of life was asymmetrical, favouring no therapy, and the funnel plot for fatigue was roughly symmetrical.\nThis hints at overall low risk of publication bias.\nYoga did not appear to reduce depression (pooled SMD -0.13, 95% CI -0.31 to 0.05; seven studies, 496 participants; low-quality evidence) or anxiety (pooled SMD -0.53, 95% CI -1.10 to 0.04; six studies, 346 participants; very low-quality evidence) in the short term and had no medium-term effects on health-related quality of life (pooled SMD 0.10, 95% CI -0.23 to 0.42; two studies, 146 participants; low-quality evidence) or fatigue (pooled SMD -0.04, 95% CI -0.36 to 0.29; two studies, 146 participants; low-quality evidence).\nInvestigators reported no serious adverse events.\nFour studies that compared yoga versus psychosocial\/educational interventions provided moderate-quality evidence indicating that yoga can reduce depression (pooled SMD -2.29, 95% CI -3.97 to -0.61; four studies, 226 participants), anxiety (pooled SMD -2.21, 95% CI -3.90 to -0.52; three studies, 195 participants) and fatigue (pooled SMD -0.90, 95% CI -1.31 to -0.50; two studies, 106 participants) in the short term.\nVery low-quality evidence showed no short-term effects on health-related quality of life (pooled SMD 0.81, 95% CI -0.50 to 2.12; two studies, 153 participants) or sleep disturbances (pooled SMD -0.21, 95% CI -0.76 to 0.34; two studies, 119 participants).\nNo trial adequately reported safety-related data.\nThree studies that compared yoga versus exercise presented very low-quality evidence showing no short-term effects on health-related quality of life (pooled SMD -0.04, 95% CI -0.30 to 0.23; three studies, 233 participants) or fatigue (pooled SMD -0.21, 95% CI -0.66 to 0.25; three studies, 233 participants); no trial provided safety-related data.\nModerate-quality evidence supports the recommendation of yoga as a supportive intervention for improving health-related quality of life and reducing fatigue and sleep disturbances when compared with no therapy, as well as for reducing depression, anxiety and fatigue, when compared with psychosocial\/educational interventions.\nVery low-quality evidence suggests that yoga might be as effective as other exercise interventions and might be used as an alternative to other exercise programmes.\n\n\nSimplified text:\nWe included 24 studies with a total of 2166 participants in this review. The quality of the evidence is moderate to very low. Moderate-quality evidence supports the recommendation of yoga as a supportive intervention for improving health-related quality of life and reducing fatigue and sleep disturbances when compared with no therapy, as well as for reducing depression, anxiety and fatigue, when compared to psychosocial\/educational interventions. Very low quality evidence suggests that yoga might be as effective as other exercise interventions and might be used as an alternative to other exercise programmes.","label":["Factuality 2","Fluency 2","Simplicity 2"]},{"id":"10.1002\/14651858.CD013137.pub2_0","text":"Unsimplified text:\nWe included one retrospective, single-institution study that compared post-operative imaging within 48 hours (early post-operative imaging) with no early post-operative imaging among 125 people who had surgery for glioblastoma (GBM: World Health Organization (WHO) grade 4 glioma).\nMost patients in the study underwent maximal surgical resection followed by combined radiotherapy and temozolomide treatment.\nAlthough patient characteristics in the study arms were comparable, the study was at high risk of bias overall.\nEvidence from this study suggested little or no difference between early and no early post-operative imaging with respect to overall survival (deaths) at one year after diagnosis of GBM (risk ratio (RR) 0.86, 95% confidence interval (CI) 0.61 to 1.21; 48% vs 55% died, respectively; very low certainty evidence) and little or no difference in overall survival (deaths) at two years after diagnosis of GBM (RR 1.06, 95% CI 0.91 to 1.25; 86% vs 81% died, respectively; very low certainty evidence).\nNo other review outcomes were reported.\nWe found no evidence on the effectiveness of other imaging schedules.\nIn addition, we identified no relevant economic evaluations assessing the efficiency of the different imaging strategies.\nThe effect of different imaging strategies on survival and other health outcomes remains largely unknown.\nExisting imaging schedules in glioma seem to be pragmatic rather than evidence-based.\nThe limited evidence suggesting that early post-operative brain imaging among GBM patients who will receive combined chemoradiation treatment may make little or no difference to survival needs to be further researched, particularly as early post-operative imaging also serves as a quality control measure that may lead to early re-operation if residual tumour is identified.\nMathematical modelling of a large glioma patient database could help to distinguish the optimal timing of surveillance imaging for different types of glioma, with stratification of patients facilitated by assessment of individual tumour growth rates, molecular biomarkers and other prognostic factors.\nIn addition, paediatric glioma study designs could be used to inform future research of imaging strategies among adults with glioma.\n\n\nSimplified text:\nWe searched the medical literature for studies that compared different imaging schedules in people who had surgery for glioblastoma. We found only one small randomised controlled study that compared early post-operative imaging within 48 hours after surgery compared to no imaging. This study included 125 people. Most patients had surgery followed by surgery and combined radiotherapy and temozolomide treatment. Although patient characteristics in the study arms were similar, the study was of low quality overall. Evidence from this study suggested little or no difference in survival between early and no early-stage brain imaging with respect to overall survival at one year after diagnosis of GBM and two years after diagnosis. No other review outcomes were reported. We did not find evidence on the effectiveness of other imaging schedules. In addition, we found no relevant economic evaluations of the effects on survival and other health outcomes. The limited evidence suggests that early-phase brain imaging among GBM patients who will receive combined chemoradiation treatment may make little or little difference to survival, particularly as it may lead to early re-operation if residual tumour is identified. More research is needed in this area.","label":["Factuality 2","Fluency 2","Simplicity 2"]},{"id":"10.1002\/14651858.CD013137.pub2_1","text":"Unsimplified text:\nWe included one retrospective, single-institution study that compared post-operative imaging within 48 hours (early post-operative imaging) with no early post-operative imaging among 125 people who had surgery for glioblastoma (GBM: World Health Organization (WHO) grade 4 glioma).\nMost patients in the study underwent maximal surgical resection followed by combined radiotherapy and temozolomide treatment.\nAlthough patient characteristics in the study arms were comparable, the study was at high risk of bias overall.\nEvidence from this study suggested little or no difference between early and no early post-operative imaging with respect to overall survival (deaths) at one year after diagnosis of GBM (risk ratio (RR) 0.86, 95% confidence interval (CI) 0.61 to 1.21; 48% vs 55% died, respectively; very low certainty evidence) and little or no difference in overall survival (deaths) at two years after diagnosis of GBM (RR 1.06, 95% CI 0.91 to 1.25; 86% vs 81% died, respectively; very low certainty evidence).\nNo other review outcomes were reported.\nWe found no evidence on the effectiveness of other imaging schedules.\nIn addition, we identified no relevant economic evaluations assessing the efficiency of the different imaging strategies.\nThe effect of different imaging strategies on survival and other health outcomes remains largely unknown.\nExisting imaging schedules in glioma seem to be pragmatic rather than evidence-based.\nThe limited evidence suggesting that early post-operative brain imaging among GBM patients who will receive combined chemoradiation treatment may make little or no difference to survival needs to be further researched, particularly as early post-operative imaging also serves as a quality control measure that may lead to early re-operation if residual tumour is identified.\nMathematical modelling of a large glioma patient database could help to distinguish the optimal timing of surveillance imaging for different types of glioma, with stratification of patients facilitated by assessment of individual tumour growth rates, molecular biomarkers and other prognostic factors.\nIn addition, paediatric glioma study designs could be used to inform future research of imaging strategies among adults with glioma.\n\n\nSimplified text:\nWe found one study that compared post-operative imaging within 48 hours after surgery with no early post-operative imaging among 125 people who had surgery for glioblastoma. Most patients in the study underwent maximal surgical resection followed by combined radiotherapy and temozolomide treatment. Although patient characteristics were comparable, the study was at high risk of bias overall. We found no evidence on the effectiveness of other imaging schedules. In addition, we found no relevant economic evaluations assessing the efficiency of the different imaging strategies. The effect of different imaging schedules on survival and other health outcomes remains largely unknown. The limited evidence suggesting that early postoperative brain imaging among GBM patients who will receive combined chemoradiation treatment may make little or no difference to survival needs to be further researched, particularly as early pre-operatory imaging also serves as a quality control measure that may lead to early re-operation if residual tumour is identified. Mathematical modelling of a large glioma patient database could help to distinguish the optimal timing of surveillance imaging for different types of gliomas, with stratification of patients facilitated by assessment of individual tumour growth rates, molecular biomarkers and other prognostic factors, in addition, paediatric studies could be used to inform future research of imaging strategies among adults.","label":["Factuality 2","Fluency 2","Simplicity 1"]},{"id":"10.1002\/14651858.CD011655.pub2_0","text":"Unsimplified text:\nWe included three studies randomising 161 people with schizophrenia.\nData were available for only two of our seven prestated main outcomes.\nClinically important improvement in global state was measured using the Clinical Global Impression (CGI).\nThere was no clear difference between chlorpromazine and metiapine groups (2 RCTs, n = 120, RR 1.11, 95% CI 0.84 to 1.47, very low quality evidence) and numbers of participants with parkinsonism at eight weeks were similar (2 RCTs, n = 70, RR 0.97, 95% CI 0.46 to 2.03, very low quality evidence).\nThere were no useable data available for the other key outcomes of clinically important improvement in mental state, readmission due to relapse, satisfaction with treatment, aggressive or violent behaviour, or cost of care.\nChlorpromazine has been the mainstay treatment for schizophrenia for decades, yet available evidence comparing this drug to metiapine fails to provide high-quality trial based data.\nHowever, the need to determine whether metiapine is more or less effective than chlorpromazine seems to be lacking in clinical relevance and future research on this comparison seems unlikely.\n\n\nSimplified text:\nWe searched for studies comparing chlorpromazine to metiapine in people with schizophrenia. We found three studies randomising 161 people. The evidence is current to January 2015. The overall quality of the studies was very low, meaning that we are very uncertain about the results. We could not combine the results from the three studies to draw any firm conclusions about the efficacy and safety. There was not enough information for us to draw firm conclusions regarding the effectiveness or safety.","label":["Factuality 0","Fluency 2","Simplicity 1"]},{"id":"10.1002\/14651858.CD011655.pub2_1","text":"Unsimplified text:\nWe included three studies randomising 161 people with schizophrenia.\nData were available for only two of our seven prestated main outcomes.\nClinically important improvement in global state was measured using the Clinical Global Impression (CGI).\nThere was no clear difference between chlorpromazine and metiapine groups (2 RCTs, n = 120, RR 1.11, 95% CI 0.84 to 1.47, very low quality evidence) and numbers of participants with parkinsonism at eight weeks were similar (2 RCTs, n = 70, RR 0.97, 95% CI 0.46 to 2.03, very low quality evidence).\nThere were no useable data available for the other key outcomes of clinically important improvement in mental state, readmission due to relapse, satisfaction with treatment, aggressive or violent behaviour, or cost of care.\nChlorpromazine has been the mainstay treatment for schizophrenia for decades, yet available evidence comparing this drug to metiapine fails to provide high-quality trial based data.\nHowever, the need to determine whether metiapine is more or less effective than chlorpromazine seems to be lacking in clinical relevance and future research on this comparison seems unlikely.\n\n\nSimplified text:\nWe found three randomised controlled trials, involving 161 people with schizophrenia, that compared chlorpromazine with metiapine. We found no data available for the other key outcomes of clinically important improvement in mental state, readmission due to relapse, satisfaction with treatment, aggressive or violent behaviour, or cost of care. Chlorpromazine has been the mainstay treatment for schizophrenia for decades, yet available evidence comparing this drug to metiabine fails to provide high-quality trial based data.","label":["Factuality 2","Fluency 2","Simplicity 2"]},{"id":"10.1002\/14651858.CD006873.pub2_0","text":"Unsimplified text:\nTwenty-three studies were identified for inclusion.\nProbiotics were not superior to placebo for any outcome measured.\nThe use of nitroimidazole antibiotics appeared to reduce the risk of clinical (RR 0.23; 95%CI 0.09 to 0.57, NNT=4) and endoscopic (RR 0.44; 95%CI 0.26 to 0.74, NNT = 4) recurrence relative to placebo.\nHowever, these agents were associated with higher risk of serious adverse events (RR 2.39, 95% CI 1.5 to 3.7).\nMesalamine therapy was associated with a significantly reduced risk of clinical recurrence (RR 0.76; 95% CI 0.62 to 0.94, NNT = 12), and severe endoscopic recurrence (RR 0.50; 95% CI 0.29 to 0.84, NNT = 8) when compared to placebo.\nAzathioprine\/6MP was also associated with a significantly reduced risk of clinical recurrence (RR 0.59; 95% CI 0.38 to 0.92, NNT = 7), and severe endoscopic recurrence (RR 0.64; 95% CI 0.44 to 0.92, NNT = 4), when compared to placebo.\nNeither agent had a higher risk than placebo of serious adverse events.\nWhen compared to azathioprine\/6MP, mesalamine was associated with a higher risk of any endoscopic recurrence (RR 1.45, 95% CI 1.03 to 2.06), but a lower risk of serious adverse events (RR 0.51; 95% CI 0.30 to 0.89).\nThere was no significant difference between mesalamine and azathioprine\/6MP for any other outcome.\nThere are insufficient randomised controlled trials of infliximab, budesonide, tenovil and interleukin-10 to draw conclusions.\nNitro-imidazole antibiotics, mesalamine and immunosuppressive therapy with azathioprine\/6-MP or infliximab all appear to be superior to placebo for the prevention of post-operative recurrence of Crohn's disease.\nThe cost, toxicity and tolerability of these approaches require careful consideration to determine the optimal approach for post-operative prophylaxis.\n\n\nSimplified text:\nThis review found that nitroimidazole antibiotics, mesalamine, azathioprine, infliximab, budesonide, tenovil and interleukin-10 all appear to prevent recurrence of Crohn's disease after surgery. However, these agents were associated with higher risks of serious side effects.","label":["Factuality 2","Fluency 2","Simplicity 2"]},{"id":"10.1002\/14651858.CD006873.pub2_1","text":"Unsimplified text:\nTwenty-three studies were identified for inclusion.\nProbiotics were not superior to placebo for any outcome measured.\nThe use of nitroimidazole antibiotics appeared to reduce the risk of clinical (RR 0.23; 95%CI 0.09 to 0.57, NNT=4) and endoscopic (RR 0.44; 95%CI 0.26 to 0.74, NNT = 4) recurrence relative to placebo.\nHowever, these agents were associated with higher risk of serious adverse events (RR 2.39, 95% CI 1.5 to 3.7).\nMesalamine therapy was associated with a significantly reduced risk of clinical recurrence (RR 0.76; 95% CI 0.62 to 0.94, NNT = 12), and severe endoscopic recurrence (RR 0.50; 95% CI 0.29 to 0.84, NNT = 8) when compared to placebo.\nAzathioprine\/6MP was also associated with a significantly reduced risk of clinical recurrence (RR 0.59; 95% CI 0.38 to 0.92, NNT = 7), and severe endoscopic recurrence (RR 0.64; 95% CI 0.44 to 0.92, NNT = 4), when compared to placebo.\nNeither agent had a higher risk than placebo of serious adverse events.\nWhen compared to azathioprine\/6MP, mesalamine was associated with a higher risk of any endoscopic recurrence (RR 1.45, 95% CI 1.03 to 2.06), but a lower risk of serious adverse events (RR 0.51; 95% CI 0.30 to 0.89).\nThere was no significant difference between mesalamine and azathioprine\/6MP for any other outcome.\nThere are insufficient randomised controlled trials of infliximab, budesonide, tenovil and interleukin-10 to draw conclusions.\nNitro-imidazole antibiotics, mesalamine and immunosuppressive therapy with azathioprine\/6-MP or infliximab all appear to be superior to placebo for the prevention of post-operative recurrence of Crohn's disease.\nThe cost, toxicity and tolerability of these approaches require careful consideration to determine the optimal approach for post-operative prophylaxis.\n\n\nSimplified text:\nTwenty-three randomised controlled trials were identified for inclusion in this review. Nitro-imidazole antibiotics, mesalamine and immunosuppressive therapy with azathioprine\/6-MP or infliximab all appear to be superior to placebo for the prevention of post-operative recurrence of Crohn's disease. Neither of these agents had a higher risk than placebo of serious adverse events. There are insufficient trials of other antibiotics, budesonide, tenovil and interleukin-10 to draw conclusions. The cost, toxicity and tolerability of these approaches require careful consideration to determine the optimal approach for post-operatively prophylaxis.","label":["Factuality 0","Fluency 2","Simplicity 0"]},{"id":"10.1002\/14651858.CD009269.pub4_0","text":"Unsimplified text:\nWe included seven trials (825 participants).\nWe judged the majority of the trials to have a high or unclear risk of bias.\nThe psychosocial interventions considered in the studies were: cognitive-behavioural coping skills training (one study), twelve-step programme (one study), brief intervention (three studies), motivational interviewing (two studies), and brief motivational interviewing (one study).\nTwo studies were considered in two comparisons.\nThere were no data for the secondary outcome, alcohol-related harm.\nThe results were as follows.\nComparison 1: cognitive-behavioural coping skills training versus twelve-step programme (one study, 41 participants)\nThere was no significant difference between groups for either of the primary outcomes (alcohol abstinence assessed with Substance Abuse Calendar and breathalyser at one year: risk ratio (RR) 2.38 (95% confidence interval\n[CI] 0.10 to 55.06); and retention in treatment, measured at end of treatment: RR 0.89 (95% CI 0.62 to 1.29), or for any of the secondary outcomes reported.\nThe quality of evidence for the primary outcomes was very low.\nComparison 2: brief intervention versus treatment as usual (three studies, 197 participants)\nThere was no significant difference between groups for either of the primary outcomes (alcohol use, measured as scores on the Alcohol Use Disorders Identification Test (AUDIT) or Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) at three months: standardised mean difference (SMD) 0.07 (95% CI -0.24 to 0.37); and retention in treatment, measured at three months: RR 0.94 (95% CI 0.78 to 1.13), or for any of the secondary outcomes reported.\nThe quality of evidence for the primary outcomes was low.\nComparison 3: motivational interviewing versus treatment as usual or educational intervention only (three studies, 462 participants)\nThere was no significant difference between groups for either of the primary outcomes (alcohol use, measured as scores on the AUDIT or ASSIST at three months: SMD 0.04 (95% CI -0.29 to 0.37); and retention in treatment, measured at three months: RR 0.93 (95% CI 0.60 to 1.43), or for any of the secondary outcomes reported.\nThe quality of evidence for the primary outcomes was low.\nComparison 4: brief motivational intervention (BMI) versus assessment only (one study, 187 participants)\nMore people reduced alcohol use (by seven or more days in the past month, measured at six months) in the BMI group than in the control group (RR 1.67; 95% CI 1.08 to 2.60).\nThere was no difference between groups for the other primary outcome, retention in treatment, measured at end of treatment: RR 0.98 (95% CI 0.94 to 1.02), or for any of the secondary outcomes reported.\nThe quality of evidence for the primary outcomes was moderate.\nComparison 5: motivational interviewing (intensive) versus motivational interviewing (one study, 163 participants)\nThere was no significant difference between groups for either of the primary outcomes (alcohol use, measured using the Addiction Severity Index-alcohol score (ASI) at two months: MD 0.03 (95% CI 0.02 to 0.08); and retention in treatment, measured at end of treatment: RR 17.63 (95% CI 1.03 to 300.48), or for any of the secondary outcomes reported.\nThe quality of evidence for the primary outcomes was low.\nWe found low to very low-quality evidence to suggest that there is no difference in effectiveness between different types of psychosocial interventions to reduce alcohol consumption among people who use illicit drugs, and that brief interventions are not superior to assessment-only or to treatment as usual.\nNo firm conclusions can be made because of the paucity of the data and the low quality of the retrieved studies.\n\n\nSimplified text:\nWe found seven randomised controlled trials (825 participants) that compared different types of psychosocial interventions to reduce alcohol consumption among people who use illicit drugs. The studies were of low or very low quality. We found low to very low-quality evidence to suggest that there is no difference in effectiveness between different types in reducing alcohol consumption, and that brief interventions are not better than assessment-only or treatment as usual. No firm conclusions can be made because of the paucity of the data and the low quality of the retrieved studies.","label":["Factuality 2","Fluency 2","Simplicity 2"]},{"id":"10.1002\/14651858.CD009269.pub4_1","text":"Unsimplified text:\nWe included seven trials (825 participants).\nWe judged the majority of the trials to have a high or unclear risk of bias.\nThe psychosocial interventions considered in the studies were: cognitive-behavioural coping skills training (one study), twelve-step programme (one study), brief intervention (three studies), motivational interviewing (two studies), and brief motivational interviewing (one study).\nTwo studies were considered in two comparisons.\nThere were no data for the secondary outcome, alcohol-related harm.\nThe results were as follows.\nComparison 1: cognitive-behavioural coping skills training versus twelve-step programme (one study, 41 participants)\nThere was no significant difference between groups for either of the primary outcomes (alcohol abstinence assessed with Substance Abuse Calendar and breathalyser at one year: risk ratio (RR) 2.38 (95% confidence interval\n[CI] 0.10 to 55.06); and retention in treatment, measured at end of treatment: RR 0.89 (95% CI 0.62 to 1.29), or for any of the secondary outcomes reported.\nThe quality of evidence for the primary outcomes was very low.\nComparison 2: brief intervention versus treatment as usual (three studies, 197 participants)\nThere was no significant difference between groups for either of the primary outcomes (alcohol use, measured as scores on the Alcohol Use Disorders Identification Test (AUDIT) or Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) at three months: standardised mean difference (SMD) 0.07 (95% CI -0.24 to 0.37); and retention in treatment, measured at three months: RR 0.94 (95% CI 0.78 to 1.13), or for any of the secondary outcomes reported.\nThe quality of evidence for the primary outcomes was low.\nComparison 3: motivational interviewing versus treatment as usual or educational intervention only (three studies, 462 participants)\nThere was no significant difference between groups for either of the primary outcomes (alcohol use, measured as scores on the AUDIT or ASSIST at three months: SMD 0.04 (95% CI -0.29 to 0.37); and retention in treatment, measured at three months: RR 0.93 (95% CI 0.60 to 1.43), or for any of the secondary outcomes reported.\nThe quality of evidence for the primary outcomes was low.\nComparison 4: brief motivational intervention (BMI) versus assessment only (one study, 187 participants)\nMore people reduced alcohol use (by seven or more days in the past month, measured at six months) in the BMI group than in the control group (RR 1.67; 95% CI 1.08 to 2.60).\nThere was no difference between groups for the other primary outcome, retention in treatment, measured at end of treatment: RR 0.98 (95% CI 0.94 to 1.02), or for any of the secondary outcomes reported.\nThe quality of evidence for the primary outcomes was moderate.\nComparison 5: motivational interviewing (intensive) versus motivational interviewing (one study, 163 participants)\nThere was no significant difference between groups for either of the primary outcomes (alcohol use, measured using the Addiction Severity Index-alcohol score (ASI) at two months: MD 0.03 (95% CI 0.02 to 0.08); and retention in treatment, measured at end of treatment: RR 17.63 (95% CI 1.03 to 300.48), or for any of the secondary outcomes reported.\nThe quality of evidence for the primary outcomes was low.\nWe found low to very low-quality evidence to suggest that there is no difference in effectiveness between different types of psychosocial interventions to reduce alcohol consumption among people who use illicit drugs, and that brief interventions are not superior to assessment-only or to treatment as usual.\nNo firm conclusions can be made because of the paucity of the data and the low quality of the retrieved studies.\n\n\nSimplified text:\nWe included seven randomised controlled trials (825 participants) in this review. The interventions included: cognitive-behavioural coping skills training (one study), twelve-step programme, brief intervention (three studies), motivational interviewing (two studies), and brief motivational interviewing. We found low to very low-quality evidence to suggest that there is no difference in effectiveness between different types of psychosocial interventions to reduce alcohol consumption among people who use illicit drugs, and that brief interventions are not superior to assessment-only or to treatment as usual. The quality of evidence for the primary outcomes was low. We judged the majority of the trials to have a high or unclear risk of bias. No firm conclusions can be made because of the paucity of the data and the low quality of the retrieved studies.","label":["Factuality 2","Fluency 2","Simplicity 1"]},{"id":"10.1002\/14651858.CD005044.pub3_0","text":"Unsimplified text:\nWe identified 23 trials with a total of 1586 participants.\nFifty-eight per cent of these participants were from five unpublished studies.\nQuinine was compared to placebo (20 trials, n = 1140), vitamin E (four trials, n = 543), a quinine-vitamin E combination (three trials, n = 510), a quinine-theophylline combination (one trial, n = 77), and xylocaine injections into the gastrocnemius muscle (one trial, n = 24).\nThe most commonly used quinine dosage was 300 mg\/day (range 200 to 500 mg).\nWe found no new trials for inclusion when searches were updated in 2014.\nThe risk of bias in the trials varied considerably.\nAll 23 trials claimed to be randomised, but only a minority described randomisation and allocation concealment adequately.\nCompared to placebo, quinine significantly reduced cramp number over two weeks by 28%, cramp intensity by 10%, and cramp days by 20%.\nCramp duration was not significantly affected.\nA significantly greater number of people suffered minor adverse events on quinine than placebo (risk difference (RD) 3%, 95% confidence interval (CI) 0% to 6%), mainly gastrointestinal symptoms.\nOverdoses of quinine have been reported elsewhere to cause potentially fatal adverse effects, but in the included trials there was no significant difference in major adverse events compared with placebo (RD 0%, 95%\nCI -1% to 2%).\nOne participant suffered from thrombocytopenia (0.12% risk) on quinine.\nA quinine-vitamin E combination, vitamin E alone, and xylocaine injections into gastrocnemius were not significantly different to quinine across all outcomes, including adverse effects.\nBased on a single trial comparison, quinine alone was significantly less effective than a quinine-theophylline combination but with no significant differences in adverse events.\nThere is low quality evidence that quinine (200 mg to 500 mg daily) significantly reduces cramp number and cramp days and moderate quality evidence that quinine reduces cramp intensity.\nThere is moderate quality evidence that with use up to 60 days, the incidence of serious adverse events is not significantly greater than for placebo in the identified trials, but because serious adverse events can be rarely fatal, in some countries prescription of quinine is severely restricted.\nEvidence from single trials suggests that theophylline combined with quinine improves cramps more than quinine alone, and the effects of xylocaine injections into gastrocnemius are not significantly different to quinine across all outcomes.\nLow or moderate quality evidence shows no significant difference between quinine and vitamin E or quinine and quinine-vitamin E mixture.\nFurther research into these alternatives, as well other pharmacological and non-pharmacological treatments, is thus warranted.\nThere is no evidence to judge optimal dosage or duration of quinine treatment.\nFurther studies using different dosages and measurement of serum quinine levels will allow a therapeutic range to be defined for muscle cramp.\nBecause serious adverse events are not common, large population studies are required to more accurately inform incidence.\nLonger lengths of follow-up in future trials will help determine the duration of action following cessation of quinine as well as long-term adverse events.\nThe search for new therapies, pharmacological and nonpharmacological, should continue and further trials should compare vitamin E, quinine-vitamin E combination, and quinine-theophylline mixture with quinine.\n\n\nSimplified text:\nWe searched for randomised controlled trials (clinical trials where people are randomly put into one of two or more treatment or control groups). We found 23 trials involving 1586 people. The most commonly used quinine dosage was 300 to 500 mg daily. We did not find any trials that compared quinines to placebo, vitamin E, or any other treatment. We found five unpublished studies. The quality of the included trials was low or moderate, meaning that we are uncertain about the results. The evidence is current up to January 2014. The review found that quinide reduced the number of muscle cramp days by 28%, cramp number by 10%, and cramp intensity by 20%. However, there was not enough evidence to say whether it was better or worse than other treatments for muscle cramps. The number of people who suffered minor side effects was higher than placebo, mainly gastrointestinal symptoms. One person had thrombocytopenia, which is a blood clotting disorder caused by a blood clots in the blood vessels in the leg. There was moderate quality evidence that with use up to 60 days, the incidence of serious side effects is not significantly greater than placebo in the identified trials, but because serious adverse events can be rarely fatal, in some countries prescription is severely restricted. Further studies using different dosages, measurement of serum quinin levels, and longer periods of treatment are needed. The search for new therapies, pharmacological and other treatments, should continue. More research into these alternatives, as well as other pharmacological treatments, is needed.","label":["Factuality 1","Fluency 1","Simplicity 1"]},{"id":"10.1002\/14651858.CD005044.pub3_1","text":"Unsimplified text:\nWe identified 23 trials with a total of 1586 participants.\nFifty-eight per cent of these participants were from five unpublished studies.\nQuinine was compared to placebo (20 trials, n = 1140), vitamin E (four trials, n = 543), a quinine-vitamin E combination (three trials, n = 510), a quinine-theophylline combination (one trial, n = 77), and xylocaine injections into the gastrocnemius muscle (one trial, n = 24).\nThe most commonly used quinine dosage was 300 mg\/day (range 200 to 500 mg).\nWe found no new trials for inclusion when searches were updated in 2014.\nThe risk of bias in the trials varied considerably.\nAll 23 trials claimed to be randomised, but only a minority described randomisation and allocation concealment adequately.\nCompared to placebo, quinine significantly reduced cramp number over two weeks by 28%, cramp intensity by 10%, and cramp days by 20%.\nCramp duration was not significantly affected.\nA significantly greater number of people suffered minor adverse events on quinine than placebo (risk difference (RD) 3%, 95% confidence interval (CI) 0% to 6%), mainly gastrointestinal symptoms.\nOverdoses of quinine have been reported elsewhere to cause potentially fatal adverse effects, but in the included trials there was no significant difference in major adverse events compared with placebo (RD 0%, 95%\nCI -1% to 2%).\nOne participant suffered from thrombocytopenia (0.12% risk) on quinine.\nA quinine-vitamin E combination, vitamin E alone, and xylocaine injections into gastrocnemius were not significantly different to quinine across all outcomes, including adverse effects.\nBased on a single trial comparison, quinine alone was significantly less effective than a quinine-theophylline combination but with no significant differences in adverse events.\nThere is low quality evidence that quinine (200 mg to 500 mg daily) significantly reduces cramp number and cramp days and moderate quality evidence that quinine reduces cramp intensity.\nThere is moderate quality evidence that with use up to 60 days, the incidence of serious adverse events is not significantly greater than for placebo in the identified trials, but because serious adverse events can be rarely fatal, in some countries prescription of quinine is severely restricted.\nEvidence from single trials suggests that theophylline combined with quinine improves cramps more than quinine alone, and the effects of xylocaine injections into gastrocnemius are not significantly different to quinine across all outcomes.\nLow or moderate quality evidence shows no significant difference between quinine and vitamin E or quinine and quinine-vitamin E mixture.\nFurther research into these alternatives, as well other pharmacological and non-pharmacological treatments, is thus warranted.\nThere is no evidence to judge optimal dosage or duration of quinine treatment.\nFurther studies using different dosages and measurement of serum quinine levels will allow a therapeutic range to be defined for muscle cramp.\nBecause serious adverse events are not common, large population studies are required to more accurately inform incidence.\nLonger lengths of follow-up in future trials will help determine the duration of action following cessation of quinine as well as long-term adverse events.\nThe search for new therapies, pharmacological and nonpharmacological, should continue and further trials should compare vitamin E, quinine-vitamin E combination, and quinine-theophylline mixture with quinine.\n\n\nSimplified text:\nWe searched for randomised controlled trials (clinical trials where people are randomly put into one of two or more treatment groups) comparing quinine with placebo or no treatment. We found 23 trials with a total of 1586 participants. Fifty-eight per cent of these participants were from five unpublished studies. The risk of bias in the trials varied considerably. Quinine alone was significantly less effective than a combination of vitamin E and theophylline but with no significant differences in adverse events compared with placebo (RD 0%, 95% CI -1% to 2%). Vitamin E, vitamin E alone, and xylocaine injections into gastrocnemius were not significantly different to quine across all outcomes, including adverse effects. The quality of the evidence was low or moderate for cramp number and cramp days and moderate quality evidence for cramps intensity. There is no evidence to judge optimal dosage or duration of treatment. Evidence from single trials suggests that theophyLLine combined with quinines improves cramps more than quinaine alone. The incidence of serious adverse events with use up to 60 days is not significantly greater than for placebo in the identified trials, but because serious side effects can be rarely fatal, in some countries prescription of the drug is severely restricted. Longer lengths of follow-up in future trials will help determine the duration of action following cessation of treatment as well as long-term adverse events. The search for new therapies, pharmacological and nonpharmacological, should continue.","label":["Factuality 2","Fluency 2","Simplicity 2"]},{"id":"10.1002\/14651858.CD009402.pub2_0","text":"Unsimplified text:\nWe identified seven trials (five parallel, two cross-over) enrolling a total of 406 individuals amongst whom 118 cross-over participants additionally served as their own controls.\nThree trials enrolled women with pregnancy-associated leg cramps (N = 202) and four trials enrolled idiopathic cramp sufferers (N = 322 including cross-over controls).\nMagnesium was compared to placebo in six trials and to no treatment in one trial.\nFor idiopathic cramps (largely older adults presumed to have nocturnal leg cramps), differences in measures of cramp frequency, magnesium versus placebo, were small, not statistically significant, and without heterogeneity (I2 = 0%).\nThis includes the primary endpoint, percentage change from baseline in the number of cramps per week at four weeks (-3.93%, 95% confidence interval (CI) -21.12% to 13.26%, moderate quality evidence) and the difference in the number of cramps per week at four weeks (0.01 cramps\/week, 95% CI -0.52 to 0.55, moderate quality evidence).\nThe percentage of individuals experiencing a 25% or better reduction in cramp rate from baseline was also no different, being 8% lower in the magnesium group (95% CI -28% to 12%, moderate quality evidence).\nSimilarly, no statistically significant difference was found at four weeks in measures of cramp intensity (moderate quality evidence) or cramp duration (low quality evidence).\nMeta-analysis was not possible for trials of pregnancy-associated leg cramps.\nThe single study comparing magnesium to no treatment failed to find statistically significant benefit on a three-point ordinal scale of overall treatment efficacy.\nThe two trials comparing magnesium to placebo differed in that one trial found no benefit on frequency or intensity measures while the other found benefit for both.\nWithdrawals due to adverse events were not significantly different than placebo.\nWhile we could not determine the number of subjects with minor adverse events, studies of oral magnesium generally described potential side effects as similar in frequency to placebo.\nIt is unlikely that magnesium supplementation provides clinically meaningful cramp prophylaxis to older adults experiencing skeletal muscle cramps.\nIn contrast, for those experiencing pregnancy-associated rest cramps the literature is conflicting and further research in this patient population is needed.\nWe found no randomized controlled trials evaluating magnesium for exercise-associated muscle cramps or disease state-associated muscle cramps (for example amyotrophic lateral sclerosis\/motor neuron disease).\n\n\nSimplified text:\nWe found seven randomised controlled trials enrolling a total of 406 individuals. Three trials enrolled pregnant women with pregnancy-associated leg cramps and four trials enrolled idiopathic cramp sufferers. In six trials, magnesium was compared with no treatment (placebo or no treatment) in six trials. In four trials, it was compared to placebo (a dummy pill). We found no randomized controlled trials evaluating muscle-related muscle cramps or disease state cramps (for example amyotrophic lateral sclerosis or motor neuron disease). The evidence is current to January 2016. We found that there was not enough information available to draw any conclusions about the benefits or harms of magnesium in older adults experiencing skeletal muscle cramp. However, we found that it is unlikely that magnesium supplements can prevent muscle pain for older adults who have nocturnal leg pain. In contrast, for those experiencing pregnancy-related rest cramps the literature is conflicting and more research is needed. Withdrawals from the studies due to side effects were not different from placebo. While we could not determine the number of people with minor side effects, studies of oral magnesium generally described potential side effects as similar to placebo.","label":["Factuality 0","Fluency 2","Simplicity 1"]},{"id":"10.1002\/14651858.CD009402.pub2_1","text":"Unsimplified text:\nWe identified seven trials (five parallel, two cross-over) enrolling a total of 406 individuals amongst whom 118 cross-over participants additionally served as their own controls.\nThree trials enrolled women with pregnancy-associated leg cramps (N = 202) and four trials enrolled idiopathic cramp sufferers (N = 322 including cross-over controls).\nMagnesium was compared to placebo in six trials and to no treatment in one trial.\nFor idiopathic cramps (largely older adults presumed to have nocturnal leg cramps), differences in measures of cramp frequency, magnesium versus placebo, were small, not statistically significant, and without heterogeneity (I2 = 0%).\nThis includes the primary endpoint, percentage change from baseline in the number of cramps per week at four weeks (-3.93%, 95% confidence interval (CI) -21.12% to 13.26%, moderate quality evidence) and the difference in the number of cramps per week at four weeks (0.01 cramps\/week, 95% CI -0.52 to 0.55, moderate quality evidence).\nThe percentage of individuals experiencing a 25% or better reduction in cramp rate from baseline was also no different, being 8% lower in the magnesium group (95% CI -28% to 12%, moderate quality evidence).\nSimilarly, no statistically significant difference was found at four weeks in measures of cramp intensity (moderate quality evidence) or cramp duration (low quality evidence).\nMeta-analysis was not possible for trials of pregnancy-associated leg cramps.\nThe single study comparing magnesium to no treatment failed to find statistically significant benefit on a three-point ordinal scale of overall treatment efficacy.\nThe two trials comparing magnesium to placebo differed in that one trial found no benefit on frequency or intensity measures while the other found benefit for both.\nWithdrawals due to adverse events were not significantly different than placebo.\nWhile we could not determine the number of subjects with minor adverse events, studies of oral magnesium generally described potential side effects as similar in frequency to placebo.\nIt is unlikely that magnesium supplementation provides clinically meaningful cramp prophylaxis to older adults experiencing skeletal muscle cramps.\nIn contrast, for those experiencing pregnancy-associated rest cramps the literature is conflicting and further research in this patient population is needed.\nWe found no randomized controlled trials evaluating magnesium for exercise-associated muscle cramps or disease state-associated muscle cramps (for example amyotrophic lateral sclerosis\/motor neuron disease).\n\n\nSimplified text:\nWe found seven trials (five parallel, two cross-over) enrolling a total of 406 participants. Three trials enrolled women with pregnancy-associated leg cramps (N = 202) and four trials enrolled idiopathic cramp sufferers (n = 322) in four trials. Magnesium was compared to placebo in six trials and to no treatment in one trial. We found no randomized controlled trials evaluating magnesium for exercise-associated muscle cramps or disease state-associated cramps. The two trials comparing magnesium to placebo differed in that one trial found no benefit on frequency or intensity measures while the other found benefit for both. The percentage of individuals experiencing a 25% or better reduction in cramp rate from baseline was also no different, being 8% lower in the magnesium group. While we could not determine the number of subjects with minor adverse events, studies of oral magnesium generally described potential side effects as similar in frequency to placebo. It is unlikely that magnesium supplementation provides clinically meaningful cramp prophylaxis to older adults experiencing skeletal muscle cramp. In contrast, for those experiencing pregnant-associated rest cramps the literature is conflicting and further research in this patient population is needed.","label":["Factuality 2","Fluency 2","Simplicity 1"]},{"id":"10.1002\/14651858.CD012120.pub2_0","text":"Unsimplified text:\nWe included one RCT that studied the effects of a six-month, home-based, combined muscle strength and recumbent cycle ergometry training program versus usual care in 14 ambulatory people with SMA.\nThe age range of the participants was between 10 years and 48 years.\nThe study was evaluator-blinded, but personnel and participants could not be blinded to the intervention, which placed the results at a high risk of bias.\nParticipants performed strength training as prescribed, but 50% of the participants did not achieve the intended aerobic exercise training regimen.\nThe trial used change in walking distance on the six-minute walk test as a measure of function; a minimal detectable change is 24.0 m. The change from baseline to six months' follow-up in the training group (9.4 m) was not detectably different from the change in the usual care group (-0.14 m) (mean difference (MD) 9.54 m, 95% confidence interval (CI) -83.04 to 102.12; N = 12).\nCardiopulmonary exercise capacity, assessed by the change from baseline to six months' follow-up in peak oxygen uptake (VO2max) was similar in the training group (-0.12 mL\/kg\/min) and the usual care group (-1.34 mL\/kg\/min) (MD 1.22 mL\/kg\/min, 95% CI -2.16 to 4.6; N = 12).\nA clinically meaningful increase in VO2max is 3.5 mL\/kg\/min.\nThe trial assessed function on the Hammersmith Functional Motor Scale - Expanded (HFMSE), which has a range of possible scores from 0 to 66, with an increase of 3 or more points indicating clinically meaningful improvement.\nThe HFMSE score in the training group increased by 2 points from baseline to six months' follow-up, with no change in the usual care group (MD 2.00, 95% CI -2.06 to 6.06; N = 12).\nThe training group showed a slight improvement in muscle strength, expressed as the manual muscle testing (MMT) total score, which ranges from 28 (weakest) to 280 (strongest).\nThe change from baseline in MMT total score was 6.8 in the training group compared to -5.14 in the usual care group (MD 11.94, 95% CI -3.44 to 27.32; N = 12).\nThe trial stated that training had no statistically significant effects on fatigue and quality of life.\nThe certainty of evidence for all outcomes was very low because of study limitations and imprecision.\nThe study did not assess the effects of physical exercise training on physical activity levels.\nNo study-related serious adverse events or adverse events leading to withdrawal occurred, but we cannot draw wider conclusions from this very low-certainty evidence.\nIt is uncertain whether combined strength and aerobic exercise training is beneficial or harmful in people with SMA type 3, as the quality of evidence is very low.\nWe need well-designed and adequately powered studies using protocols that meet international standards for the development of training interventions, in order to improve our understanding of the exercise response in people with SMA type 3 and eventually develop exercise guidelines for this condition.\n\n\nSimplified text:\nWe searched the medical literature up until January 2014. We found one randomised controlled trials that compared a six-month, home-based, combined muscle strength and exercise training program with usual care. The age range of the participants was between 10 years and 48 years. The study did not assess the effects on physical activity levels. Participants performed strength training as prescribed, but about half of the people did not achieve the intended exercise training regimen. The results showed that exercise training did not improve walking distance in people with SMA type 3, which was not different from the usual care group. However, muscle strength in the training group increased by 2 points from the start to six months after the start of the exercise program compared to usual care, while muscle strength did not change at the end of the training program. The quality of the evidence was very low, which means that we cannot draw any conclusions from this review. No serious side effects or side effects leading to withdrawal occurred. The certainty in the results of this review is very low because the results were imprecise. We need more research in this area.","label":["Factuality 0","Fluency 2","Simplicity 1"]},{"id":"10.1002\/14651858.CD012120.pub2_1","text":"Unsimplified text:\nWe included one RCT that studied the effects of a six-month, home-based, combined muscle strength and recumbent cycle ergometry training program versus usual care in 14 ambulatory people with SMA.\nThe age range of the participants was between 10 years and 48 years.\nThe study was evaluator-blinded, but personnel and participants could not be blinded to the intervention, which placed the results at a high risk of bias.\nParticipants performed strength training as prescribed, but 50% of the participants did not achieve the intended aerobic exercise training regimen.\nThe trial used change in walking distance on the six-minute walk test as a measure of function; a minimal detectable change is 24.0 m. The change from baseline to six months' follow-up in the training group (9.4 m) was not detectably different from the change in the usual care group (-0.14 m) (mean difference (MD) 9.54 m, 95% confidence interval (CI) -83.04 to 102.12; N = 12).\nCardiopulmonary exercise capacity, assessed by the change from baseline to six months' follow-up in peak oxygen uptake (VO2max) was similar in the training group (-0.12 mL\/kg\/min) and the usual care group (-1.34 mL\/kg\/min) (MD 1.22 mL\/kg\/min, 95% CI -2.16 to 4.6; N = 12).\nA clinically meaningful increase in VO2max is 3.5 mL\/kg\/min.\nThe trial assessed function on the Hammersmith Functional Motor Scale - Expanded (HFMSE), which has a range of possible scores from 0 to 66, with an increase of 3 or more points indicating clinically meaningful improvement.\nThe HFMSE score in the training group increased by 2 points from baseline to six months' follow-up, with no change in the usual care group (MD 2.00, 95% CI -2.06 to 6.06; N = 12).\nThe training group showed a slight improvement in muscle strength, expressed as the manual muscle testing (MMT) total score, which ranges from 28 (weakest) to 280 (strongest).\nThe change from baseline in MMT total score was 6.8 in the training group compared to -5.14 in the usual care group (MD 11.94, 95% CI -3.44 to 27.32; N = 12).\nThe trial stated that training had no statistically significant effects on fatigue and quality of life.\nThe certainty of evidence for all outcomes was very low because of study limitations and imprecision.\nThe study did not assess the effects of physical exercise training on physical activity levels.\nNo study-related serious adverse events or adverse events leading to withdrawal occurred, but we cannot draw wider conclusions from this very low-certainty evidence.\nIt is uncertain whether combined strength and aerobic exercise training is beneficial or harmful in people with SMA type 3, as the quality of evidence is very low.\nWe need well-designed and adequately powered studies using protocols that meet international standards for the development of training interventions, in order to improve our understanding of the exercise response in people with SMA type 3 and eventually develop exercise guidelines for this condition.\n\n\nSimplified text:\nWe included one randomised controlled trial (RCT) that compared a six-month, home-based, combined muscle strength and recumbent cycle ergometry training program versus usual care in 14 ambulatory people with SMA type 3. The age range of the participants was between 10 years and 48 years. The study was evaluator-blinded, but personnel and participants could not be blinded to the intervention, which placed the results at a high risk of bias. Participants performed strength training as prescribed, but 50% did not achieve the intended aerobic exercise training regimen. The trial stated that training had no statistically significant effects on fatigue and quality of life. No study-related serious adverse events or adverse events leading to withdrawal occurred, but we cannot draw wider conclusions from this very low-certainty evidence. The certainty of evidence for all outcomes was very low because of study limitations and imprecision. We need well-designed and adequately powered studies using protocols that meet international standards for the development of training interventions, in order to improve our understanding of the exercise response in people with spinal cord injury and eventually develop exercise guidelines for this condition.","label":["Factuality 2","Fluency 2","Simplicity 1"]},{"id":"10.1002\/14651858.CD001466.pub3_0","text":"Unsimplified text:\nTwo trials (N = 149) were included.\nIn both trials, allocation concealment was inadequate and arrangements for blinding of outcome assessment were unclear.\nOne trial (81 patients with cervical radiculopathy) found that surgical decompression was superior tophysiotherapy or cervical collar immobilization in the short-term for pain, weakness or sensory loss; at one year, there were no significant differences between groups.\nOne trial (68 patients with mild functional deficit associated with cervical myelopathy) foundno significant differences between surgery and conservative treatment in three years following treatment.\nA substantial proportion of cases were lost to follow-up.\nBoth small trials had significant risks of bias and do not provide reliable evidence on the effects of surgery for cervical spondylotic radiculopathy or myelopathy.\nIt is unclear whether the short-term risks of surgery are offset by long-term benefits.\nFurther research is very likely to have an impact on the estimate of effect and our confidence in it.\nThere is low quality evidence that surgery may provide pain relief faster than physiotherapy or hard collar immobilization in patients with cervical radiculopathy; but there is little or no difference in the long-term.\nThere is very low quality evidence that patients with mild myelopathy feel subjectively better shortly after surgery, but there is little or no difference in the long-term.\n\n\nSimplified text:\nWe searched the medical literature for clinical trials comparing surgery with physiotherapy or hard collar immobilization in patients with spondylosis or myelopathy. We found two small trials with 149 patients. One trial found that surgical decompression was better than physiotherapy in the short-term for pain, weakness or sensory loss, but there was little or no difference in the long-term. There is very low quality evidence that patients with mild myelitis feel subjectively better shortly after surgery, and there is little or more evidence that surgery may provide pain relief faster than physiotherapy or hardcollar immobilization. However, it is unclear whether the short term risks of surgery are offset by longterm benefits. Further research is very likely to have an impact on the estimate of effect and our confidence in it.","label":["Factuality 2","Fluency 2","Simplicity 2"]},{"id":"10.1002\/14651858.CD001466.pub3_1","text":"Unsimplified text:\nTwo trials (N = 149) were included.\nIn both trials, allocation concealment was inadequate and arrangements for blinding of outcome assessment were unclear.\nOne trial (81 patients with cervical radiculopathy) found that surgical decompression was superior tophysiotherapy or cervical collar immobilization in the short-term for pain, weakness or sensory loss; at one year, there were no significant differences between groups.\nOne trial (68 patients with mild functional deficit associated with cervical myelopathy) foundno significant differences between surgery and conservative treatment in three years following treatment.\nA substantial proportion of cases were lost to follow-up.\nBoth small trials had significant risks of bias and do not provide reliable evidence on the effects of surgery for cervical spondylotic radiculopathy or myelopathy.\nIt is unclear whether the short-term risks of surgery are offset by long-term benefits.\nFurther research is very likely to have an impact on the estimate of effect and our confidence in it.\nThere is low quality evidence that surgery may provide pain relief faster than physiotherapy or hard collar immobilization in patients with cervical radiculopathy; but there is little or no difference in the long-term.\nThere is very low quality evidence that patients with mild myelopathy feel subjectively better shortly after surgery, but there is little or no difference in the long-term.\n\n\nSimplified text:\nThis review of two small trials found that surgery may provide pain relief faster than physiotherapy or hard collar immobilization, but there is little or no difference in the long-term. One trial (81 patients with cervical radiculopathy) found that surgical decompression was superior tophysiotherapy orcollar immobilization in the short-term for pain, weakness or sensory loss; at one year, there were no significant differences between groups. There is very low quality evidence that patients with mild myelopathy feel subjectively better shortly after surgery, but it is unclear whether there is any difference between surgery and conservative treatment in the longer term. It is not clear whether the short term risks of surgery are offset by long term benefits. Further research is very likely to have an impact on the estimate of effect and our confidence in it. Both small trials had significant risks of bias and do not provide reliable evidence on the effects of surgery for cervical spondylosis.","label":["Factuality 2","Fluency 2","Simplicity 0"]},{"id":"10.1002\/14651858.CD004180.pub2_0","text":"Unsimplified text:\nNine studies met our inclusion criteria, five RCTs, one CCT and three ITSs.\nSix studies compared telephone consultation versus normal care; four by a doctor, one by a nurse and one by a clinic clerk.\nThree studies compared telephone consultation by different types of health care workers; two compared nurses with doctors and one compared health assistants with doctors or nurses.\nThree of five studies found a decrease in visits to GP's but two found a significant increase in return consultations.\nIn general at least 50% of calls were handled by telephone advice alone.\nSeven studies looked at accident and emergency department visits, six showed no difference between the groups and one, of nurse telephone consultation, found an increase in visits.\nTwo studies reported deaths and found no difference between nurse telephone triage and normal care.\nTelephone consultation appears to reduce the number of surgery contacts and out-of-hours visits by general practitioners.\nHowever, questions remain about its affect on service use and further rigorous evaluation is needed with emphasis on service use, safety, cost and patient satisfaction.\n\n\nSimplified text:\nThis review found nine studies that evaluated the effectiveness and safety of telephone consultation. Telephone consultation appears to reduce the number of visits by doctors or nurses to GP's. However, questions remain about its affect on service use and further rigorous evaluation is needed with emphasis on service quality, safety, cost and patient satisfaction.","label":["Factuality 1","Fluency 2","Simplicity 2"]},{"id":"10.1002\/14651858.CD004180.pub2_1","text":"Unsimplified text:\nNine studies met our inclusion criteria, five RCTs, one CCT and three ITSs.\nSix studies compared telephone consultation versus normal care; four by a doctor, one by a nurse and one by a clinic clerk.\nThree studies compared telephone consultation by different types of health care workers; two compared nurses with doctors and one compared health assistants with doctors or nurses.\nThree of five studies found a decrease in visits to GP's but two found a significant increase in return consultations.\nIn general at least 50% of calls were handled by telephone advice alone.\nSeven studies looked at accident and emergency department visits, six showed no difference between the groups and one, of nurse telephone consultation, found an increase in visits.\nTwo studies reported deaths and found no difference between nurse telephone triage and normal care.\nTelephone consultation appears to reduce the number of surgery contacts and out-of-hours visits by general practitioners.\nHowever, questions remain about its affect on service use and further rigorous evaluation is needed with emphasis on service use, safety, cost and patient satisfaction.\n\n\nSimplified text:\nNine studies met our inclusion criteria, five RCTs, one CCT and three ITSs. Six studies compared telephone consultation versus normal care; four by a doctor, one by a nurse and one by clinic clerk. Three studies compared different types of health care workers; two compared nurses with doctors and one compared health assistants with doctors or nurses. Three of five studies found a decrease in visits to GP's but two found a significant increase in return consultations. Seven studies looked at accident and emergency department visits, six showed no difference between the groups and one, of nurse telephone consultation, found an increase in visits. Telephone consultation appears to reduce the number of surgery contacts and out-of-hours visits by general practitioners. However, questions remain about its affect on service use and further rigorous evaluation is needed.","label":["Factuality 2","Fluency 2","Simplicity 0"]},{"id":"10.1002\/14651858.CD007025.pub4_0","text":"Unsimplified text:\nWe included a total of 84 trials (22,872 participants), with 70\/84 studies reporting interventions in higher risk individuals or settings.\nStudies with follow-up periods of at least four months were of more interest in assessing the sustainability of intervention effects and were also less susceptible to short-term reporting or publication bias.\nOverall, the risk of bias assessment showed that these studies provided moderate or low quality evidence.\nAt four or more months follow-up, we found effects in favour of MI for the quantity of alcohol consumed (standardised mean difference (SMD) 0.11, 95% confidence interval (CI) 0.15 to 0.06 or a reduction from 13.7 drinks\/week to 12.5 drinks\/week; moderate quality evidence); frequency of alcohol consumption (SMD 0.14, 95% CI 0.21 to 0.07 or a reduction in the number of days\/week alcohol was consumed from 2.74 days to 2.52 days; moderate quality evidence); and peak blood alcohol concentration, or BAC (SMD 0.12, 95% CI 0.20 to 0.05, or a reduction from 0.144% to 0.131%; moderate quality evidence).\nWe found a marginal effect in favour of MI for alcohol problems (SMD 0.08, 95% CI 0.17 to 0.00 or a reduction in an alcohol problems scale score from 8.91 to 8.18; low quality evidence) and no effects for binge drinking (SMD 0.04, 95% CI 0.09 to 0.02, moderate quality evidence) or for average BAC (SMD 0.05, 95% CI 0.18 to 0.08; moderate quality evidence).\nWe also considered other alcohol-related behavioural outcomes, and at four or more months follow-up, we found no effects on drink-driving (SMD 0.13, 95% CI 0.36 to 0.10; moderate quality of evidence) or other alcohol-related risky behaviour (SMD 0.15, 95% CI 0.31 to 0.01; moderate quality evidence).\nFurther analyses showed that there was no clear relationship between the duration of the MI intervention (in minutes) and effect size.\nSubgroup analyses revealed no clear subgroup effects for longer-term outcomes (four or more months) for assessment only versus alternative intervention controls; for university\/college vs other settings; or for higher risk vs all\/low risk participants.\nNone of the studies reported harms related to MI.\nThe results of this review indicate that there are no substantive, meaningful benefits of MI interventions for preventing alcohol use, misuse or alcohol-related problems.\nAlthough we found some statistically significant effects, the effect sizes were too small, given the measurement scales used in the included studies, to be of relevance to policy or practice.\nMoreover, the statistically significant effects are not consistent for all misuse measures, and the quality of evidence is not strong, implying that any effects could be inflated by risk of bias.\n\n\nSimplified text:\nWe found 84 studies, involving 22,872 participants, that compared MI with no MI. The evidence is current to January 2016. We found that MI reduced the number and frequency of alcohol consumption, the number of days\/week that alcohol was consumed, the amount that was consumed and the number that was binge-drinking. However, MI did not reduce the number or severity of misuse of alcohol. We also found that there was not enough evidence that MI had any beneficial effects on drink-driving, binge drinking, or other alcohol-related risky behaviours. None of the studies reported harms related to MI. Overall, the evidence is of moderate or low quality, meaning that we are uncertain about the results of this review.","label":["Factuality 2","Fluency 2","Simplicity 2"]},{"id":"10.1002\/14651858.CD007025.pub4_1","text":"Unsimplified text:\nWe included a total of 84 trials (22,872 participants), with 70\/84 studies reporting interventions in higher risk individuals or settings.\nStudies with follow-up periods of at least four months were of more interest in assessing the sustainability of intervention effects and were also less susceptible to short-term reporting or publication bias.\nOverall, the risk of bias assessment showed that these studies provided moderate or low quality evidence.\nAt four or more months follow-up, we found effects in favour of MI for the quantity of alcohol consumed (standardised mean difference (SMD) 0.11, 95% confidence interval (CI) 0.15 to 0.06 or a reduction from 13.7 drinks\/week to 12.5 drinks\/week; moderate quality evidence); frequency of alcohol consumption (SMD 0.14, 95% CI 0.21 to 0.07 or a reduction in the number of days\/week alcohol was consumed from 2.74 days to 2.52 days; moderate quality evidence); and peak blood alcohol concentration, or BAC (SMD 0.12, 95% CI 0.20 to 0.05, or a reduction from 0.144% to 0.131%; moderate quality evidence).\nWe found a marginal effect in favour of MI for alcohol problems (SMD 0.08, 95% CI 0.17 to 0.00 or a reduction in an alcohol problems scale score from 8.91 to 8.18; low quality evidence) and no effects for binge drinking (SMD 0.04, 95% CI 0.09 to 0.02, moderate quality evidence) or for average BAC (SMD 0.05, 95% CI 0.18 to 0.08; moderate quality evidence).\nWe also considered other alcohol-related behavioural outcomes, and at four or more months follow-up, we found no effects on drink-driving (SMD 0.13, 95% CI 0.36 to 0.10; moderate quality of evidence) or other alcohol-related risky behaviour (SMD 0.15, 95% CI 0.31 to 0.01; moderate quality evidence).\nFurther analyses showed that there was no clear relationship between the duration of the MI intervention (in minutes) and effect size.\nSubgroup analyses revealed no clear subgroup effects for longer-term outcomes (four or more months) for assessment only versus alternative intervention controls; for university\/college vs other settings; or for higher risk vs all\/low risk participants.\nNone of the studies reported harms related to MI.\nThe results of this review indicate that there are no substantive, meaningful benefits of MI interventions for preventing alcohol use, misuse or alcohol-related problems.\nAlthough we found some statistically significant effects, the effect sizes were too small, given the measurement scales used in the included studies, to be of relevance to policy or practice.\nMoreover, the statistically significant effects are not consistent for all misuse measures, and the quality of evidence is not strong, implying that any effects could be inflated by risk of bias.\n\n\nSimplified text:\nWe included 84 studies with a total of 22,872 participants, with 70\/84 studies reporting interventions in higher risk individuals or settings. Studies with follow-up periods of at least four months were of more interest in assessing the sustainability of intervention effects and were also less susceptible to short-term reporting or publication bias. None of the studies reported harms related to MI. Overall, the risk of bias assessment showed that these studies provided moderate or low quality evidence. The results of this review indicate that there are no substantive, meaningful benefits of MI interventions for preventing alcohol use, misuse or alcohol-related problems. Although we found some statistically significant effects, the effect sizes were too small, given the measurement scales used in the included studies, to be of relevance to policy or practice. Moreover, the quality of evidence is not strong, implying that any effects could be inflated by chance.","label":["Factuality 1","Fluency 0","Simplicity 0"]},{"id":"10.1002\/14651858.CD012286.pub2_0","text":"Unsimplified text:\nThis review includes 29 parallel randomised controlled trials (RCTs) (n = 2210), although not all reported relevant or useable data.\nAll participants had asthma, and follow-up ranged from 2 to 26 weeks.\nMost studies were at low or unclear risk of selection and attrition biases and at high risk for biases associated with blinding.\nWe considered most of the evidence to be of low quality owing to these biases and to imprecision in the estimates of effect.\nWe classified studies into three comparisons: enhanced face-to-face training session(s), multi-media-delivered inhaler training (e.g. DVD, computer app or game) and technique feedback devices.\nDifferences between interventions, populations and outcome measures limited quantitative analyses, particularly for exacerbations, adverse events, unscheduled visits to a healthcare provider and absenteeism from work or school.\nEnhanced inhaler technique education and multi-media training improved technique in most studies immediately after the intervention and at follow-up, although the variety of checklists used meant that this was difficult to assess reliably.\nFor both adults and children, how and when inhaler technique was assessed appeared to affect whether inhaler technique improved and by how much.\nAnalyses of the numbers of people who demonstrated correct or 'good enough' technique were generally more useful than checklist scores.\nAdult studies of enhanced education showed benefit when this metric was used at 2 to 26 weeks' follow-up (odds ratio (OR) 5.00, 95% confidence interval (CI) 1.83 to 13.65; 258 participants; three studies; 31 per 100 with correct technique in the control group compared with 69 (95% CI 45 to 86) in the education group; moderate-quality evidence).\nA similar result was seen in studies looking at feedback devices at four weeks' follow-up (OR 4.80, 95% CI 1.87 to 12.33; 97 participants; one study; 51 per 100 with correct technique in the control group compared with 83 (95% CI 66 to 93) in the feedback group; low-quality evidence).\nHowever, the benefit of multi-media training for adults even immediately after the intervention was uncertain (OR 2.15, 95% CI 0.84 to 5.50; 164 participants; two studies; I = 49%; 30 per 100 in the control group with correct technique compared with 47 (95% CI 26 to 70) in the multi-media group; moderate-quality evidence).\nEvidence tended to be less clear for children, usually because results were based on fewer and smaller studies.\nSome studies did not report exacerbations in a way that allowed meta-analysis; others provided inconclusive results.\nInhaler technique interventions provided some benefit for asthma control and quality of life but generally did not lead to consistent or important clinical benefits for adults or children.\nConfidence intervals included no difference or did not reach a threshold that could be considered clinically important.\nResponder analyses sometimes showed improvement among more people in the intervention groups, even though the mean difference between groups was small.\nWe found no evidence about harms.\nAlthough interventions to improve inhaler technique may work in some circumstances, the variety of interventions and measurement methods used hampered our ability to perform meta-analyses and led to low to moderate confidence in our findings.\nMost included studies did not report important improvement in clinical outcomes.\nGuidelines consistently recommend that clinicians check regularly the inhaler technique of their patients; what is not clear is how clinicians can most effectively intervene if they find a patient's technique to be inadequate, and whether such interventions will have a discernible impact on clinical outcomes.\n\n\nSimplified text:\nWe searched the medical literature up until July 2015. We found 29 randomised controlled trials involving 2210 people. All participants had asthma, and follow up ranged from two weeks to 26 weeks. Most of the studies were at low or unclear quality, which means that we are uncertain about their results. Most included studies did not report important results, such as the number of people who experienced an asthma attack, side effects or missed work or school. The evidence is current up to June 2015. Most studies were funded by pharmaceutical companies. We rated the quality as low or very low, meaning that we were very uncertain about the results. We judged the overall quality of the evidence to have been low or low because we could not combine the results of the included studies. We did not find clear evidence about harms. In summary, we found that inhaler technique training may improve people's ability to control their asthma, improve their quality of life and improve their ability to use their inhaler, but it is not clear if it will lead to consistent or important benefits or whether it will have an impact. We also found no clear benefits or harms for children or adults. The quality was low to moderate because of the small number of studies that we found, the different ways in which studies were conducted, and the variety in the methods used, which meant that our results were imprecise. More research is needed.","label":["Factuality 1","Fluency 1","Simplicity 0"]},{"id":"10.1002\/14651858.CD012286.pub2_1","text":"Unsimplified text:\nThis review includes 29 parallel randomised controlled trials (RCTs) (n = 2210), although not all reported relevant or useable data.\nAll participants had asthma, and follow-up ranged from 2 to 26 weeks.\nMost studies were at low or unclear risk of selection and attrition biases and at high risk for biases associated with blinding.\nWe considered most of the evidence to be of low quality owing to these biases and to imprecision in the estimates of effect.\nWe classified studies into three comparisons: enhanced face-to-face training session(s), multi-media-delivered inhaler training (e.g. DVD, computer app or game) and technique feedback devices.\nDifferences between interventions, populations and outcome measures limited quantitative analyses, particularly for exacerbations, adverse events, unscheduled visits to a healthcare provider and absenteeism from work or school.\nEnhanced inhaler technique education and multi-media training improved technique in most studies immediately after the intervention and at follow-up, although the variety of checklists used meant that this was difficult to assess reliably.\nFor both adults and children, how and when inhaler technique was assessed appeared to affect whether inhaler technique improved and by how much.\nAnalyses of the numbers of people who demonstrated correct or 'good enough' technique were generally more useful than checklist scores.\nAdult studies of enhanced education showed benefit when this metric was used at 2 to 26 weeks' follow-up (odds ratio (OR) 5.00, 95% confidence interval (CI) 1.83 to 13.65; 258 participants; three studies; 31 per 100 with correct technique in the control group compared with 69 (95% CI 45 to 86) in the education group; moderate-quality evidence).\nA similar result was seen in studies looking at feedback devices at four weeks' follow-up (OR 4.80, 95% CI 1.87 to 12.33; 97 participants; one study; 51 per 100 with correct technique in the control group compared with 83 (95% CI 66 to 93) in the feedback group; low-quality evidence).\nHowever, the benefit of multi-media training for adults even immediately after the intervention was uncertain (OR 2.15, 95% CI 0.84 to 5.50; 164 participants; two studies; I = 49%; 30 per 100 in the control group with correct technique compared with 47 (95% CI 26 to 70) in the multi-media group; moderate-quality evidence).\nEvidence tended to be less clear for children, usually because results were based on fewer and smaller studies.\nSome studies did not report exacerbations in a way that allowed meta-analysis; others provided inconclusive results.\nInhaler technique interventions provided some benefit for asthma control and quality of life but generally did not lead to consistent or important clinical benefits for adults or children.\nConfidence intervals included no difference or did not reach a threshold that could be considered clinically important.\nResponder analyses sometimes showed improvement among more people in the intervention groups, even though the mean difference between groups was small.\nWe found no evidence about harms.\nAlthough interventions to improve inhaler technique may work in some circumstances, the variety of interventions and measurement methods used hampered our ability to perform meta-analyses and led to low to moderate confidence in our findings.\nMost included studies did not report important improvement in clinical outcomes.\nGuidelines consistently recommend that clinicians check regularly the inhaler technique of their patients; what is not clear is how clinicians can most effectively intervene if they find a patient's technique to be inadequate, and whether such interventions will have a discernible impact on clinical outcomes.\n\n\nSimplified text:\nWe found 15 studies with a total of 2,811 participants. All participants had asthma, and follow-up ranged from 2 to 26 weeks. Inhaler technique interventions provided some benefit for asthma control and quality of life, but generally did not lead to consistent or important clinical benefits for adults or children. Enhanced inhaler technique education and multi-media training improved technique in most studies immediately after the intervention and at follow up, although the variety of checklists used meant that this was difficult to assess reliably. Analyses of the numbers of people who demonstrated correct or 'good enough' technique were generally more useful than checklist scores. Evidence tended to be less clear for children, usually because results were based on fewer and smaller studies. Most included studies did not report important improvement in clinical outcomes. We found no evidence about harms. Most studies were at low or unclear risk of selection and attrition biases and at high risk for biases associated with blinding. We considered most of the evidence to be of low quality owing to these biases and to imprecision in the estimates of effect. Although interventions to improve inhalers may work in some circumstances, the variety and measurement methods used hampered our ability to perform meta-analyses and led to low to moderate confidence in our findings. Guidelines consistently recommend that clinicians check regularly the inhalers of their patients; what is not clear is how clinicians can most effectively intervene if they find a patient's technique to be inadequate, and whether such interventions will have a discernible impact on clinical outcome.","label":["Factuality 2","Fluency 2","Simplicity 2"]},{"id":"10.1002\/14651858.CD001153.pub2_0","text":"Unsimplified text:\nThree small trials, involving 226 participants, were included.\nOne trial included patients with presumed ischaemic stroke without computerised tomography (CT) verification, and the other two trials included patients with CT-verified ICH.\nData on the primary outcome measure (death and dependency) were not available in any of the trials.\nDeath and disability could be calculated in the larger ICH trial without differences between the mannitol and control groups.\nCase fatality was not reported in the trial of ischaemic stroke.\nCase fatality did not differ between the mannitol and control groups in the ICH trials.\nAdverse events were either not found or not reported.\nThe change in clinical condition was reported in two trials, and the proportion of those with worsening or not improving condition did not differ significantly between mannitol-treated patients and controls.\nBased on these three trials neither beneficial nor harmful effects of mannitol could be proved.\nAlthough no statistically significant differences were found between the mannitol-treated and control groups, the confidence intervals for the treatment effect estimates were wide and included both clinically significant benefits and clinically significant harms as possibilities.\nThere is currently not enough evidence to support the routine use of mannitol in acute stroke patients.\nFurther trials are needed to confirm or refute whether mannitol is beneficial in acute stroke.\n\n\nSimplified text:\nThis review of three small trials, involving 226 participants, found that there is currently not enough evidence to support the routine use of mannitol in acute stroke patients. Further trials are needed to confirm or refute whether mananitol is beneficial or harmful.","label":["Factuality 2","Fluency 2","Simplicity 2"]},{"id":"10.1002\/14651858.CD001153.pub2_1","text":"Unsimplified text:\nThree small trials, involving 226 participants, were included.\nOne trial included patients with presumed ischaemic stroke without computerised tomography (CT) verification, and the other two trials included patients with CT-verified ICH.\nData on the primary outcome measure (death and dependency) were not available in any of the trials.\nDeath and disability could be calculated in the larger ICH trial without differences between the mannitol and control groups.\nCase fatality was not reported in the trial of ischaemic stroke.\nCase fatality did not differ between the mannitol and control groups in the ICH trials.\nAdverse events were either not found or not reported.\nThe change in clinical condition was reported in two trials, and the proportion of those with worsening or not improving condition did not differ significantly between mannitol-treated patients and controls.\nBased on these three trials neither beneficial nor harmful effects of mannitol could be proved.\nAlthough no statistically significant differences were found between the mannitol-treated and control groups, the confidence intervals for the treatment effect estimates were wide and included both clinically significant benefits and clinically significant harms as possibilities.\nThere is currently not enough evidence to support the routine use of mannitol in acute stroke patients.\nFurther trials are needed to confirm or refute whether mannitol is beneficial in acute stroke.\n\n\nSimplified text:\nThree small trials, involving 226 participants, were included in this review. One trial included patients with presumed ischaemic stroke without computerised tomography (CT) verification, and the other two trials involved patients with CT-verified ICH. Data on the primary outcome measure (death and dependency) were not available in any of the trials. Death and disability could be calculated in the larger ICH trial without differences between the mannitol and control groups. The change in clinical condition was reported in two trials, but the proportion of those with worsening or not improving condition did not differ significantly between the treatment groups and controls. Case fatality was not reported in either trial. Based on these three trials neither beneficial nor harmful effects could be proved. There is currently not enough evidence to support the routine use of mannitor in acute stroke patients. Further trials are needed.","label":["Factuality 2","Fluency 1","Simplicity 0"]},{"id":"10.1002\/14651858.CD001460_0","text":"Unsimplified text:\nSix trials were identified, with 425 patients randomized to D-penicillamine and 258 to placebo.\nA statistically significant benefit was observed for D-penicillamine when compared to placebo for all three-dose ranges and for most outcome measures including: tender joint counts, pain, physician's global assessments and ESR.\nThe standardized weighted mean differences between treatment and placebo in moderate doses were -0.51 [95% CI -0.88, -0.14] for tender joint counts, -0.56 (95% CI -0.87, -0.26) for pain and -0.97 (95% CI -1.25, -0.70) for global assessment.\nThe difference for ESR was -10.6 mm\/hr.\nSimilar results were observed for the higher dose group.\nTotal withdrawals were significantly higher in the moderate and high dosage D-penicillamine groups (OR=1.63 and 2.13 respectively), mostly due to increased adverse reactions (OR = 2.60 and 4.95 respectively), including renal and hematological abnormalities.\nD-penicillamine appears to have a clinically and statistically significant benefit on the disease activity of patients with rheumatoid arthritis.\nIts efficacy appears to be similar to that of other disease modifying anti-rheumatic drugs (DMARDs), but with a significantly higher toxicity.\nIts effects on long-term functional status and radiological progression are not clear from this review.\n\n\nSimplified text:\nThis review of six randomised controlled trials found that D-penicillamine appears to have a beneficial effect on the disease activity of patients with rheumatoid arthritis. However, its effects on long-term functional status and radiological progression are not clear from this review. Its efficacy appears to be similar to that of other disease modifying anti-rheumatic drugs (DMARDs), but with a significantly higher toxicity.","label":["Factuality 2","Fluency 2","Simplicity 2"]},{"id":"10.1002\/14651858.CD001460_1","text":"Unsimplified text:\nSix trials were identified, with 425 patients randomized to D-penicillamine and 258 to placebo.\nA statistically significant benefit was observed for D-penicillamine when compared to placebo for all three-dose ranges and for most outcome measures including: tender joint counts, pain, physician's global assessments and ESR.\nThe standardized weighted mean differences between treatment and placebo in moderate doses were -0.51 [95% CI -0.88, -0.14] for tender joint counts, -0.56 (95% CI -0.87, -0.26) for pain and -0.97 (95% CI -1.25, -0.70) for global assessment.\nThe difference for ESR was -10.6 mm\/hr.\nSimilar results were observed for the higher dose group.\nTotal withdrawals were significantly higher in the moderate and high dosage D-penicillamine groups (OR=1.63 and 2.13 respectively), mostly due to increased adverse reactions (OR = 2.60 and 4.95 respectively), including renal and hematological abnormalities.\nD-penicillamine appears to have a clinically and statistically significant benefit on the disease activity of patients with rheumatoid arthritis.\nIts efficacy appears to be similar to that of other disease modifying anti-rheumatic drugs (DMARDs), but with a significantly higher toxicity.\nIts effects on long-term functional status and radiological progression are not clear from this review.\n\n\nSimplified text:\nSix trials were identified, with 425 patients randomized to D-penicillamine and 258 to placebo, with a total of 258 patients treated with either drug. The review of these trials found that D-Penicillamines appears to have a clinically and statistically significant benefit on the disease activity of patients with rheumatoid arthritis. Its efficacy appears to be similar to that of other disease modifying anti-rheumatic drugs (DMARDs), but with a significantly higher toxicity. Its effects on long-term functional status and radiological progression are not clear from this review.","label":["Factuality 2","Fluency 2","Simplicity 0"]},{"id":"10.1002\/14651858.CD004540.pub2_0","text":"Unsimplified text:\nWe included four relevant trials.\nAll of them were of low quality.\nAll of studies used a decoction containing Huangqi compounds as the intervention with chemotherapy.\nThe intervention groups of three studies were compared to a chemotherapy alone control group, the fourth study compared the decoction of Huangqi compounds with two other Chinese herbal interventions.\nNone of the studies reported on primary outcome using Common Toxicity Criteria (CTC).\nThere was a significant reduction in the proportion of patients who experienced nausea & vomiting when decoctions of Huangqi compounds were given in addition to chemotherapy.\nThere was also a decrease in the rate of leucopenia (WBC <3 x 10^9 per L).\nHuangqi compounds were also associated with increases in the proportions of T-lymphocyte subsets: CD3; CD4 and CD8.\nHuangqi decoctions had no significant effects on Immunoglobulins G, A or M. Despite the included studies being of low quality, the results suggest that decoctions of Huangqi compounds may stimulate immunocompetent cells and decrease side effects in patients treated with chemotherapy.\nDue to the methodological limitations of the studies, there is no robust demonstration of benefit.\nWe found no evidence of harm arising from the use of Chinese herbs.\nWe need high quality randomised controlled studies investigating the effects of decoctions of Chinese herbs, particularly Astragalus spp.(as in Huangqi), upon chemotherapy-related side effects.\n\n\nSimplified text:\nWe found four relevant trials. All of the studies used Huangqi compounds as the intervention with chemotherapy. The studies were of low quality. We found that there was a reduction in the proportion of patients who experienced nausea & vomiting when decoctions of Huangqi were given in addition to chemotherapy. There was also a decrease in the rate of leucopenia, which is a condition in which the white blood cells (WBC) in the blood are too small. Huangqi drugs may stimulate immunocompetent cells and decrease side effects in patients treated with chemotherapy-related side effects. However, because the studies were low quality, there is not enough evidence of benefit from these treatments. We need high quality randomised controlled studies investigating the effects on side effects of Chinese herbs, particularly Astragalus spp.","label":["Factuality 2","Fluency 2","Simplicity 2"]},{"id":"10.1002\/14651858.CD004540.pub2_1","text":"Unsimplified text:\nWe included four relevant trials.\nAll of them were of low quality.\nAll of studies used a decoction containing Huangqi compounds as the intervention with chemotherapy.\nThe intervention groups of three studies were compared to a chemotherapy alone control group, the fourth study compared the decoction of Huangqi compounds with two other Chinese herbal interventions.\nNone of the studies reported on primary outcome using Common Toxicity Criteria (CTC).\nThere was a significant reduction in the proportion of patients who experienced nausea & vomiting when decoctions of Huangqi compounds were given in addition to chemotherapy.\nThere was also a decrease in the rate of leucopenia (WBC <3 x 10^9 per L).\nHuangqi compounds were also associated with increases in the proportions of T-lymphocyte subsets: CD3; CD4 and CD8.\nHuangqi decoctions had no significant effects on Immunoglobulins G, A or M. Despite the included studies being of low quality, the results suggest that decoctions of Huangqi compounds may stimulate immunocompetent cells and decrease side effects in patients treated with chemotherapy.\nDue to the methodological limitations of the studies, there is no robust demonstration of benefit.\nWe found no evidence of harm arising from the use of Chinese herbs.\nWe need high quality randomised controlled studies investigating the effects of decoctions of Chinese herbs, particularly Astragalus spp.(as in Huangqi), upon chemotherapy-related side effects.\n\n\nSimplified text:\nWe found four relevant trials, all of them of low quality. All of studies used a decoction containing Huangqi compounds as the intervention with chemotherapy. The intervention groups of three studies were compared to a chemotherapy alone control group, the fourth study compared the decoctions with two other Chinese herbal interventions. There was a significant reduction in the proportion of patients who experienced nausea & vomiting when Huangqi treatments were given in addition to chemotherapy. Huangqi drugs were also associated with increases in the proportions of T-lymphocyte subsets: CD3, CD4, CD8 and CD8. There were no significant effects on Immunoglobulins G, A or M. We found no evidence of harm arising from the use of Chinese herbs. Due to the methodological limitations of the studies, there is no robust evidence of benefit. We need high quality randomised controlled studies investigating the effects of Chinese herbal treatments, particularly Astragalus spp.(as in Huangqi), upon chemotherapy-related side effects.","label":["Factuality 1","Fluency 2","Simplicity 0"]},{"id":"10.1002\/14651858.CD008428.pub2_0","text":"Unsimplified text:\nWe reviewed 394 titles and abstracts and nine ClinicalTrials.gov records and included three RCTs that met our eligibility criteria.\nThe three trials included a total of 866 participants aged four to 55 years with RP of all forms of genetic predisposition.\nOne trial evaluated the effect of vitamin A alone, one trial evaluated DHA alone, and a third trial evaluated DHA and vitamin A versus vitamin A alone.\nNone of the RCTs had protocols available, so selective reporting bias was unclear for all.\nIn addition, one trial did not specify the method for random sequence generation, so there was an unclear risk of bias.\nAll three trials were graded as low risk of bias for all other domains.\nWe did not perform meta-analysis due to clinical heterogeneity of participants and interventions across the included trials.\nThe primary outcome, mean change of visual field from baseline at one year, was not reported in any of the studies.\nNo toxicity or adverse events were reported in these three trials.\nNo trial reported a statistically significant benefit of vitamin supplementation on the progression of visual field loss or visual acuity loss.\nTwo of the three trials reported statistically significant differences in ERG amplitudes among some subgroups of participants, but these results have not been replicated or substantiated by findings in any of the other trials.\nBased on the results of three RCTs, there is no clear evidence for benefit of treatment with vitamin A and\/or DHA for people with RP, in terms of the mean change in visual field and ERG amplitudes at one year and the mean change in visual acuity at five years follow-up.\nIn future RCTs, since some of the studies in this review included unplanned subgroup analysis that suggested differential effects based on previous vitamin A exposure, investigators should consider examining this issue.\nFuture trials should take into account the changes observed in ERG amplitudes and other outcome measures from trials included in this review, in addition to previous cohort studies, when calculating sample sizes to assure adequate power to detect clinically and statistically meaningful difference between treatment arms.\n\n\nSimplified text:\nWe searched the medical literature up to January 2015. We found three random controlled trials that evaluated the effects on visual field loss and visual acuity in people aged four to 55 years with RP. These trials included a total of 866 participants aged four years or older. The evidence is current to February 2015. The review found no clear evidence for benefit for treatment with vitamin A or DHA for people with RP, in terms of the mean change in visual field and ERG amplitudes at one year and the mean increase or decrease of vision at five years follow up. No adverse effects or side effects were reported in these three trials. Two of the three trials did not report on the progression of visual field or acuity loss, but these results have not been replicated or substantiated by findings in the other trials. In future trials, since some of the studies in this review included unplanned subgroup analysis that suggested differential effects based on previous vitamin A exposure, investigators should consider examining this issue.","label":["Factuality 2","Fluency 2","Simplicity 2"]},{"id":"10.1002\/14651858.CD008428.pub2_1","text":"Unsimplified text:\nWe reviewed 394 titles and abstracts and nine ClinicalTrials.gov records and included three RCTs that met our eligibility criteria.\nThe three trials included a total of 866 participants aged four to 55 years with RP of all forms of genetic predisposition.\nOne trial evaluated the effect of vitamin A alone, one trial evaluated DHA alone, and a third trial evaluated DHA and vitamin A versus vitamin A alone.\nNone of the RCTs had protocols available, so selective reporting bias was unclear for all.\nIn addition, one trial did not specify the method for random sequence generation, so there was an unclear risk of bias.\nAll three trials were graded as low risk of bias for all other domains.\nWe did not perform meta-analysis due to clinical heterogeneity of participants and interventions across the included trials.\nThe primary outcome, mean change of visual field from baseline at one year, was not reported in any of the studies.\nNo toxicity or adverse events were reported in these three trials.\nNo trial reported a statistically significant benefit of vitamin supplementation on the progression of visual field loss or visual acuity loss.\nTwo of the three trials reported statistically significant differences in ERG amplitudes among some subgroups of participants, but these results have not been replicated or substantiated by findings in any of the other trials.\nBased on the results of three RCTs, there is no clear evidence for benefit of treatment with vitamin A and\/or DHA for people with RP, in terms of the mean change in visual field and ERG amplitudes at one year and the mean change in visual acuity at five years follow-up.\nIn future RCTs, since some of the studies in this review included unplanned subgroup analysis that suggested differential effects based on previous vitamin A exposure, investigators should consider examining this issue.\nFuture trials should take into account the changes observed in ERG amplitudes and other outcome measures from trials included in this review, in addition to previous cohort studies, when calculating sample sizes to assure adequate power to detect clinically and statistically meaningful difference between treatment arms.\n\n\nSimplified text:\nWe found three randomised controlled trials (RCTs) that included a total of 866 participants aged four to 55 years with RP of all forms of genetic predisposition. One trial evaluated the effect of vitamin A alone, one trial evaluated vitamin A and DHA alone, and a third trial evaluated DHA and vitamin A versus vitamin A only. We did not perform a meta-analysis due to clinical heterogeneity of participants and interventions across the included trials. The primary outcome, mean change in visual field from baseline at one year, was not reported in any of the studies. No trial reported a statistically significant benefit of vitamin supplementation on the progression of visual field loss or visual acuity loss. Two of the three trials reported statistically significant differences in ERG amplitudes among some subgroups of participants, but these results have not been replicated or substantiated by findings in any other trials. No toxicity or adverse events were reported in these three trials. Based on the results of three RCTs, there is no clear evidence for benefit of treatment with vitamin A or DHA for people with RP, in terms of the change in vision and visual field at one and five years follow-up. In future studies, future trials should take into account the changes observed in the ERG Amplitudes and other outcome measures from trials included in this review, in addition to previous cohort studies, when calculating sample sizes to assure adequate power to detect clinically and statistically meaningful difference between treatment arms. In addition, since some of the included studies included unplanned subgroup analysis that suggested differential effects based on previous vitamin A exposure, investigators should consider examining this issue.","label":["Factuality 1","Fluency 1","Simplicity 0"]},{"id":"10.1002\/14651858.CD010208.pub2_0","text":"Unsimplified text:\nWe included three RCTs with a total of 414 participants at risk of job loss.\nThe majority of participants had IA, most with RA and to a lesser degree AS.\nThe interventions aimed to prevent job loss and improve work functioning in several ways: firstly by evaluating work changes or adaptations and secondly by providing any person-directed interventions including vocational counselling, advice or education.\nInterventions directly targeted at the work environment were minimal and included workplace visits (one trial) or any actions by an occupational physician (one trial).\nThe duration or dose of the interventions varied from two 1.5-hour sessions (one RCT) over five months, two consultation and multidisciplinary treatments during three months (one RCT), to six to eight individual or group sessions over six months (also one RCT).\nAll participants were recruited through rheumatology clinics, both in or outside hospitals.\nIncluded trials investigated job loss (n = two RCTs; 382 participants), work absenteeism and work functioning (n = one RCT; 32 participants).\nOverall, we evaluated the two smaller trials as having a high risk of bias and the large trial as having a low risk of bias.\nTrials showed marked differences in how they performed on risk of bias items, particularly on performance bias.\nWe assessed the quality of the evidence using the GRADE approach and judged there to be very low quality evidence across the three reported outcomes.\nOf the two RCTs investigating job loss, the larger one (n = 242 participants) reported a large statistically significant reduction in job loss (relative risk (RR) = 0.35, 95% confidence interval (CI) 0.18 to 0.68) and the other RCT (n = 140) reported similar effects in both groups, although the CI was very wide (RR = 1.05, 95% CI 0.53 to 2.06).\nThe latter one probably suffered from performance bias and we judged it to have a high risk of bias.\nThe one small trial investigating sickness absenteeism found uncertain results at six months' follow-up (MD = -2.42 days, 95% CI -5.03 to 0.19).\nFinally, in the same small trial investigating work functioning using the Rheumatoid Arthritis-Work Instability Scale (RA-WIS), there was a moderate improvement of intermediate term work functioning (six months; scale range 0 to 23; mean improvement -4.67 points, 95% CI -8.43 to -0.91).\nWe identified no adverse effects in the publications of the three trials.\nThis Cochrane review of three RCTs found very low quality evidence overall for job loss prevention interventions having an effect on job loss, work absenteeism and work functioning in workers with inflammatory arthritis.\nWhile this review highlights that further high quality RCTs are required, the results suggest that these strategies have potential to be effective.\n\n\nSimplified text:\nWe searched for randomised controlled trials that compared the effects on job loss, work absenteeism and work functioning (i.e. the number of people who dropped out of work because they were sick or did not show up to work) or who were not able or unwilling to work. We found three studies with 414 people. The majority had IA, most with RA and to a lesser degree AS. The interventions aimed to prevent job loss and improve work functioning by evaluating work changes or adaptations and by providing vocational counselling, advice or education. The duration or dose of the interventions varied from six to eight sessions over six months, but the majority of the studies were of very low quality. We assessed the quality of the evidence as very low. The evidence is current up to January 2015. We judged the quality to have been very low, meaning that we are very uncertain about the results. The results suggest that these strategies have potential to be effective. However, we need more high quality studies in this area before we can draw firm conclusions. This Cochrane review highlights that further high quality trials are needed.","label":["Factuality 2","Fluency 1","Simplicity 2"]},{"id":"10.1002\/14651858.CD010208.pub2_1","text":"Unsimplified text:\nWe included three RCTs with a total of 414 participants at risk of job loss.\nThe majority of participants had IA, most with RA and to a lesser degree AS.\nThe interventions aimed to prevent job loss and improve work functioning in several ways: firstly by evaluating work changes or adaptations and secondly by providing any person-directed interventions including vocational counselling, advice or education.\nInterventions directly targeted at the work environment were minimal and included workplace visits (one trial) or any actions by an occupational physician (one trial).\nThe duration or dose of the interventions varied from two 1.5-hour sessions (one RCT) over five months, two consultation and multidisciplinary treatments during three months (one RCT), to six to eight individual or group sessions over six months (also one RCT).\nAll participants were recruited through rheumatology clinics, both in or outside hospitals.\nIncluded trials investigated job loss (n = two RCTs; 382 participants), work absenteeism and work functioning (n = one RCT; 32 participants).\nOverall, we evaluated the two smaller trials as having a high risk of bias and the large trial as having a low risk of bias.\nTrials showed marked differences in how they performed on risk of bias items, particularly on performance bias.\nWe assessed the quality of the evidence using the GRADE approach and judged there to be very low quality evidence across the three reported outcomes.\nOf the two RCTs investigating job loss, the larger one (n = 242 participants) reported a large statistically significant reduction in job loss (relative risk (RR) = 0.35, 95% confidence interval (CI) 0.18 to 0.68) and the other RCT (n = 140) reported similar effects in both groups, although the CI was very wide (RR = 1.05, 95% CI 0.53 to 2.06).\nThe latter one probably suffered from performance bias and we judged it to have a high risk of bias.\nThe one small trial investigating sickness absenteeism found uncertain results at six months' follow-up (MD = -2.42 days, 95% CI -5.03 to 0.19).\nFinally, in the same small trial investigating work functioning using the Rheumatoid Arthritis-Work Instability Scale (RA-WIS), there was a moderate improvement of intermediate term work functioning (six months; scale range 0 to 23; mean improvement -4.67 points, 95% CI -8.43 to -0.91).\nWe identified no adverse effects in the publications of the three trials.\nThis Cochrane review of three RCTs found very low quality evidence overall for job loss prevention interventions having an effect on job loss, work absenteeism and work functioning in workers with inflammatory arthritis.\nWhile this review highlights that further high quality RCTs are required, the results suggest that these strategies have potential to be effective.\n\n\nSimplified text:\nWe included three randomised controlled trials with a total of 414 participants at risk of job loss. All participants were recruited through rheumatology clinics, both in or outside hospitals. The majority of participants had IA, most with RA and to a lesser degree AS. The interventions aimed to prevent job loss and improve work functioning in several ways: firstly by evaluating work changes or adaptations and secondly by providing any person-directed interventions including vocational counselling, advice or education. Interventions directly targeted at the work environment were minimal and included workplace visits (one trial) or any actions by an occupational physician. The duration or dose of the interventions varied from two 1.5-hour sessions (one RCT) over five months, two consultation and multidisciplinary treatments during three months, to six to eight individual or group sessions over six months (also one RCT). Overall, we evaluated the two smaller trials as having a high risk of bias and the large trial as having low risk. We assessed the quality of the evidence using the GRADE approach and judged there to be very low quality evidence across the three reported outcomes. We identified no adverse effects in the publications of the three trials. The latter one probably suffered from performance bias and we judged it to have a high rate of bias. The results suggest that these strategies have potential to be effective. While this review highlights that further high quality RCTs are required, the results of this Cochrane review show that job loss prevention interventions may have an effect on job loss, work absenteeism and work functioning.","label":["Factuality 2","Fluency 2","Simplicity 0"]},{"id":"10.1002\/14651858.CD004339.pub4_0","text":"Unsimplified text:\nWe identified three eligible studies that included a total of 285 neonates (140 received arginine) from three countries.\nWe assessed the overall methodological quality of the included studies as good.\nWe noted a statistically significant reduction in risk of development of NEC (any stage) among preterm neonates in the arginine group compared with the placebo group (RR 0.38, 95% confidence interval (CI) 0.23 to 0.64; I2 = 27%) (RD -0.19, 95% CI -0.28 to -0.10; I2 = 0%) and rated the quality of evidence as moderate.\nThe number needed to treat for an additional beneficial outcome (NNTB) as required to prevent the development of NEC (any stage) was 6 (95% CI 4 to 10).\nStudy results showed a statistically significant reduction in risk of development of NEC stage 1 (RR 0.37, 95% CI 0.15 to 0.90; I2 = 52%) (RD -0.07, 95% CI -0.14 to -0.01; I2 = 0%) and NEC stage 3 (RR 0.13, 95% CI 0.02 to 1.03; I2 = 0%) (RD -0.05, 95% CI -0.09 to -0.01; I2 = 89%) in the arginine group compared with the control group; the quality of evidence was moderate.\nArginine supplementation was associated with a significant reduction in death related to NEC (RR 0.18, 95% CI 0.03 to 1.00; I2 = 0%) (RD -0.05, 95% CI -0.09 to -0.01; I2 = 87%).\nResults showed clinical heterogeneity in mortality rates.\nMortality due to any cause was not significantly different between arginine and control or no treatment groups (RR 0.77, 95% CI 0.41 to 1.45; I2 = 42%) (RD -0.03, 95% CI -0.10 to 0.04; I2 = 79%).\nInvestigators noted no significant side effects directly attributable to arginine, including hypotension or alterations in glucose homeostasis.\nFollow-up data from one trial revealed no statistically significant differences in adverse outcomes (cerebral palsy, cognitive delay, bilateral blindness or hearing loss requiring hearing aids) at 36 months.\nLimitations of the present findings include a relatively small overall sample size.\nAdministration of arginine to preterm infants may prevent development of NEC.\nBecause information was provided by three small trials that included 285 participants, the data are insufficient at present to support a practice recommendation.\nA multi-centre randomised controlled study that is focused on the incidence of NEC, particularly at more severe stages (2 and 3), is needed.\n\n\nSimplified text:\nWe found three randomised controlled trials that included a total of 285 newborn infants from three countries. The evidence is current to January 2016. We found that arginine supplementation may prevent NEC in preterm infants. We assessed the overall methodological quality of the included studies as good. We noted that the number needed to treat for an additional beneficial outcome (NNTB) as required to prevent the development of NEC was 6. We also found that there was a reduction in the number of deaths related to NEC. We did not find any evidence that there were differences between groups of infants who received or did not receive the treatment. The quality of evidence was moderate. There was not enough information available at present to recommend a specific treatment for NEC, and more research is needed in this area. Limitations in the present findings include a relatively small overall sample size. Because information was provided by three small trials that studied 285 infants, the results of this review are insufficient at present.","label":["Factuality 2","Fluency 1","Simplicity 2"]},{"id":"10.1002\/14651858.CD004339.pub4_1","text":"Unsimplified text:\nWe identified three eligible studies that included a total of 285 neonates (140 received arginine) from three countries.\nWe assessed the overall methodological quality of the included studies as good.\nWe noted a statistically significant reduction in risk of development of NEC (any stage) among preterm neonates in the arginine group compared with the placebo group (RR 0.38, 95% confidence interval (CI) 0.23 to 0.64; I2 = 27%) (RD -0.19, 95% CI -0.28 to -0.10; I2 = 0%) and rated the quality of evidence as moderate.\nThe number needed to treat for an additional beneficial outcome (NNTB) as required to prevent the development of NEC (any stage) was 6 (95% CI 4 to 10).\nStudy results showed a statistically significant reduction in risk of development of NEC stage 1 (RR 0.37, 95% CI 0.15 to 0.90; I2 = 52%) (RD -0.07, 95% CI -0.14 to -0.01; I2 = 0%) and NEC stage 3 (RR 0.13, 95% CI 0.02 to 1.03; I2 = 0%) (RD -0.05, 95% CI -0.09 to -0.01; I2 = 89%) in the arginine group compared with the control group; the quality of evidence was moderate.\nArginine supplementation was associated with a significant reduction in death related to NEC (RR 0.18, 95% CI 0.03 to 1.00; I2 = 0%) (RD -0.05, 95% CI -0.09 to -0.01; I2 = 87%).\nResults showed clinical heterogeneity in mortality rates.\nMortality due to any cause was not significantly different between arginine and control or no treatment groups (RR 0.77, 95% CI 0.41 to 1.45; I2 = 42%) (RD -0.03, 95% CI -0.10 to 0.04; I2 = 79%).\nInvestigators noted no significant side effects directly attributable to arginine, including hypotension or alterations in glucose homeostasis.\nFollow-up data from one trial revealed no statistically significant differences in adverse outcomes (cerebral palsy, cognitive delay, bilateral blindness or hearing loss requiring hearing aids) at 36 months.\nLimitations of the present findings include a relatively small overall sample size.\nAdministration of arginine to preterm infants may prevent development of NEC.\nBecause information was provided by three small trials that included 285 participants, the data are insufficient at present to support a practice recommendation.\nA multi-centre randomised controlled study that is focused on the incidence of NEC, particularly at more severe stages (2 and 3), is needed.\n\n\nSimplified text:\nWe found three eligible studies that included a total of 285 preterm infants (140 received arginine) from three countries. We assessed the overall methodological quality of the included studies as good. The evidence is current to August 2015. We found no evidence to support the use of this drug to prevent the development of NEC in preterm babies. Because of the small number of infants included in the studies, the data are insufficient at present to support a practice recommendation. A multi-centre randomised controlled study that is focused on the incidence of NEC, particularly at more severe stages (2 and 3), is needed.","label":["Factuality 0","Fluency 2","Simplicity 1"]},{"id":"10.1002\/14651858.CD005149.pub4_0","text":"Unsimplified text:\nNo new trials were found for inclusion in this update.\nFour studies involving 1943 participants with acute sinusitis met our inclusion criteria.\nThe trials were well-designed and double-blind and studied INCS versus placebo or no intervention for 15 or 21 days.\nThe rates of loss to follow-up were 7%, 11%, 41% and 10%.\nWhen we combined the results from the three trials included in the meta-analysis, participants receiving INCS were more likely to experience resolution or improvement in symptoms than those receiving placebo (73% versus 66.4%; risk ratio (RR) 1.11; 95% confidence interval (CI) 1.04 to 1.18).\nHigher doses of INCS had a stronger effect on improvement of symptoms or complete relief: for mometasone furoate 400 g versus 200 g (RR 1.10; 95% CI 1.02 to 1.18 versus RR 1.04; 95% CI 0.98 to 1.11).\nNo significant adverse events were reported and there was no significant difference in the drop-out and recurrence rates for the two treatment groups and for groups receiving higher doses of INCS.\nCurrent evidence is limited for acute sinusitis confirmed by radiology or nasal endoscopy but supports the use of INCS as a monotherapy or as an adjuvant therapy to antibiotics.\nClinicians should weigh the modest but clinically important benefits against possible minor adverse events when prescribing therapy.\n\n\nSimplified text:\nThis review included four trials involving 1943 participants with acute sinusitis. The trials were well-designed and double-blind and studied INCS versus placebo or no treatment for 15 or 21 days. The studies showed that INCS was more likely to improve symptoms than those receiving placebo. In addition, INCS had a stronger effect than mometasone furoate 400 g on improvement of symptoms or complete relief of symptoms. However, there was no difference between the two treatment groups for the drop-out and recurrence rates for the treatment groups and for groups receiving higher doses of INCS. There was not enough evidence to recommend INCS as a monotherapy or as an adjuvant treatment to antibiotics. Clinicians should weigh the modest but clinically important benefits against possible minor side effects when prescribing INCS when prescribing therapy.","label":["Factuality 2","Fluency 2","Simplicity 2"]},{"id":"10.1002\/14651858.CD005149.pub4_1","text":"Unsimplified text:\nNo new trials were found for inclusion in this update.\nFour studies involving 1943 participants with acute sinusitis met our inclusion criteria.\nThe trials were well-designed and double-blind and studied INCS versus placebo or no intervention for 15 or 21 days.\nThe rates of loss to follow-up were 7%, 11%, 41% and 10%.\nWhen we combined the results from the three trials included in the meta-analysis, participants receiving INCS were more likely to experience resolution or improvement in symptoms than those receiving placebo (73% versus 66.4%; risk ratio (RR) 1.11; 95% confidence interval (CI) 1.04 to 1.18).\nHigher doses of INCS had a stronger effect on improvement of symptoms or complete relief: for mometasone furoate 400 g versus 200 g (RR 1.10; 95% CI 1.02 to 1.18 versus RR 1.04; 95% CI 0.98 to 1.11).\nNo significant adverse events were reported and there was no significant difference in the drop-out and recurrence rates for the two treatment groups and for groups receiving higher doses of INCS.\nCurrent evidence is limited for acute sinusitis confirmed by radiology or nasal endoscopy but supports the use of INCS as a monotherapy or as an adjuvant therapy to antibiotics.\nClinicians should weigh the modest but clinically important benefits against possible minor adverse events when prescribing therapy.\n\n\nSimplified text:\nWe searched for randomised controlled trials (clinical trials where people are randomly put into one of two or more treatment groups) that compared INCS with placebo or no intervention for 15 or 21 days. Four studies involving 1943 participants with acute sinusitis met our inclusion criteria. The trials were well-designed and double-blind and studied INCS versus placebo (a dummy treatment) or no treatment for 15 to 21 days in a total of 1943 participants. No new trials were found for inclusion in this update. No significant adverse events were reported and there was no significant difference in the drop-out and recurrence rates for the two treatment groups and for groups receiving higher doses of INCS. Clinicians should weigh the modest but clinically important benefits against possible minor adverse events when prescribing INCS when prescribing therapy. Current evidence is limited for the treatment of acute sinuitis confirmed by radiology or nasal endoscopy but supports the use of inseminators as a monotherapy or as an adjuvant therapy to antibiotics.","label":["Factuality 1","Fluency 2","Simplicity 1"]},{"id":"10.1002\/14651858.CD001971_0","text":"Unsimplified text:\nThe administration of prophylactic vancomycin reduced the incidence of both total neonatal nosocomial sepsis and coagulase negative staphylococcal sepsis in eligible preterm infants.\nMortality, length of stay, and evidence of vancomycin toxicity were not significantly different between the two groups.\nThere was insufficient evidence to ascertain the risks of development of vancomycin resistant organisms in the nurseries involved in these trials.\nThe use of prophylactic vancomycin in low doses reduces the incidence of nosocomial sepsis in the neonate.\nThe methodologies of these studies may have contributed to the low rate of sepsis in the treated groups, as the blood cultures drawn from central lines may have failed to grow due to the low levels of vancomycin in the infusate.\nAlthough there is a theoretical concern regarding the development of resistant organisms with the administration of prophylactic antibiotic, there is insufficient evidence to ascertain the risks of development of vancomycin resistant organisms.\nFew clinically important benefits have been demonstrated for very low birth weight infants treated with prophylactic vancomycin.\nIt therefore appears that routine prophylaxis with vancomycin should not be undertaken at present.\n\n\nSimplified text:\nThis review of trials found that the administration of prophylactic vancomycin reduced the incidence of both total neonatal nosocomial sepsis and coagulase negative staphylococcal infections in eligible preterm infants. However, there was not enough evidence to assess the risks of developing resistance to the antibiotic in the nurseries involved in these trials. The methodologies of these studies may have contributed to the low rate of sepsi in the treated groups, as the blood cultures drawn from central lines may have failed to grow because the low levels in the infusate.","label":["Factuality 2","Fluency 2","Simplicity 2"]},{"id":"10.1002\/14651858.CD001971_1","text":"Unsimplified text:\nThe administration of prophylactic vancomycin reduced the incidence of both total neonatal nosocomial sepsis and coagulase negative staphylococcal sepsis in eligible preterm infants.\nMortality, length of stay, and evidence of vancomycin toxicity were not significantly different between the two groups.\nThere was insufficient evidence to ascertain the risks of development of vancomycin resistant organisms in the nurseries involved in these trials.\nThe use of prophylactic vancomycin in low doses reduces the incidence of nosocomial sepsis in the neonate.\nThe methodologies of these studies may have contributed to the low rate of sepsis in the treated groups, as the blood cultures drawn from central lines may have failed to grow due to the low levels of vancomycin in the infusate.\nAlthough there is a theoretical concern regarding the development of resistant organisms with the administration of prophylactic antibiotic, there is insufficient evidence to ascertain the risks of development of vancomycin resistant organisms.\nFew clinically important benefits have been demonstrated for very low birth weight infants treated with prophylactic vancomycin.\nIt therefore appears that routine prophylaxis with vancomycin should not be undertaken at present.\n\n\nSimplified text:\nThis review of trials found that prophylactic vancomycin reduced the incidence of both total and coagulase negative staphylococcal sepsis in eligible preterm infants. There was insufficient evidence to assess the risks of development of resistant organisms in the nurseries involved in these trials. Mortality, length of stay, and evidence of side effects were not significantly different between the two groups. The methodologies of these studies may have contributed to the low rate of sepsi in the treated groups, as the blood cultures drawn from central lines may have failed to grow due to low levels of vancomate in the infusate. Few clinically important benefits have been demonstrated for very low birth weight infants treated with low doses of antibiotics. It therefore appears that routine treatment with low dose antibiotics should not be undertaken at present.","label":["Factuality 2","Fluency 2","Simplicity 1"]},{"id":"10.1002\/14651858.CD003554.pub2_0","text":"Unsimplified text:\nFourteen reports of 13 RCTs on dressings or topical agents for postoperative wounds healing by secondary intention were identified.\nWOUND HEALING: Whilst a single small trial of aloe vera supplementation vs gauze suggests delayed healing with aloe vera, the results of this trial are un interpretable since there was a large differential loss to follow up.\nA plaster cast applied to an amputation stump accelerated wound healing compared with elastic compression, WMD -25.60 days, 95% CI -49.08 to -2.12 days (1 trial).\nThere were no statistically significant differences in healing for other dressing comparisons (e.g. gauze, foam, alginate; 11 trials).  \nPAIN:\nGauze was associated with significantly more pain for patients than other dressings (4 trials).  \nPATIENT SATISFACTION:\nPatients treated with gauze were less satisfied compared with those receiving alternative dressings (3 trials).  \nCOSTS: Gauze is inexpensive but its use is associated with the use of significantly more nursing time than foam (2 trials).  \nLENGTH OF HOSPITAL STAY:\nFour trials showed no difference in length of hospital stay.\nOne trial found shorter hospital stay in people after amputation when plaster casts were applied compared with elastic compression (WMD -30.10 days; 95% CI -49.82 to -10.38).\nWe found only small, poor quality trials; the evidence is therefore insufficient to determine whether the choice of dressing or topical agent affects the healing of surgical wounds healing by secondary intention.\nFoam is best studied as an alternative for gauze and appears to be preferable as to pain reduction, patient satisfaction and nursing time.\n\n\nSimplified text:\nWe searched for randomised controlled trials (clinical trials where people are randomly put into one or more treatment or another) that compared different types of dressings or topical treatments with each other. We found only a small number and poor quality trials. The evidence is therefore insufficient to determine whether the choice of dressing or topical treatment affects the healing of surgical wounds healing by secondary intention. A single small trial of aloe vera supplementation compared with gauze suggests delayed healing, although the results of this trial are un interpretable since there was a large loss to follow up. A plaster cast applied to an amputation stump accelerated wound healing compared with elastic compression. There were no differences between gauze, foam, or alginate for other dressing comparisons. Gauze was associated with more pain than other dressings (4 trials) and patients were less satisfied than those receiving alternative dressings. The cost of gauze was low but its use is associated with the use of more nursing time than foam. One trial found shorter hospital stay in people after amputation when plaster casts were applied compared to elastic compression (30.10 fewer days). We found no difference in length of hospital stay. Foam is best studied as an alternative for gauze and appears to be preferable as to pain reduction, patient satisfaction and nursing time.","label":["Factuality 2","Fluency 2","Simplicity 1"]},{"id":"10.1002\/14651858.CD003554.pub2_1","text":"Unsimplified text:\nFourteen reports of 13 RCTs on dressings or topical agents for postoperative wounds healing by secondary intention were identified.\nWOUND HEALING: Whilst a single small trial of aloe vera supplementation vs gauze suggests delayed healing with aloe vera, the results of this trial are un interpretable since there was a large differential loss to follow up.\nA plaster cast applied to an amputation stump accelerated wound healing compared with elastic compression, WMD -25.60 days, 95% CI -49.08 to -2.12 days (1 trial).\nThere were no statistically significant differences in healing for other dressing comparisons (e.g. gauze, foam, alginate; 11 trials).  \nPAIN:\nGauze was associated with significantly more pain for patients than other dressings (4 trials).  \nPATIENT SATISFACTION:\nPatients treated with gauze were less satisfied compared with those receiving alternative dressings (3 trials).  \nCOSTS: Gauze is inexpensive but its use is associated with the use of significantly more nursing time than foam (2 trials).  \nLENGTH OF HOSPITAL STAY:\nFour trials showed no difference in length of hospital stay.\nOne trial found shorter hospital stay in people after amputation when plaster casts were applied compared with elastic compression (WMD -30.10 days; 95% CI -49.82 to -10.38).\nWe found only small, poor quality trials; the evidence is therefore insufficient to determine whether the choice of dressing or topical agent affects the healing of surgical wounds healing by secondary intention.\nFoam is best studied as an alternative for gauze and appears to be preferable as to pain reduction, patient satisfaction and nursing time.\n\n\nSimplified text:\nWe searched for randomised controlled trials (clinical trials where people are randomly put into one of two or more treatment groups) that compared different dressings or topical agents for wound healing by secondary intention. Fourteen trials were identified, with a total of 13 studies. The evidence is current to May 2015. We found only small, poor quality trials; the evidence is therefore insufficient to determine whether the choice of dressing or topical agent affects the healing of surgical wounds healing by second intention. Gauze was associated with significantly more pain for patients than other dressings (4 trials). Gauze is inexpensive but its use is associated with the use of significantly more nursing time than foam. Foam is best studied as an alternative for gauze and appears to be preferable as to pain reduction, patient satisfaction and nursing time. One trial found shorter hospital stay in people after amputation when plaster casts were applied compared with elastic compression (WMD -30.10 days; 95% CI -49.82 to -10.38). However, the results of this trial are un interpretable since there was a large differential loss to follow up.","label":["Factuality 2","Fluency 2","Simplicity 1"]},{"id":"10.1002\/14651858.CD003988.pub2_0","text":"Unsimplified text:\nIn 2014, we added seven trials for a new total of 11.\nFive reports were published before 1985 and six from 2005 to 2014.\nThey included 1482 women.\nFour trials examined combined oral contraceptives (COCs), and three studied a levonorgestrel-releasing intrauterine system (LNG-IUS).\nWe found two trials of progestin-only pills (POPs) and two of the etonogestrel-releasing implant.\nOlder studies often lacked quantified results.\nMost trials did not report significant differences between the study arms in breastfeeding duration, breast milk composition, or infant growth.\nExceptions were seen mainly in older studies with limited information.\nFor breastfeeding duration, two of eight trials indicated a negative effect on lactation.\nA COC study reported a negative effect on lactation duration compared to placebo but did not quantify results.\nAnother trial showed a lower percentage of the LNG-IUS group breastfeeding at 75 days versus the nonhormonal IUD group (reported P < 0.05) but no significant difference at one year.\nFor breast milk volume, two older studies indicated lower volume for the COC group versus the placebo group.\nOne trial did not quantify results.\nThe other showed lower means (mL) for the COC group, e.g. at 16 weeks (MD -24.00, 95% CI -34.53 to -13.47) and at 24 weeks (MD -24.90, 95% CI -36.01 to -13.79).\nAnother four trials did not report any significant difference between the study groups in milk volume or composition with two POPs, a COC, or the etonogestrel implant.\nSeven trials studied infant growth; one showed greater weight gain (grams) for the etonogestrel implant versus no method for six weeks (MD 426.00, 95% CI 58.94 to 793.06) but less compared with depot medroxyprogesterone acetate (DMPA) from 6 to 12 weeks (MD -271.00, 95% CI -355.10 to -186.90).\nThe others studied POPs, COCs versus POPs, or an LNG-IUS.\nResults were not consistent across the 11 trials.\nThe evidence was limited for any particular hormonal method.\nThe quality of evidence was moderate overall and low for three of four placebo-controlled trials of COCs or POPs.\nThe sensitivity analysis included six trials with moderate quality evidence and sufficient outcome data.\nFive trials indicated no significant difference between groups in breastfeeding duration (etonogestrel implant insertion times, COC versus POP, and LNG-IUS).\nFor breast milk volume or composition, a COC study showed a negative effect, while an implant trial showed no significant difference.\nOf four trials that assessed infant growth, three indicated no significant difference between groups.\nOne showed greater weight gain in the etonogestrel implant group versus no method but less versus DMPA.\n\n\nSimplified text:\nWe found 11 randomised controlled trials (involving a total of 1482 women) that compared different methods of birth control with each other. Most of the studies were published before 1985 and six from 2005 to 2014. Four trials examined combined oral contraceptives (POPs), three studies studied a levonorgestrel-releasing intrauterine system (LNG-IUS), two studies studied the etonogestrel implant, two studies of the progestin-only pills, and one study of the implant. We found seven trials in 2014, which included seven more women. The evidence is current to February 2015. Most trials did not report any significant differences between the study arms in breastfeeding duration, breast milk volume, or infant growth. The quality of the evidence was moderate overall and low for three of four placebo-controlled trials. Exceptions were seen mainly in older studies with limited information. Five trials indicated that there was little or no difference between the two methods for the length of time women breastfed their babies. For breast milk weight gain, two older studies indicated lower milk volume for the COC group compared to the placebo. One of the other studies did not quantify results. Of four trials that assessed infant growth, one showed greater weight gain for the implant group but less compared with depot medroxyprogesterone acetate (DMPA) from 6 weeks to 12 weeks. Another four trials reported that there were no differences for the study groups. The overall quality was moderate to low. The main limitations of this review were the small number of women included in the studies and the small numbers.","label":["Factuality 1","Fluency 2","Simplicity 0"]},{"id":"10.1002\/14651858.CD003988.pub2_1","text":"Unsimplified text:\nIn 2014, we added seven trials for a new total of 11.\nFive reports were published before 1985 and six from 2005 to 2014.\nThey included 1482 women.\nFour trials examined combined oral contraceptives (COCs), and three studied a levonorgestrel-releasing intrauterine system (LNG-IUS).\nWe found two trials of progestin-only pills (POPs) and two of the etonogestrel-releasing implant.\nOlder studies often lacked quantified results.\nMost trials did not report significant differences between the study arms in breastfeeding duration, breast milk composition, or infant growth.\nExceptions were seen mainly in older studies with limited information.\nFor breastfeeding duration, two of eight trials indicated a negative effect on lactation.\nA COC study reported a negative effect on lactation duration compared to placebo but did not quantify results.\nAnother trial showed a lower percentage of the LNG-IUS group breastfeeding at 75 days versus the nonhormonal IUD group (reported P < 0.05) but no significant difference at one year.\nFor breast milk volume, two older studies indicated lower volume for the COC group versus the placebo group.\nOne trial did not quantify results.\nThe other showed lower means (mL) for the COC group, e.g. at 16 weeks (MD -24.00, 95% CI -34.53 to -13.47) and at 24 weeks (MD -24.90, 95% CI -36.01 to -13.79).\nAnother four trials did not report any significant difference between the study groups in milk volume or composition with two POPs, a COC, or the etonogestrel implant.\nSeven trials studied infant growth; one showed greater weight gain (grams) for the etonogestrel implant versus no method for six weeks (MD 426.00, 95% CI 58.94 to 793.06) but less compared with depot medroxyprogesterone acetate (DMPA) from 6 to 12 weeks (MD -271.00, 95% CI -355.10 to -186.90).\nThe others studied POPs, COCs versus POPs, or an LNG-IUS.\nResults were not consistent across the 11 trials.\nThe evidence was limited for any particular hormonal method.\nThe quality of evidence was moderate overall and low for three of four placebo-controlled trials of COCs or POPs.\nThe sensitivity analysis included six trials with moderate quality evidence and sufficient outcome data.\nFive trials indicated no significant difference between groups in breastfeeding duration (etonogestrel implant insertion times, COC versus POP, and LNG-IUS).\nFor breast milk volume or composition, a COC study showed a negative effect, while an implant trial showed no significant difference.\nOf four trials that assessed infant growth, three indicated no significant difference between groups.\nOne showed greater weight gain in the etonogestrel implant group versus no method but less versus DMPA.\n\n\nSimplified text:\nWe found seven randomised controlled trials (RCTs) that included 1482 women. Five trials were published before 1985 and six from 2005 to 2014. Four trials examined combined oral contraceptives (COCs), and three studied a levonorgestrel-releasing intrauterine system (LNG-IUS). We found two trials of progestin-only pills (POPs) and two of the etonogestrel implant. Most trials did not report significant differences between the study arms in breastfeeding duration, breast milk composition, or infant growth. Another four trials reported no significant difference in milk volume or composition with two POPs, a COC, or an implant. The quality of evidence was moderate overall and low for three of four placebo-controlled trials of COCs or POPs. The sensitivity analysis included six trials with moderate quality evidence and sufficient outcome data. The evidence was limited for any particular hormonal method.","label":["Factuality 2","Fluency 2","Simplicity 2"]},{"id":"10.1002\/14651858.CD003862.pub2_0","text":"Unsimplified text:\nNo randomised controlled trials were identified but 10 controlled before-after studies from Australia, Singapore and the USA met our inclusion criteria.\nWe grouped them according to the extent to which they adjusted for regression to the mean (RTM) and spillover effects.\nTotal casualty crashes: the only study that adjusted for both reported a rate ratio of 0.71 (95% CI to 0.55, 0.93); for three that partially adjusted for RTM but failed to consider spillover, rate ratio was 0.87 (95% CI to 0.77, 0.98); one that made no adjustments had a rate ratio of 0.80 (95% CI 0.58 to 1.12).\nRight-angle casualty crashes: rate ratio for two studies that partially addressed RTM was 0.76 (95% CI 0.54 to 1.07).\nTotal crashes: the study addressing both RTM and spillover reported a rate ratio of 0.93 (95% CI 0.83 to 1.05); one study that partially addressed RTM had a rate ratio of 0.92 (95% CI 0.73 to 1.15); the pooled rate ratio from the five studies with no adjustments was 0.74 (95% CI 0.53 to 1.03).\nRed-light violations: one study found a rate ratio of 0.53 (95% CI 0.17 to 1.66).\nRed-light cameras are effective in reducing total casualty crashes.\nThe evidence is less conclusive on total collisions, specific casualty collision types and violations, where reductions achieved could be explained by the play of chance.\nMost evaluations did not adjust for RTM or spillover, affecting their accuracy.\nLarger and better controlled studies are needed.\n\n\nSimplified text:\nWe searched scientific databases to find randomised controlled trials that compared the effectiveness of red-light cameras. We included 10 studies from Australia, Singapore, the USA, the UK and the Netherlands. We found 10 studies that assessed the effectiveness in reducing total crashes, total collisions, total injuries, injuries caused by red light cameras, injuries sustained by other vehicles, injuries from red light violations and injuries from traffic accidents. Most studies did not adjust the way they were conducted, which may have affected their accuracy. The results of this review show that redlight cameras are effective in reducing the number of people injured, injured or killed. However, the evidence is less conclusive on total accidents, injuries and injuries, where reductions could be explained by the play of chance. Larger and better controlled studies are needed.","label":["Factuality 2","Fluency 2","Simplicity 0"]},{"id":"10.1002\/14651858.CD003862.pub2_1","text":"Unsimplified text:\nNo randomised controlled trials were identified but 10 controlled before-after studies from Australia, Singapore and the USA met our inclusion criteria.\nWe grouped them according to the extent to which they adjusted for regression to the mean (RTM) and spillover effects.\nTotal casualty crashes: the only study that adjusted for both reported a rate ratio of 0.71 (95% CI to 0.55, 0.93); for three that partially adjusted for RTM but failed to consider spillover, rate ratio was 0.87 (95% CI to 0.77, 0.98); one that made no adjustments had a rate ratio of 0.80 (95% CI 0.58 to 1.12).\nRight-angle casualty crashes: rate ratio for two studies that partially addressed RTM was 0.76 (95% CI 0.54 to 1.07).\nTotal crashes: the study addressing both RTM and spillover reported a rate ratio of 0.93 (95% CI 0.83 to 1.05); one study that partially addressed RTM had a rate ratio of 0.92 (95% CI 0.73 to 1.15); the pooled rate ratio from the five studies with no adjustments was 0.74 (95% CI 0.53 to 1.03).\nRed-light violations: one study found a rate ratio of 0.53 (95% CI 0.17 to 1.66).\nRed-light cameras are effective in reducing total casualty crashes.\nThe evidence is less conclusive on total collisions, specific casualty collision types and violations, where reductions achieved could be explained by the play of chance.\nMost evaluations did not adjust for RTM or spillover, affecting their accuracy.\nLarger and better controlled studies are needed.\n\n\nSimplified text:\nNo randomised controlled trials were identified but 10 controlled before-after studies from Australia, Singapore and the USA met our inclusion criteria. Red-light cameras are effective in reducing total casualty crashes. The evidence is less conclusive on total collisions, specific casualty collision types and violations, where reductions achieved could be explained by the play of chance. Larger and better controlled studies are needed.","label":["Factuality 2","Fluency 2","Simplicity 2"]},{"id":"10.1002\/14651858.CD007699.pub3_0","text":"Unsimplified text:\nFour trials involving 494 participants were included.\nThree studies involving 383 participants provided data on the proportion of participants who had achieved a therapeutic INR by day five.\nSignificant benefit of a 10-mg warfarin nomogram was observed (risk ratio (RR) 1.27, 95% confidence interval (CI) 1.05 to 1.54; moderate quality evidence), although with substantial heterogeneity (I2 = 90%).\nThe review authors analyzed each study separately because it was not possible to perform a subgroup analysis by inpatient or outpatient status.\nOne study showed significant benefit of a 10-mg warfarin nomogram for the proportion of outpatients with VTE who had achieved a therapeutic INR by day five (RR 1.78, 95% CI 1.41 to 2.25), with the number needed to treat for an additional beneficial outcome (NNTB = 3, 95% CI 2 to 4); another study showed significant benefit of a 5-mg warfarin nomogram in outpatients with VTE (RR 0.58, 95% CI 0.36 to 0.93) with NNTB\n= 5 (95% CI 3 to 28); a third study, consisting of both inpatients and outpatients, showed no difference (RR 1.08, 95% CI 0.65 to 1.80).\nNo difference was observed in recurrent venous thromboembolism at 90 days when the warfarin nomogram of 10 mg was compared with the warfarin nomogram of 5 mg (RR 1.48, 95% CI 0.39 to 5.56; 3 studies, 362 participants, low quality evidence); no difference was observed in major bleeding at 14 to 90 days (RR 0.97, 95% CI 0.27 to 3.51; 4 studies, 494 participants, moderate quality evidence).\nNo difference was observed in minor bleeding at 14 to 90 days (RR 0.52, 95% CI 0.15 to 1.83; 2 studies, 243 participants, very low quality evidence) or in length of hospital stay (mean difference (MD) -2.3 days, 95% CI -7.96 to 3.36; 1 study, 111 participants, low quality evidence).\nIn patients with acute thromboembolism (DVT or PE) aged 18 years or older, considerable uncertainty surrounds the use of a 10-mg or a 5-mg loading dose for initiation of warfarin to achieve an INR of 2.0 to 3.0 on the fifth day of therapy.\nHeterogeneity among analyzed studies, mainly caused by differences in types of study participants and length of follow-up, limits certainty surrounding optimal warfarin initiation nomograms.\n\n\nSimplified text:\nThis review included four trials involving a total of 494 people aged 18 years or older. The evidence is current to January 2014. Three studies involving 383 people provided information on the proportion of participants who had achieved a therapeutic INR by day five. The other three studies provided information about the proportion who had no bleeding. The review authors found that a 10-mg warfarin nomogram was more likely than a 5-mg one to achieve an INR of 2.0 to 3.0 on the fifth day of therapy. There was not enough information to determine whether or not this was beneficial or harmful. The overall quality of the available evidence was rated as moderate to low.","label":["Factuality 2","Fluency 2","Simplicity 1"]},{"id":"10.1002\/14651858.CD007699.pub3_1","text":"Unsimplified text:\nFour trials involving 494 participants were included.\nThree studies involving 383 participants provided data on the proportion of participants who had achieved a therapeutic INR by day five.\nSignificant benefit of a 10-mg warfarin nomogram was observed (risk ratio (RR) 1.27, 95% confidence interval (CI) 1.05 to 1.54; moderate quality evidence), although with substantial heterogeneity (I2 = 90%).\nThe review authors analyzed each study separately because it was not possible to perform a subgroup analysis by inpatient or outpatient status.\nOne study showed significant benefit of a 10-mg warfarin nomogram for the proportion of outpatients with VTE who had achieved a therapeutic INR by day five (RR 1.78, 95% CI 1.41 to 2.25), with the number needed to treat for an additional beneficial outcome (NNTB = 3, 95% CI 2 to 4); another study showed significant benefit of a 5-mg warfarin nomogram in outpatients with VTE (RR 0.58, 95% CI 0.36 to 0.93) with NNTB\n= 5 (95% CI 3 to 28); a third study, consisting of both inpatients and outpatients, showed no difference (RR 1.08, 95% CI 0.65 to 1.80).\nNo difference was observed in recurrent venous thromboembolism at 90 days when the warfarin nomogram of 10 mg was compared with the warfarin nomogram of 5 mg (RR 1.48, 95% CI 0.39 to 5.56; 3 studies, 362 participants, low quality evidence); no difference was observed in major bleeding at 14 to 90 days (RR 0.97, 95% CI 0.27 to 3.51; 4 studies, 494 participants, moderate quality evidence).\nNo difference was observed in minor bleeding at 14 to 90 days (RR 0.52, 95% CI 0.15 to 1.83; 2 studies, 243 participants, very low quality evidence) or in length of hospital stay (mean difference (MD) -2.3 days, 95% CI -7.96 to 3.36; 1 study, 111 participants, low quality evidence).\nIn patients with acute thromboembolism (DVT or PE) aged 18 years or older, considerable uncertainty surrounds the use of a 10-mg or a 5-mg loading dose for initiation of warfarin to achieve an INR of 2.0 to 3.0 on the fifth day of therapy.\nHeterogeneity among analyzed studies, mainly caused by differences in types of study participants and length of follow-up, limits certainty surrounding optimal warfarin initiation nomograms.\n\n\nSimplified text:\nFour trials involving 494 participants were included in this review. Three studies involving 383 participants provided data on the proportion of participants who had achieved a therapeutic INR by day five. The review authors analyzed each study separately because it was not possible to perform a subgroup analysis by inpatient or outpatient status. In patients with acute thromboembolism (DVT or PE) aged 18 years or older, considerable uncertainty surrounds the use of a 10-mg or a 5-mg loading dose for initiation of warfarin to achieve an INR of 2.0 to 3.0 on the fifth day of therapy.","label":["Factuality 1","Fluency 2","Simplicity 2"]}]